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Abstract
A key regulator of translation is the mammalian target of rapamycin (mTOR), a 
protein kinase member of the family of phosphatidylinositol kinase (PIK)-related 
kinases. mTOR is dually regulated by growth factors and nutrient availability, 
though the precise mechanisms by which mTOR is regulated are not well 
understood. The C-terminal of the mTOR catalytic domain has been of regulatory 
interest by the identification of the insulin stimulated and nutrient sensitive S2448 
phosphorylation site. The functional significance of S2448 phosphorylation on the 
mTOR downstream targets p70 S6 kinase (S6K1) and eIF4E-binding protein 1 (4E- 
BP1) are unclear.
A novel nutrient responsive mTOR phosphorylation site has been identified at 
T2446. In contrast to S2448 phosphorylation, T2446 is dephosphorylated when 
CHO-IR cells are insulin stimulated and phosphorylated when cells are nutrient 
deprived. Studies show that activation of AMP-activated kinase (AMPK) is 
concomitant with an increase in mTOR T2446 phosphorylation, paralleled by a 
decrease in S6K1 phosphorylation. Regulation of T2446 phosphorylation may 
involve AMPK. Phosphorylation at T2446 and S2448 is mutually exclusive. The 
functional significance of phosphorylation at T2446 and S2448 on the downstream 
target S6K1 was investigated by a mutational strategy where each site was 
substituted with non-phosphorylatable alanine or phospho-mimic glutamic acid. 
Evidence indicates that although phosphorylation of T2446 and S2448 is mutually 
exclusive in response to growth factors and nutrients, their individual 
phosphorylation may not be enough to have a direct effect on downstream S6K1 
activity.
Additionally, the tuberous sclerosis complex (TSC) may have positive regulatory 
effects on insulin signalling. Loss of TSC2 impairs insulin signalling by down- 
regulating the turnover of insulin receptor substrate-1 (IRS-1) protein, affecting 
associated class la  phosphoinositide 3-kinase (PI3K) activity and downstream 
signalling; including suppression of PKB activation and mTOR S2448 
phosphorylation.
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Chapter 1 Introduction
1 Introduction
Insulin signalling plays a major role in the regulation of several cellular processes. A 
key role of insulin signalling is the acute stimulation of protein synthesis in 
mammalian cells, a process which is part of a complex signalling pathway involving 
many signalling elements orchestrating endpoint responses that result in cell survival, 
growth, proliferation and differentiation.
1.1 Initiation of the insulin signalling cascade
Insulin binding to the insulin receptor (IR) activates the intrinsic IR-tyrosine kinase 
activity, initiating the recruitment of several downstream signalling proteins 
containing Src homology 2 domains (SH2). These include; the insulin receptor 
substrate (IRS) family of proteins (White, 1997) and the adaptor protein, Src- 
homology-collagen-like (SHC) protein (Pelicci et al., 1992). IRS proteins and SHC 
are phosphorylated by the IR on specific tyrosine residues; activating two major 
insulin stimulated signalling cascades (Fig. 1.1). Tyrosine-phosphorylated SHC and 
IRS-1 mediate the recruitment of growth factor receptor-binding protein 2 (Grb2) via 
its SH2 domains. Grb2 is tightly associated with the Ras-GDP exchange factor son- 
of-sevenless protein (SOS) via Src homology 3 (SH3) domains. Recruitment of the 
Grb2-SOS complex activates the small G-protein Ras at the plasma membrane 
(Takai et al., 2001) by SOS mediated GDP/GTP exchange. Ras-GTP activates Raf-1 
triggering the activation of the mitogen-activated protein kinase (MAPK) cascade via 
MAP/ERK kinase (MEK) and extracellular-ligand-regulated kinase-1 and -2 
(ERK1/2) (Proud and Denton, 1997). Tyrosine-phosphorylation of the IRS proteins 
is also the main mechanism of activating class la  phosphatidylinositol 3-kinase 
(PI3K), one of the main starting points of insulin stimulated signalling cascades 
(Shepherd et al., 1998).
18
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Insiiin
Plasma Membrane
Ras
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Figure 1.1 Initiation of the insulin signalling cascade
Key events induced by insulin stimulation, as described in the text. Figure modified 
from Shepherd et al., (1996). ‘Y(P)’ denotes tyrosine phosphorylation.
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Multi-site tyrosine phosphorylation of IRS-1 initiates the recruitment of PI3K to the 
plasma membrane via the SH2 domain of the p85 subunit. PI3K catalyses the 
phosphorylation of phosphatidylinositol 4, 5-bisphosphate (Ptdlns (4, 5)P2) on the 3’ 
position of the inositol ring to generate phosphatidylinositol 3, 4, 5-triphosphate 
(Ptdlns (3, 4, 5)P3). Elevated levels of Ptdlns (3, 4, 5)P3 induces the recruitment of 
proteins containing the pleckstrin-homology (PH) domain to the plasma membrane, 
including; phosphoinositide-dependent kinase 1 (PDK1) and protein kinase B (PKB). 
PKB recruitment to the plasma membrane initiates its activation by phosphorylation 
at residues T308 and S473. T308 phosphorylation is mediated by PDK1 (Alessi et 
al., 1997a) while phosphorylation at S473 may be mediated by a kinase termed 
PDK2, though the identity of the latter is not yet known (Alessi and Downes, 1998). 
PKB is an important protein kinase link between IR activation and downstream 
kinase cascades which mediate endpoint metabolic responses including; glucose 
uptake, glycogen synthesis, fatty acid synthesis and protein synthesis (Shepherd et 
al., 1998; Toker and Cantley, 1997).
1.2 Overview of Translation
Insulin can regulate the rate of mRNA translation which can increase the overall rate 
of protein synthesis by 2-3 fold (Gingras et al., 2001b). Translation is a multi-step 
process that can be divided into 3 phases: initiation, elongation and termination. 
Translation initiation is the most complex phase and will be discussed in greater 
detail than elongation and termination. Many translation factors in the translational 
machinery are tightly regulated to permit control of global and specific mRNA 
translation (Dever, 1999). Translation initiation involves several stages that are 
numerically ordered as shown in Fig. 1.2, but each stage may also occur in parallel 
(Dever, 1999; Proud and Denton, 1997). Stage 1 involves dissociation of the 80S 
ribosome into the 60S and 40S subunits, a process which also requires eukaryotic 
initiation factor (elF) 3 and elFlA. In stage 2 a ternary complex is formed between 
the initiator methionyl-tRNA (Met-tRNA) and GTP bound eIF2 which associates
20
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with the 40S ribosomal subunit together with eIF3 and elFlA to form the 43 S pre­
initiation complex. Stage 3 and 4 involves formation and assembly of the trimeric 
eIF4F complex on mRNA. eIF4F comprises eIF4E, eIF4A and eIF4G. eIF4E 
recognizes and binds to the 5’ 7-methyl-GTP-cap of mRNA to allow cap-dependent 
translation, eIF4A acts as a RNA helicase involved in uncoiling secondary structure 
in the 5’-untranslated region (5’UTR) a process that may also involve eIF4B, and 
eIF4G acts as the protein scaffold which has contacts with both eIF4E and eIF4A. In 
stage 5, the 43S pre-initiation complex interacts with the eIF4F complex via contacts 
between eIF4G and eIF3, permitting the 40S ribosome to bind to the mRNA near its 
5’ end and begin ‘scanning’ for the initiation AUG codon, which is recognised by 
Met-tRNA. Finally in stage 6, hydrolysis of ribosome bound eIF2-GTP is stimulated 
by eIF5 resulting in the release of eIF2-GDP and all the initiation factors from the 
40S ribosome. Re-association of the 60S ribosomal subunit to form the 80S 
initiation complex is then permitted and translation elongation can proceed. This 
final stage also recycles eIF2-GDP to regenerate eIF2-GTP, a process requiring the 
guanine nucleotide-exchange factor eIF2B.
Translation initiation is a less energy consuming process than elongation and 
termination. As such, the translational machinery can be regulated by insulin and 
nutrient availability. Stage 2 and stage 3/4 of translation initiation are particularly 
sensitive to these changes. Another mechanism of translational control can be 
exerted through a specific subset of mRNA. The mRNAs which encode several 
ribosomal proteins and translation factors contain a distinctive 5’ tract of 
oligopyrimidine (5’TOP) structure, adjacent to the 5’-cap. 5’TOP mRNA are 
selectively translated in response to mitogenic stimuli (Shah et al., 2000).
21
Chapter 1 Introduction
STAGE 1
SOS » ; 4 0 3
e l F 3
elF4F complex
elF4G
e l F 4 E  I W
m^ GTP------- AUG*
STAGE 3 & 4
Met-tRNA
e l F 1 A
GTP -
<3TP
Met-tRNA, 
STAGE 2
e l F 1 A
e l F 3 * S t f JP
•Met-tRNA, 
43S preinitiation complex
"//An
STAGE 5
e l F 4 E
nvGTP’
elF4G
1 / - - - - - - - - - -
e l F 1 A
‘ O S®
GTP
---------------- AUG-
43S mRNA complex
STAGE 6
“//An
GDP
m7GTP
80S initiation complex
i
ELONGATION
GDP
GTP
Figure 1.2 Overview of translation initiation
The six key stages of translation initiation are described in detail in the text. 
Although stages are numerically labelled here, each stage may also occur in parallel. 
Briefly, stage 1: dissociation of 80S ribosome, stage 2: formation of 43S pre­
initiation complex, stage 3 & 4: Cap recognition and eIF4F complex assembly on 
mRNA, stage 5: 43 S mRNA complex formation and ribosomal scanning and stage 6: 
formation of the 80S initiation complex. Modified from Proud and Denton (1997).
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Translation elongation is a highly energy-dependent process that is regulated by 
eukaryotic elongation factors (eEF) eEFlA, eEFIB (a, P, y subunits) and eEF2, 
which control the speed and accuracy of the elongation process. The mechanism of 
elongation is briefly described here: firstly, recruitment of amino acyl-tRNA to the 
A-site of the ribosome requires eEFlA-GTP which is subsequently hydrolysed and 
released; eEFIB acts as a guanine nucleotide-exchange factor (GEF) and mediates 
GDP/GTP exchange on eEFlA, which is then recycled for amino acyl-tRNA 
recruitment; the nascent peptide chain transfers to the ribosomal A-site and a peptide 
bond is formed between the C-terminal of the peptide and the recruited amino acyl- 
tRNA, forming peptidyl-tRNA; eEF2 and GTP mediate the translocation of the 
ribosome by one codon along the mRNA, shifting the peptidyl-tRNA into the empty 
ribosomal P-site following GTP hydrolysis and release of eEF2. The cycle is 
repeated along the mRNA until a stop codon is reached (Merrick and Nyborg, 2000). 
The translation elongation factors are also subject to reversible phosphorylation 
under the regulation of growth factors and nutrient availability (Browne and Proud, 
2002).
Polypeptide chain termination occurs when a stop codon (UAA, UAG and UGA) is 
reached by the A-site of the ribosome initiating the recruitment of eukaryotic release 
factors (eRFs) to the A-site and catalyzing the hydrolysis of the ester bond between 
the final amino acid of the nascent peptide chain and the tRNA. Termination also 
requires GTP hydrolysis mediating the release of the polypeptide chain, the 
termination factors and the ribosomal subunits are then recycled for translation 
initiation (Welch et al., 2000).
The process of translation is dependent on both energy and nutrient availability and 
control of translation is important for cell growth and proliferation. As mentioned 
above, there are several stages in which translation can be controlled. Moreover, the 
molecular mechanisms involved in translation initiation have been subject to much 
analysis. A key signalling pathway involved in the regulation of translation initiation 
is sensitive to the immunosuppressant rapamycin which specifically inhibits the
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mammalian target of rapamycin (mTOR). mTOR is able to integrate growth factor, 
nutrient and energy signalling and its role is best characterised in the regulation of 
p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E-binding protein 1(4E-BP1), 
a protein which controls eIF4E availability (Gingras et al., 2001b; Proud, 2002a, 
2002b, 2004a, 2004b). Both, these downstream effectors exert some control on 
translation initiation.
It has become increasingly clear that mTOR is a multi-functional and important 
regulatory protein. Much advancement has been made in understanding the factors 
which regulate mTOR and how mTOR regulates its downstream effectors. 
Furthermore novel sensory pathways and proteins have been implicated with the 
control of mTOR and these will be discussed in subsequent sections.
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1.3 The TOR kinase family
The macrolide ester rapamycin was widely used as a potent anti-fungal, anti­
neoplastic and immunosuppressant (Abraham and Wiederrecht, 1996; Diggle et al., 
1996) and was subsequently found to be a highly specific inhibitor of a cellular 
protein which lead to identification of the target of rapamycin proteins (TOR).
Two related proteins termed target of rapamycin 1 and 2 (TORI and TOR2) (from 
separate genes) were first identified in the budding yeast Saccharomyces cerevisiae. 
Mutation in either gene confers rapamycin resistance to allow Gi progression. The 
TOR proteins share 67% overall identity (Heitman et al., 1991; Zheng et al., 1995). 
The mammalian homologue was subsequently identified and has -40% identity to 
the yeast TOR proteins (Sabatini et al., 1994; Sabers et al., 1995). The mammalian 
homologue has been termed FRAP (FKBP12-rapamycin associated protein), RAFT 
(rapamycin and FKBP12 target 1) and mammalian target of rapamycin (mTOR) and 
will be referred to as mTOR throughout. Additionally the Drosophila melanogaster 
homologue was identified and has 35% and 38% overall amino acid identity to 
TORI and TOR2 respectively, while sharing 56% identity to mTOR (Oldham et al., 
2000).
TOR2 has dual function: control of cell cycle-dependent organisation of the actin 
cytoskeleton by a GTPase switch involving RHOl, RH02, ROM2 and SAC7 
(Schmidt et al., 1997) -  this process is not sensitive to rapamycin; and in common 
with TORI, signalling activation of translation initiation in response to nutrient 
availability (Barbet et al., 1996), a function that is preserved from yeast to mammals 
(Manteuffel et al., 1996). The TOR proteins are therefore implicated in important 
signalling cascades involving mitogen stimulation and nutrient availability in the 
regulation of protein synthesis.
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1.4 The Mammalian Target of Rapamycin
mTOR is a 290kDa protein of 2549 amino acids which acts as a checkpoint protein 
in the integration of growth factor signalling and nutrient availability (Gingras et al., 
2001b; Proud, 2002a, 2002b, 2004a, 2004b). mTOR has been localised to 
intracellular membrane fractions that are distributed in the cytoplasm (Sabatini et 
al., 1999; Withers et al., 1997). Similarly the TOR2 protein is membrane associated 
and localises on the surface of the yeast vacuole (Cardenas and Heitman, 1995).
1.4.1 The modular domains of mTOR
The TOR proteins possess the same domain architecture and contain several well 
defined domains as shown in Fig. 1.3.
1.4.1.1 mTOR HEAT domain
The mTOR HEAT domain comprises two blocks which occupy the first 1200 amino 
acids of the mTOR protein (Andrade and Bork, 1995) and is named after the four 
functionally characterised proteins containing the structural motif, namely, 
Huntingtin, Elongation Factor 3 (EF3), Alpha subunit of protein phosphatase 2A & 
TOR 1 (yeast). The domain consists of consecutive repeating units of a degenerate 
hydrophobic 37-43 amino acid motif, of which mTOR contains 20 units (Andrade 
and Bork, 1995). The hydrophobic nature of the HEAT repeats suggests it may act 
as a scaffold and contribute to protein-protein interaction. Gephryin, a tubulin- 
binding protein involved in postsynaptic clustering of neuronal glycine receptors 
(Sabatini et al., 1999), Ubiquilin 1 (Wu et al., 2002) and the recently identified 
regulatory associated protein of mTOR (Raptor) (Kim et al., 2002) were all found to 
interact with the HEAT domain of mTOR.
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Figure 1.3 Domain architecture of mTOR
The TOR family of proteins possess the domain structure represented in this generic 
figure. The domains are described in the text.
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1.4.1.2 mTOR FKBP/rapamycin binding domain (FRB)
The cytosolic receptor FK506 binding protein (FKBP-12), a prolyl isomerase, binds to 
rapamycin which complexes with the FKBP/rapamycin binding domain (FRB) of 
mTOR (Sabers et al., 1995). The FRB domain spans residues 2025-2114 (Chen et al.,
1995) and the FKBP-12-rapamycin complex binds solely to the FRB domain of mTOR 
in mammalian cells (Sabatini et al., 1994). Rapamycin is a highly specific inhibitor of 
mTOR (Davies et al., 2000) and has been a valuable tool in dissecting pathways which 
converge or diverge from mTOR. The crystal structure of the ternary FKBP12- 
rapamycin complex interacting with the FRB domain of mTOR has been solved, 
revealing that rapamycin interacts extensively with both protein partners while limiting 
actual protein-protein interaction (Choi et al., 1996). Additionally, evidence indicates 
that the FRB domain is required for mTOR kinase activity (Vilella-Bach et al., 1999). A 
point mutation at S2035 to aspartate, glutamate, threonine, or isoleucine prevents the 
binding of the rapamycin/FKBP12 complex producing a rapamycin resistant mutant in 
mTOR (Chen et al., 1995; Hara et al., 1997). Corresponding rapamycin resistant 
mutations were also identified in yeast (Lorenz and Heitman, 1995). However, the 
S2035I mutant can affect the substrate preference of mTOR (Lawrence et al., 2004; 
McMahon et al., 2002).
1.4.1.3 mTOR catalytic domain
The TOR proteins are members of a family of phosphatidylinositol kinase related- 
kinases (PIKK) that contain a domain which has homology to the catalytic domain of PI- 
3 kinase. This family also includes DNA dependent protein kinase catalytic subunit 
(DNA-PKcs) and ataxia telangiectasia mutated (ATM) (Abraham, 1996). The C- 
terminal catalytic domain of mTOR exhibits autokinase activity (Brown et al., 1995) but 
lacks lipid kinase activity (Brown et al., 1995); however, mTOR and TOR2 have been 
isolated with phosphatidylinositol-4 (PI-4) kinase activity but this activity was not 
inhibited by binding of the FKBP12/rapamycin complex so it is unclear whether the PI-4
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kinase activity is intrinsic or associated via another kinase (Cardenas and Heitman, 
1995; Sabatini et al., 1995). In contrast, TORI has been isolated with protein kinase 
activity towards 4E-BP1 (Alarcon et al., 1999), much-like the serine/threonine (ser/thr) 
protein kinase activity isolated with mTOR (Brunn et al., 1997b). mTAbl is an 
antibody raised against a peptide spanning residues 2433-2450 of the mTOR catalytic 
domain and can activate mTOR protein kinase activity in vitro (Brunn et al., 1997b). 
The substrates of mTOR will be discussed in subsequent sections.
1.4.1.3.1 mTOR autokinase activity and regulation by phosphorylation
mTOR possesses serine-specific autokinase activity (Brown et al., 1995; Peterson et al., 
2000; Withers et al., 1997) which is sensitive to the PI3K inhibitors wortmannin and 
LY294002 (Brunn et al., 1996; Peterson et al., 2000; Withers et al., 1997). The 
concentration of wortmannin required for 50% inhibition (IC50) of mTOR auto­
phosphorylation is ~200nM in vitro and ~300nM in vivo. mTOR is 100 fold less 
sensitive to wortmannin than the phosphoinositide activity of PI3K (IC50 ~ 2-5nM); 
LY294002 inhibits mTOR autokinase activity in vivo and in vitro (IC50 5pM) at a 
similar concentration needed to inhibit PI3K activity (~3pM) (Brunn et al., 1996). 
S2481 has been reported as a site of auto-phosphorylation in vivo and in vitro which is 
sensitive to wortmannin but not to rapamycin, amino acid starvation or serum 
withdrawal (Peterson et al., 2000), conditions which affect phosphorylation of the 
mTOR effectors S6K1 and 4E-BP1 (Section 1.72). Thus the autokinase activity of 
mTOR S2481 may not reflect mTOR activity for other substrates. However, c-Abl a 
non-receptor-tyrosine kinase activated by DNA damage, was found to negatively 
regulate mTOR. c-Abl can associate and phosphorylate mTOR in vivo and in vitro to 
prevent mTOR auto-phosphorylation (Kumar et al., 2000b). The functional significance 
of auto-phosphorylation on mTOR catalytic activity is therefore unclear. Insulin 
stimulation of mTOR may be dependent on activation of PI3K and PKB (Gingras et al., 
1998; Scott et al., 1998; Takata et al., 1999). Furthermore, mTOR is also 
phosphorylated at S2448 at the C-terminus of the catalytic domain (Bolster et al., 2002; 
Nave et al., 1999; Reynolds et al., 2002; Sekulic et al., 2000). Phosphorylation at this
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site is wortmannin sensitive but rapamycin insensitive and phosphorylation is mediated 
by PKB. In vivo phosphorylation of mTOR-S2448 is stimulated by insulin and 
modulated by nutrient availability (Bolster et al., 2002; Nave et al., 1999; Reynolds et 
al., 2002; Sekulic et al., 2000). Thus, mTOR is a target of PKB and is phosphorylated in 
a linear pathway in response to mitogenic stimuli as depicted in Fig. 1.1. However, 
additional factors such as amino acid availability may also regulate mTOR activity.
1.4.1.4 mTOR FAT and FATC domain
Apart from homology to the lipid kinase domain, all PIKK family members possess a 
FRAP, ATM and TRRAP (FAT) domain which is always accompanied by the FAT- 
carboxy-terminal homology domain (FATC) at the extreme C-terminus. Neither the 
FAT nor FATC domains are common to PI3K or PI4K (Alarcon et al., 1999; Bosotti et 
al., 2000). The functions of the FAT and FATC domain are unclear though it has been 
speculated that they interact together or are important for protein-protein interaction or 
modulation of kinase activity (Bosotti et al., 2000). In yeast, the FAT domain has been 
described as a ‘toxic effector’ domain because it inhibited growth when over-expressed; 
however, the mechanism of conferring toxicity is undefined (Alarcon et al., 1999).
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1.5 Targets of mTOR kinase activity
Several downstream pathways have been implicated in the mTOR signalling pathway by 
use of the specific mTOR inhibitor, rapamycin.
1.5.1 eIF4E binding protein (4E-BP1)
eIF4E is the 5'cap recognition component of the eIF4F complex that interacts with the 
43S pre-initiation complex required for translation initiation (Dever, 1999; Proud and 
Denton, 1997) (Section 1.2). Under translationally repressive conditions eIF4E is tightly 
associated with the eIF4E-binding protein 1 (4E-BP1, also known as phosphorylated 
heat- and acid- stable protein, PHAS-I) which prevents eIF4E contribution to the eIF4F 
complex. There are three 4E-BPs (4E-BP1, 4E-BP2 and 4E-BP3) whereby multi-site 
ser/thr phosphorylation dictates 4E-BP association with eIF4E; 4E-BP1 is the best 
characterised (Gingras et al., 1999b). Upon mitogenic stimulation 4E-BP1 becomes 
hyper-phosphorylated, causing it to dissociate from eIF4E to permit Cap-dependent 
translation (Diggle et al., 1996; Herbert et al., 2000; Manteuffel et al., 1996). In 
contrast, nutrient deprivation and rapamycin causes the rapid dephosphorylation of 4E- 
BP1 to promote 4E-BP1 association with eIF4E (Beretta et al., 1996; Fadden et al., 
1997; Hara et al., 1998). 4E-BP1 is phosphorylated on at least five ser/thr-proline (S/T- 
P) directed sites, namely T37, T46, S65, T70, S83 (Fadden et al., 1997) and at SI 12 (a 
ser-glutamine site) (Heesom et al., 1998); numbered according to the human sequence of 
4E-BP1, minus 1 for numbering to rat sequence. Each site has varied sensitivity to 
serum-stimulation and inhibitors like wortmannin and rapamycin (Brunn et al., 1997a; 
Fadden et al., 1997; Gingras et al., 1998; Heesom and Denton, 1999; Manteuffel et al.,
1996). The precise order of phosphorylation has been contested; however the sites are 
considered to be phosphorylated in a hierarchal system (Gingras et al., 2001a).
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1.5.1.1 Phosphorylation of 4E-BP1
The hierarchal phosphorylation begins with the ‘priming phosphorylation’ at T37 and 
T46 which does not cause 4E-BP1 to dissociate from eIF4E. These two sites are not 
sensitive to serum deprivation and are only mildly rapamycin sensitive (Burnett et al., 
1998; Gingras et al., 1999a, 2001a). T70 is phosphorylated next which then allows 
phosphorylation of S65. Both these phosphorylation sites are sensitive to serum 
withdrawal and rapamycin (Gingras et al., 1999a, 2001a; Mothe-Satney et al., 2000a). 
Phosphorylation at S65 and T70 is required for release of eIF4E from 4E-BP1 and 
prevention of their re-association (Gingras et al., 1999a, 2001a; Heesom and Denton, 
1999; Mothe-Satney et al., 2000a). Recently, an additional phosphorylation site was 
identified at S101 which was constitutively phosphorylated and rapamycin insensitive. 
S101 may be required for S65 phosphorylation (Wang et al., 2003). S83 is
constitutively phosphorylated independently of the ‘priming phosphorylation’ and is not 
sensitive to insulin, amino acids or rapamycin (Mothe-Satney et al., 2000b). 
Phosphorylation at SI 12 is rapamycin-insensitive but there is conflicting evidence as to 
whether SI 12 is sensitive to insulin (Heesom et al., 1998; Wang et al., 2003).
Several kinases have been shown to phosphorylate the S/T-P sites including MAPK 
(Haystead et al., 1994; Lin et al., 1994), casein kinase 2 (CK2) (Lin et al., 1994) and 
mTOR (Burnett et al., 1998; Gingras et al., 1999a, 2001a; Heesom and Denton, 1999; 
Mothe-Satney et al., 2000a). However, in vivo, MAPK activity does not seem to be 
sufficient for 4E-BP1 phosphorylation and dissociation from eIF4E (Azpiazu et al., 
1996; Diggle et al., 1996). However, rapamycin treatment does attenuate insulin 
stimulated phosphorylation of 4E-BP1 (Azpiazu et al., 1996). This supports a role for 
mTOR in growth factor regulation of 4E-BP1. Several groups have shown in vitro 
phosphorylation of T37/T46 (Burnett et al., 1998; Gingras et al., 1999a, 2001a; Heesom 
and Denton, 1999). mTOR can also phosphorylate the S65 and T70 sites in vitro with 
use of the activating mTAbl antibody (Brunn et al., 1997b; Mothe-Satney et al., 2000a), 
however, an mTOR associated kinase was also credited with phosphorylation of S65 and 
T70 (Heesom and Denton, 1999). Whether mTOR is responsible for the in vivo
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phosphorylationof the sites it phosphorylates in vitro remains to be determined; 
nevertheless, the sensitivity to rapamycin at these phosphorylation sites indicates that 
mTOR is closely involved in the regulation of 4E-BP1 phosphorylation and translation 
initiation (Fig. 1.4). Caspase cleavage of 4E-BP1 truncates the protein by twenty four 
amino acids and although the 4E-BP1 phosphorylation sites are intact, insulin stimulated 
phosphorylation is reduced, leading to identification of the RAIP motif (Tee and Proud, 
2002). The RAIP motif is named after the amino acids in the motif. RAIP is located at 
the N-terminus of 4E-BP1 and is required for mTOR-dependent regulation (Tee and 
Proud, 2002).
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Figure 1.4 Connections between mTOR and control of translation initiation
Mitogenic stimulation activates signalling cascades through PI3K which stimulates PKB 
mediated phosphorylation of mTOR, which may cause mTOR activation. Two 
signalling pathways diverge from mTOR both of which are positively regulated by 
mTOR and affect translation initiation. Multi-site phosphorylation of 4E-BP1 is 
mediated by a wortmannin and rapamycin sensitive pathway which initiates the release 
of eIF4E; this permits formation of the eIF4F complex which is required for 5’cap 
dependent translation. mTOR signalling also mediates phosphorylation of S6K1 which 
also requires wortmannin sensitive signalling to activate. Active S6K1 phosphorylates 
the S6 protein of the 40S ribosomal subunit; however, the role of S6K1 in translation is 
unclear (Pende et al., 2004). Figure modified from Proud, (2004). mTOR and its 
downstream effectors are also sensitive to changes in amino acid availability. mTOR 
may also be regulated by amino acids as indicated (e.g. Hara et al., 1998).
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1.5.2 S6 Kinases
The S6 kinases (S6K) phosphorylate the S6 protein of the 40S ribosome to stimulate 
translation of a specific subset of mRNAs, namely 5'TOP containing transcripts which 
encode ribosomal proteins and translational machinery; factors which contribute to cell 
growth and proliferation (Dufiier and Thomas, 1999; Jeffries et al., 1997; Kawasame et 
al., 1998; Kimball, 2002; Loreni et al., 2000). However, recent evidence suggests that 
S6K1 phosphorylation of the S6 protein is insufficient for 5’ TOP mRNA translation in 
response to amino acids (Tang et al., 2001). Furthermore, in S6Kl(-/-)/S6K2(-/-) cells 
5’TOP mRNAs are still modulated by mitogens in a rapamycin-dependent manner, 
suggesting the involvement of an alternative rapamycin-sensitive kinase (Pende et al., 
2004). Nevertheless, S6K1 is involved in the regulation of translation and its activation 
is sensitive to rapamycin; moreover it is a major target of mTOR signalling (Chung et 
al., 1992; Hara et al., 1998; Kuo et al., 1992; Shigemitsu et al., 1999; Weng et al., 1998; 
Xu etal., 1998a).
Two isoforms of S6K1 (or p70 S6 kinase a), denoted S6KlaI (also known as p70al and 
p85 S6 kinase) and S6KlaII (also known as p70a2 and p70 S6 kinase), are generated 
from a single gene by alternative mRNA splicing and use of translational start sites 
(Groves et al., 1999). The S6KlaI isoform has a 23 amino acid nuclear localisation 
sequence (NLS) at the N-terminus which targets it exclusively to the nucleus, but is 
otherwise identical to S6KlaII which is expressed in the cytoplasm (Groves et al., 1999) 
(Fig. 1.5). Both isoforms are collectively known as S6K1 and have identical 
phosphorylation sites. The sites mentioned herein will refer to S6KlaII (p70 S6 kinase); 
plus 23 amino acids for numbering to S6KlaI (p85 S6 kinase). A novel isoform of S6K 
has been identified, termed S6K2 (or p70 S6 kinase P) which also has two variants 
generated from a single gene by alternative translational start sites (Gout et al., 1998). 
The variants are denoted S6K2pI (or p70pi) and S6K2piI (or p70p2) (Gout et al., 1998) 
(Fig. 1.5). S6KlaI and S6K2piI possess 70% identity and 85% similarity at the protein 
level (Minami et al., 2001).
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Figure 1.5 Schematic representation of the S6 kinases
S6K1 and S6K2 and their splice variants are shown with their alternative nomenclature 
(Minami et al., 2001). The domains are as indicated and the phosphorylation sites are 
shown with the corresponding amino acid. Phosphorylation sites are numbered 
according to the short form (p70 and p56 for S6K1 and S6K2 respectively); the arrow 
indicates the order of phosphorylation. S6KlaI has an N-terminal nuclear localisation 
signal (NLS) but is otherwise identical to S6KlaII. Similarly, S6K2pII is identical to 
S6K2pi through residues 14-495 but lacks the NLS located at both the -N and -C 
termini.
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1.5.2.1 Regulation of S6K1 by phosphorylation
Mitogenic stimulation activates S6K1 by mediating a complex series of ser/thr 
phosphorylations associated with phosphorylation at eight sites: T229 in the catalytic 
domain; S371 and T389 in the linker domain; and S404, S411, S418, T421, S424 in the 
auto-inhibitory domain which are in a S/T-P motif (Dufher and Thomas, 1999). 
Phosphorylation of S6K1 can be mediated by several kinases which include: MAPK, 
atypical PKCs, PKB and mTOR (Dufher and Thomas, 1999), though the precise 
mechanisms and pathways involved still require clarification. S6K1 activation requires 
hierarchal phosphorylation beginning with the S/T-P sites in the autoinhibitory domain. 
This is proposed to facilitate phosphorylation of T389 which disrupts interaction 
between the -N and -C terminus to allow phosphorylation of T229 (Dufher and Thomas, 
1999; Volarevic et al., 2000). Phosphorylation of S6K1 is sensitive to rapamycin and 
wortmannin which indicates that mTOR and PI3K signalling is important for its 
activation. PDK1 was identified as phosphorylating S6K1 in vitro at T229 (Alessi et al., 
1997b; Pullen et al., 1998) and when PDK1 was over-expressed, phosphorylation was 
also induced at T389 in vivo (Balendran et al., 1999). Activation was determined to be 
dependent on co-operative phosphorylation at T229 and T389 (Alessi et al., 1997b).
Aside from mitogenic activation, S6K1 is also sensitive to nutrient availability, 
particularly amino acid levels and it is regulated through mTOR as determined through 
use of rapamycin (Chung et al., 1992; Hara et al., 1998; Kuo et al., 1992; Shigemitsu et 
al., 1999; Weng et a l , 1998; Xu et al., 1998a). The T229 and T389 S6K1 
phosphorylation sites are sensitive to rapamycin (Weng et al., 1998) and mTOR was 
subsequently found to directly phosphorylate the T389 site in vitro on bacterially 
expressed S6K1 (Burnett et al., 1998) and on full length native S6K1. Phosphorylation 
of T389 was required for kinase activation (Isotani et al., 1999) implicating mTOR in 
the direct regulation of S6K1. Another mTOR phosphorylation site exists in the S6K1 
linker domain; S371 is regulated by mTOR in vivo and phosphorylated by mTOR in 
vitro. Phosphorylation at S371 modulates T389 phosphorylation though the mechanism 
is as yet unresolved (Saitoh et al., 2002). S6K2 activation also requires mTOR kinase
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activity (Park et al., 2002); however, S6K2 is less sensitive to rapamycin and amino acid 
availability (Gout et al., 1998; Minami et al., 2001). Figure 1.4 shows mTOR regulation 
of S6K1 in translation initiation.
Many protein kinases recognise their substrate by identification of specific sequence 
motifs (Pinna and Ruzzene, 1996). As mentioned earlier, mTOR phosphorylates 4E- 
BP1 at S/T-P directed sites; however, the S/T-P sites in the autoinhibitory domain of 
S6K1 are not phosphorylated by mTOR. Although the S371 phosphorylation site is in 
an S-P motif, the rapamycin sensitive mTOR phosphorylation site T389 is in an FTY 
motif suggesting that mTOR kinase activity is either less stringent than other kinases for 
substrate selectivity or that other mechanisms are in place for regulation of S6K1 and/or 
4E-BP1 e.g. mTOR regulation of a phosphatase.
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1.6 Additional targets of mTOR
1.6.1 mTOR and Protein Phosphatase 2A (PP2A)
A common mechanism employed to regulate enzyme activity is reversible substrate 
phosphorylation. Protein phosphatase 2A (PP2A) is a major cellular ser/thr phosphatase 
involved in a wide range of processes which include metabolism, transcription and 
translation (Janssens and Goris, 2001; Millward et al., 1999; Wera and Hemmings,
1995). PP2A exists as a heterotrimer (A, B and C subunits) with a core heterodimer, 
consisting of a 36 kDa catalytic subunit (PP2Ac or C subunit) and a 65 kDa scaffolding 
subunit (PR 65/A or A subunit), which binds to one of 15 identified regulatory B 
subunits (Zolnierowicz, 2000). The A subunit contains 15 HEAT repeats for which the 
crystal structure has been solved (Groves et al., 1999).
There has been speculation that mTOR acts by restraining phosphatase activity towards 
the mTOR effectors S6K1 and 4E-BP1. In support of this hypothesis, osmotic stress and 
rapamycin induced down-regulation of S6K1 activity via a calyculin A-sensitive 
phosphatase (Parrott and Templeton, 1999). Similarly, activation of S6K1 by amino 
acids is also inhibited by the phosphatase inhibitors okadaic acid and calyculin-A 
(Krause et al., 2002). Moreover, nutrient deprivation increased PP2A activity toward 
4E-BP1 and this was enhanced by rapamycin treatment (Peterson et al., 1999). PP2A 
was also found to interact with full length S6K1 but not with a truncated S6K1 which 
was resistant to rapamycin and nutrient deprivation and also resistant to de­
phosphorylation. Additionally, mTOR was shown to phosphorylate PP2A in vitro with 
greater efficiency than towards GST-4EBP1 (Peterson et al., 1999), though the precise 
phosphorylation sites were not determined. Phosphorylation of PP2A-C is associated 
with inactivation of phosphatase activity (Janssens and Goris, 2001), suggesting that 
mTOR can act as a negative regulator of PP2A.
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1.6.1.1 Model for mTOR control of PP2A
The interest toward PP2A within the mTOR signalling pathway arose by comparison to 
the equivalent TOR signalling pathway in S. cerevisiae. The yeast PP6 and PP2A 
homologue Sit4 can bind the regulatory Sit4-associated proteins (SAP) as well as Tap42 
(DiComo and Arndt, 1996; Duvel and Broach, 2004). Nutrients promote the association 
of Tap42 with Sit4 and the yeast PP2A-C subunit, independently of SAP or the PP2A-A 
and B subunits respectively, acting in a positive regulatory manner for translation 
initiation and cell cycle progression. In contrast nutrient deprivation and rapamycin 
inhibits growth by dissociation of Tap42 (DiComo and Arndt, 1996). Tap42 is a 
phospho-protein and TOR is able to directly phosphorylate Tap42 and improve it as a 
competitor for association with Sit4 and PP2A-C (Jiang and Broach, 1999). Tap42 
dephosphorylation is mediated by activated trimeric PP2A (A, B and C subunits).
It is possible that the yeast PP2A/Tap42 regulatory system exists in mammalian cells 
(Gingras et al., 2001b; Goldberg, 1999). A mammalian homologue to Tap42 has been 
identified. a4 is a phospho-protein identified by its association with the 
immunoglobulin (Ig) receptor-related MB-1 protein complex. a4 has 24% identity and 
37% similarity to yeast Tap42 (Inui et al, 1995; Kuwahara et al., 1994). The cellular 
and biochemical functions of a4 are not well characterised but it has been shown to 
associate consistently with the N terminus of PP4, PP6 (Chen et al., 1998; Nanahoshi et 
al., 1999) and PP2A catalytic subunit (Chen et a l , 1998; Murata et al., 1997) and 
modulate phosphatase activity. Binding of a4 to PP2A-C can be disrupted by 
rapamycin in COS7 (Murata et al., 1997) and Jurkat cells (Inui et al., 1998), which also 
decreases phosphatase activity in vitro. Conflicting reports show constitutive 
association between PP2A/a4 which is rapamycin-insensitive in HEK293 (Nanahoshi et 
al., 1998) and Jurkat cells (Chen et al., 1998). Moreover, a4 has negative regulatory 
effects on PP2A-C phosphatase activity toward 4E-BP1 that had been pre- 
phosphorylated by mTOR; however the phosphatase activity was not sensitive to 
rapamycin (Nanahoshi et al., 1998). In contrast association of a4 augmented PP2A-C
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phosphatase activity toward myelin basic protein (MBP) and rapamycin inhibited 
phosphatase activity by disrupting PP2A/a4 association (Inui et al., 1998). Similarly, 
over-expression of a4 reduced phosphorylation of eEF2 but not of S6K1 or 4E-BP1 
(Chung et al., 1999).
The phosphatase activity of PP2A/a4 may be cell-type specific and substrate selective. 
Nevertheless, those studies which demonstrate rapamycin sensitivity of PP2A/a4 
phosphatase activity implicate an mTOR-dependent pathway. A study in rat skeletal 
muscle showed that insulin inactivated PP2A, a process inhibited by wortmannin and 
rapamycin (Begum and Ragolia, 1996), suggesting deactivation of PP2A via a 
PI3K/mTOR dependent pathway. Furthermore, a4 has been shown to mediate B-cell 
receptor (BCR) signalling via an mTOR-dependent pathway; loss of a4 caused a 
decrease in cell growth and S6K1 signalling while increasing rapamycin sensitivity 
(Inui et al., 2002). A model of mTOR regulation of PP2A via a rapamycin sensitive 
pathway is depicted in Fig. 1.6.
Though the yeast Sit4/Tap42, PP2A/Tap42 system is seemingly conserved in 
mammalian cells, as yet there are no reports of the direct phosphorylation of a4 by 
mTOR; furthermore, the substrates of PP2A/a4 phosphatase activity and its interaction 
and interplay with the mTOR signalling pathway needs further clarification.
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Figure 1.6 Model of mTOR regulation of PP2A via a rapamycin sensitive pathway 
in response to nutrient availability
Figure 1.6 is a simplified representation of the interaction of mTOR and PP2A/a4. 
During high nutrient availability, mTOR signalling to a4 promotes its association with 
PP2A-C and inhibits phosphatase activity toward S6K1 and 4E-BP1; translation 
initiation proceeds. During low nutrient availability, reduced signalling through mTOR 
causes the dissociation of a4 from PP2A-C and the PP2A trimeric complex is formed 
activating phosphatase activity toward S6K1 and 4E-BP1; translation initiation is 
inhibited.
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1.6.2 mTOR regulation of eEF2
As mentioned in Section 1.2, eEF2 is involved in the translocation step of translation 
elongation and is a 90kD protein that is able to bind GTP. eEF2 is negatively regulated 
by phosphorylation at T56 by eEF2-kinase, formerly known as calcium/calmodulin- 
dependent kinase (Ca/CaM-kinase III) (Browne and Proud, 2002; Proud, 2004a). 
Insulin stimulates a decrease in the phosphorylation of eEF2 to promote elongation 
which is concomitant with inhibited eEF2-kinase activity in many cell types including 
Chinese hamster ovary expressing human insulin receptor (CHO-IR) (Redpath et al.,
1996) and mouse embryonic fibroblasts (MEFs) (Wang et al., 2001). Insulin causes 
dephosphorylation of eEF2, requiring the presence of both amino acids and glucose 
(Campbell et al., 1999). Amino acid withdrawal increases phosphorylation of eEF2 to 
inhibit elongation (Wang et al., 1998). Rapamycin blocks insulin stimulation of eEF2, 
implicating the mTOR signalling pathway (Redpath et al., 1996). S6K1 and also 
p90*SK7 were founcj t0 inactivate eEF2-kinase at low Ca2+ concentrations (l-5pM) by 
phosphorylating a single residue at S366 (of the human eEF2 kinase sequence) in the C- 
terminus of the catalytic domain (Wang et al., 2001). Additionally, eEF2 kinase can be 
phosphorylated in vitro at S359 by stress-activated protein kinase 4 (SAPK4), causing 
eEF2 kinase inactivation (Knebel et al., 2001). S359 can also be phosphorylated in vivo 
in a rapamycin-sensitive manner, though SAPK4 is not a rapamycin sensitive kinase 
(Knebel et al., 2001). Thus control of eEF2-kinase can be mediated by an mTOR- 
independent pathway, via MAPK, and by mTOR-dependent signalling, via S6K1 and 
possibly by an mTOR-regulated kinase. More recently, a novel mTOR-regulated 
phosphorylation site was identified in eEF2 kinase, located at the N-terminus, adjacent 
to the calmodulin (CAM) binding domain at S78 (Browne and Proud, 2004). 
Phosphorylation at S78 is stimulated by insulin in a rapamycin sensitive manner and is 
also modulated by amino acids. It appears that S78 phosphorylation inhibits binding of 
CAM and thus inhibits eEF2 kinase activity; however, the mTOR-dependent kinase 
responsible for S78 phosphorylation is not S6K1 (Browne and Proud, 2004), and the 
kinase remains to be identified.
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1.6.3 mTOR regulation of other translation initiation 
factors
Apart from controlling the availability of the translation initiation factor eIF4E through 
control of 4E-BP1, there is evidence that mTOR controls additional members of the 
translational machinery. eIF4G, the scaffold element of the eIF4F complex (Fig. 1.2) 
exists as two homologues (eIF4GI and eIF4GII) and is a phospho-protein. Three serum- 
stimulated phosphorylation sites were identified in the eIF4GI hinge region at SI 108, 
SI 148 and SI 192 (Raught et al., 2000). Phosphorylation at these sites is wortmannin 
and rapamycin sensitive (Raught et al., 2000). Interestingly, truncation of the N- 
terminus of eIF4GI confers resistance to wortmannin and rapamycin, and 
phosphorylation at SI 108, SI 148 and SI 192 becomes constitutive. This indicates that 
eIF4GI phosphorylation is modulated through a PI3K- and mTOR- dependent signalling 
pathway through the C-terminal portion of the protein. The kinase responsible for 
phosphorylation remains elusive as neither mTOR nor S6K1 can phosphorylate elFGI in 
vitro (Raught et al., 2000). Additionally, eIF4B is reported to be controlled through an 
mTOR-dependent signalling pathway (Gingras et al., 2004). S6K1 is able to 
phosphorylate eIF4B at a serum-responsive and rapamycin sensitive phosphorylation 
site in vitro (Gingras et al., 2004). This provides further evidence that the mTOR 
signalling pathway is important for modulating translation initiation.
1.6.4 mTOR regulation of IRS-1
Insulin stimulation mediates activation of the insulin signalling cascade via the insulin 
receptor substrate (IRS) proteins and IRS-1 is the most well characterised IRS protein 
(White, 1997). Multi-site tyrosine phosphorylation of IRS-1 is associated with 
activation of the insulin signalling cascade (White, 1997) while a feedback mechanism 
involving ser/thr phosphorylation of IRS-1 is responsible for the degradation of IRS-1 
(Cengal and Freund, 1999; DeFea and Roth, 1997a, 1997b; Li and DeFea, 1999; Paz et 
al., 1997). This appears to initiate IRS-1 degradation by the proteasome and 
downregulate insulin action (Haruta et al., 2000). Ser/thr phosphorylation of IRS-1 has
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also been implicated in the development of insulin resistance; tumour necrosis factor a 
(TNFa) is a pro-inflammatary cytokine that increases ser/thr phosphorylation and 
prevents insulin receptor mediated tyrosine phosphorylation of IRS-1. TNFa is 
commonly over-expressed in models of obesity and insulin resistance (Marchand- 
Brustel et al., 2003; White, 1997).
Evidence suggests an additional role for mTOR in the negative feedback regulation of 
IRS-1. PDGF signalling is implicated in downregulation of insulin signalling via the 
negative regulation of IRS-1, a process which may involve mTOR (Li and DeFea, 1999; 
Ricort et al., 1997; Staubs et al., 1998). Insulin-induced redistribution of IRS-1 from 
low-density microsomes (LDM) to the cytosol is inhibited by rapamycin and sensitive to 
amino acid availability (Takano et al., 2001). Additionally, amino acid treatment of 
muscle cells activates the mTOR/S6Kl pathway while concomitantly decreasing IRS-1 
associated PI3K signalling, a process also sensitive to rapamycin (Tremblay and 
Marette, 2001).
Several kinases have been shown to phosphorylate serine residues on IRS-1 in vitro 
which inhibits IR-tyrosine-phosphorylation of IRS-1. These include: MAPK (DeFea 
and Roth, 1997), PKC£ (Ravichandron et al., 2001), GSK3 (glycogen synthase kinase-3) 
(Eldar-Finkelman and Krebs, 1997), S6K1 (Hartman et al., 2001) and mTOR (Hartman 
et al., 2001). Furthermore, serine phosphorylation of IRS-1 has been shown to be both 
wortmannin and rapamycin sensitive which suggests that IRS-1 degradation can occur 
via an mTOR dependent pathway which is downstream of PI3K but independent of the 
Ras/MAPK pathway (Hartley and Cooper, 2002; Hartman et al., 2001; Haruta et al., 
2000; Li and DeFea, 1999). mTOR and S6K1 are both capable of phosphorylating ser 
residues on IRS-1 in vitro (between residues 511-722) (Hartman et al., 2001). 
Moreover, mTOR was found to constitutively associate with IRS-1 and TNFa was able 
to activate mTOR which specifically phosphorylated S636 and S639 of IRS-1 (Ozes et 
al., 2001). This suggests a direct role for mTOR in the negative regulation of IRS-1. 
There is evidence that mTOR regulates IRS-1 degradation indirectly by negatively 
regulating PP2A activity (Hartley and Cooper, 2002). Nevertheless, it seems the mTOR
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pathway is implicated in modulating IRS-1 signalling and mTOR may be a component 
in the onset of insulin resistance.
1.6.5 mTOR regulation of PKC
Ca2+ phospholipid activated protein kinase C (PKC) has been implicated in many 
cellular processes including apoptosis, cell growth and proliferation. There are 10 PKC 
isozymes which can be split into 3 classes: conventional PKCs (a, pi, pil and y) which 
are stimulated by diacyglycerol, phosphatidylserine and are dependent on Ca2+; novel 
PKCs (8, e, rj/L and 0) which are stimulated by diacyglycerol and phosphatidylserine but 
are not Ca2+ dependent; atypical PKCs (£ and iJX) which are stimulated by 
phosphatidylserine (Newton, 2001). PKCs possess a modular structure comprising a 
regulatory and catalytic domain; three ordered phosphorylation steps in the catalytic 
domain are required for activation (Newton, 2001). PDK1 is able to phosphorylate 
PKCS and PKC£ (Good et al., 1998) and is implicated in activation of other PKC 
isozymes (Newton, 2001). mTOR may positively regulate the novel PKCs (Parekh et 
al., 1999). Serum-dependent phosphorylation of PKCS and PKCe at the C-terminal 
hydrophobic residue S662 and S729 respectively is inhibited by rapamycin and amino 
acid deprivation (Parekh et al., 1999). Conditions which modulated the rapamycin 
sensitive phosphorylation sites did not affect PDK1 mediated phosphorylation of PKCS 
which suggests that mTOR mediated phosphorylation is distinct from that of PDK1 and 
implicates the novel PKCs (8 and e) in the mTOR pathway. Constitutive association 
between PKCS and mTOR has been reported whereby PKCS potentiates mTOR 
mediated phosphorylation of 4E-BP1 thus stimulating cap-dependent translation (Kumar 
et al., 2000a). mTOR was not demonstrated to directly phosphorylate PKCS; however 
the S662 phosphorylation site is similar to the mTOR mediated S6K1 T389 
phosphorylation site in being flanked by bulky hydrophobic residues. mTOR may 
therefore modulate phosphorylation of PKCS directly or via inhibition of a phosphatase.
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1.6.6 mTOR regulation of STATs
Cytokine signalling is mediated by the JAK/STAT pathway (Janus kinase/signal 
transducers and activators of transcription). Upon cytokine binding, receptor associated 
JAKs are activated which mediate phosphorylation of specific tyrosine residues on the 
receptor, initiating recruitment of the STAT family of transcription factors (Kisseleva et 
al., 2002). STATs are a family of seven structurally and functionally related proteins 
which can be phosphorylated by JAKs on a single conserved tyrosine residue, mediating 
STAT dissociation from receptor, STAT dimerisation and translocation to the nucleus 
(Kisseleva et al., 2002; Rawlings et al., 2004). However, maximal STAT activation 
requires both tyrosine and serine phosphorylation (S727 of STAT 1 and STAT3) (Wen et 
al., 1995), thus implicating a serine kinase. mTOR has been implicated in the regulation 
of STAT1 (Kristof et al., 2003) and STAT3 (Yokogami et al., 1999). The cytokine 
ciliary neurotrophic factor (CNTF) stimulates STAT3 phosphorylation at S727 in 
neuroblastoma cells in a rapamycin sensitive manner and mTOR was shown to 
phosphorylate a STAT3 peptide containing the S727 phosphorylation site (Yokogami et 
al., 1999). HEK293 cells transfected with a reporter that had a STAT3-responsive 
promoter, demonstrated decreased activation of the reporter construct when treated with 
rapamycin. The decrease in transcriptional activity was similar to that observed with the 
STAT3 point mutation S727A (Yokogami et al., 1999); this demonstrated that mTOR- 
dependent phosphorylation of STAT3 was required for its activation. However, in lung 
epithelial adenocarcinoma cells (A549) treated with a combination of the cytokine 
interferon-y (IFN-y) and lipopolysaccharide (LPS), STAT1 phosphorylation at S727 was 
sensitive to LY294002 but not wortmannin or rapamycin (Kristof et al., 2003). 
LY294002 was used at a concentration (lOOpM) which inhibited PI3K and mTOR 
signalling as demonstrated by reduced S6K1 T389 phosphorylation and mTOR 
autophosphorylation (S2481) but not phosphorylation of the PKB mediated mTOR 
S2448 site (Kristof et al., 2003). Over-expression of mTOR increased basal S727 
phosphorylation of STAT1 in IFN-y/LPS-stimulated cells which was insensitive to 
rapamycin treatment; this implicates mTOR in the regulation of STAT1 but not via a 
PKB-dependent or rapamycin-sensitive pathway. Further, mTOR, PKC8 and STAT1
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were shown to be recruited into a macromolecular complex in vivo in the presence of 
IFN-y/LPS (Kristof et al., 2003). As mentioned above, constitutive association between 
PKC5 and mTOR has been reported (Kumar et al., 2000a). Since STAT1 
phosphorylation is rapamycin insensitive, it is possible that mTOR mediates association 
between the two and PKC5 phosphorylates S727 of STAT1 to regulate transcription in a 
rapamycin insensitive manner (Uddin et al., 2002). It seems likely that various 
cytokines mediate different effects through mTOR but the present evidence suggests that 
in addition to regulation of translation, mTOR may also be involved in the regulation of 
transcription activation.
1.7 Regulation of mTOR
As discussed mTOR has been implicated in the regulation of several pathways; however, 
the regulation of mTOR itself has also been subject to intense investigation. Apart from 
growth factor stimulation and amino acid sensing there are many novel factors which 
have recently been implicated in the regulation of mTOR or of factors in the mTOR 
regulatory pathway.
1.7.1 The role of Raptor association with mTOR
The kinase activity of mTOR has been difficult to assess. Previous reports indicated that 
mTOR in vitro kinase activity, but not mTOR autokinase activity, was sensitive to the 
detergent NP40 (Nishiuma et al., 1998). This suggested the loss of a stabilising mTOR- 
associated protein during isolation of mTOR. An mTOR binding partner has been 
identified in which the interaction is salt, detergent and rapamycin sensitive. The 150kD 
regulatory associated protein of mTOR (Raptor) was isolated and found to be highly 
conserved in most eukaryotes including D. melanogaster and S. cerevisiae (Hara et al., 
2002; Kim et al., 2002). Raptor homologues all contain the novel Raptor N-terminal 
conserved (RNC) domain which comprises 3 blocks with 67-79% sequence identity, 
followed by a region of three HEAT repeats, ending with seven WD40 repeats at the C-
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terminus. Raptor not only binds mTOR but also its downstream effectors S6K1 and 4E- 
BP1, an association that is detergent insensitive (Hara et al., 2002). This may occur via 
the mTOR signalling motif (TOS) (Schalm and Blenis, 2002). TOS is a conserved five 
amino acid motif identified as a minimal requirement for mTOR mediated signalling and 
has been located at the N-terminus of the S6 kinases (FDIDL) and in the C-terminus of 
4E-BP1 (FEMDI) (Schalm and Blenis, 2002), both major downstream targets of mTOR. 
Raptor can bind S6K1 and 4E-BP1 through their TOS motif. Mutation of the TOS motif 
in 4E-BP1 inhibits its phosphorylation by mTOR in vitro (Nojima et al., 2003). Thus, 
the TOS motif may be a requirement for mTOR signalling by mediating interaction of 
Raptor-mTOR with mTOR target proteins. Raptor seems to be an essential factor for 
mTOR kinase activity towards 4E-BP1 (Hara et al., 2002) but not towards S6Kla in 
vitro (Hara et al., 2002; Kim et al., 2002) and is necessary for the positive regulation of 
cell size and growth (Kim et al., 2002). A model has been proposed (Kim and Sabatini, 
2004; Kim et al., 2002) whereby Raptor forms a complex with mTOR via two 
interactions, one which is ‘constitutive’ and the other ‘nutrient sensitive’. The 
‘constitutive’ interaction is proposed to play a positive regulatory role, existing 
irrespective of the nutrient status of the cell. The ‘nutrient sensitive’ interaction is 
proposed to have negative regulatory effects since nutrient poor conditions increases the 
stability of the ‘nutrient sensitive’ interaction which decreases mTOR in vitro kinase 
activity. Conversely, a nutrient rich condition disrupts the complex to increase mTOR 
activity. The mechanism which regulates the switch between the two proposed 
interactions is yet to be identified. However, the mechanism proposed by Kim et al., 
(2002) is not consistent with the studies performed by Hara et al., (2002), which again 
may arise from differences in isolation procedures. Data from Kim et al., (2002) suggest 
that mitochondrial metabolism or oxidative stress may play a part in the regulation of the 
Raptor-mTOR complex, specifically via intracellular levels of ATP, to which mTOR 
may be sensitive (Section 1.7.5). The present evidence suggests that Raptor functions as 
an important scaffold between mTOR and both 4E-BP1 and S6K. While the 
mechanisms involved in the regulation and interaction of Raptor with mTOR await 
clarification, further investigation should shed light on other proposed mTOR interacting 
proteins.
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1.7.2 Amino acid regulation of mTOR and its downstream 
effectors
Amino acid deprivation of CHO-IR (Campbell et al., 1999; Hara et al., 1998; 
Shigemitsu et al., 1999), HEK293 (Hara et al., 1998) and Jurkat cells (Iiboshi et al.,
1999) results in rapid deactivation of S6K1 and de-phosphorylation of 4E-BP1, with 
cells becoming unresponsive to insulin stimulation; re-addition of amino acids restores 
S6K1 activity and 4E-BP1 phosphorylation and cells regain responsiveness to agonists 
(Campbell et al., 1999; Hara et al., 1998). These effects are specific to amino acid 
withdrawal as omissions of glucose or vitamins do not affect S6K1 activity (Campbell et 
al., 1999; Hara et al., 1998) but phosphorylation of 4E-BP1 can be dependent on glucose 
availability (Patel et al., 2001). Amino acid withdrawal also increases eEF2 
phosphorylation in CHO-K1 cells to inhibit translation (Wang et al., 1998). This 
indicates that amino acid availability exerts control over translation but this may be cell 
type specific. In hepatocyte H4IIE cells, withdrawal of amino acids does not abolish 
insulin stimulation of S6K1 and phosphorylation of 4E-BP1 (Shigemitsu et al., 1999). 
Nevertheless, the effects of amino acid deprivation are the same as rapamycin treatment, 
where re-addition of amino acids could not overcome effects of rapamycin (Hara et al., 
1998), indicating a role for mTOR in the amino acid regulation of 4E-BP1 and S6K1. 
Rhabdomyosarcoma Rh30 cells stably expressing mTOR, containing the rapamycin 
resistant S2035I mutation, supported S6K1 activity in the presence of rapamycin when 
amino acids were re-introduced after amino acid starvation (Iiboshi et al., 1999). 
Moreover, an S6K1 deletion mutant A2-46/ACT104 (Weng et al., 1995), sensitive to 
wortmannin but resistant to rapamycin, was also resistant to amino acid deprivation 
(Hara et al., 1998). However, mTOR fully inhibited in situ, as judged by inhibition of 
S6K1, retains in vitro autokinase and protein kinase activity (Dennis et al., 2001; Hara et 
al., 1998), so whether mTOR directly phosphorylates 4E-BP1 or S6K1 in vivo is 
unclear. Nevertheless, mTOR is involved in the regulation of S6K1 and 4E-BP1 as 
amino acid deprivation does not affect PI3K, PKB or MAPK activity in CHO-IR cells
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(Hara et al., 1998; Kimball et al., 1999; Patel et al., 2001; Wang et al., 1998). Similarly 
in Jurkat cells, activation of S6K1 and phosphorylation of 4E-BP1 is dependent on 
amino acid availability but other ser/thr kinases (PKB and p90rsk) are less affected 
(Iiboshi et al., 1999). Use of 3-methyladenine, an inhibitor of autophagy (protein 
breakdown), inhibited insulin stimulation of S6K1 and 4E-BP1 in amino acid deprived 
H4IIE cells but did not inhibit insulin stimulated tyrosine phosphorylation, activation of 
PI3K or MAPK (Shigemitsu et al., 1999). This suggests that amino acid signalling may 
not be propagated through growth factor signalling cascades. However, the PI3K 
inhibitor wortmannin can partially inhibit amino acid activation of S6K1 without 
inhibiting PKB activation (Iiboshi et al., 1999; Patti et al., 1998; Wang et al., 1998; Xu 
et al., 1998b); in these cases wortmannin was used at lOOnM which is lower than the 
IC50 required for inhibition of mTOR (~200nM). Therefore, in addition to mTOR 
regulation by amino acids, PI3K may also be involved in regulation of S6K1 in response 
to amino acids but not via PKB.
1.7.2.1 Branched chain amino acids and mTOR signalling
Withdrawing individual amino acids from cells incubated complete with 1 x amino acids 
(D-PBS containing all the amino acids at I* standard concentration minus an individual 
amino acid) inhibits S6K1 with varied potency (Hara et al., 1998). Withdrawal of 
arginine or leucine caused 70-90% inhibition; lysine or tyrosine caused 30-50% 
inhibition in CHO-IR cells (Hara et al., 1998). This demonstrates differential sensitivity 
of the mTOR pathway to individual amino acids. Re-addition of individual amino acids 
at the standard l x concentration (D-PBS containing the individual amino acid at l x 
standard concentration) did not stimulate S6K1 activation (Hara et al., 1998) but re­
addition at 4 or 5 x the standard concentration of leucine (in buffer) did stimulate S6K1 
activity but with less potency than the complete amino acid mixture in CHO-K1 
(Campbell et al., 1999; Wang et al., 1998), L6 myoblasts (Kimball et al., 1999), 
hepatocytes (Patti et al., 1998) and adipocytes (Lynch et al., 2000). Similarly, leucine, 
valine and isoleucine induce phosphorylation of 4E-BP1 and S6K1 to the same level as 
complete amino acids in the RINm5F pancreatic p cell-line (Xu et al., 1998a) but only
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leucine was effective at stimulating S6K1 phosphorylation at a physiological 
concentration (Xu et al., 1998a). Recently, leucine was reported to stimulate production 
of the hormone leptin in rat adipocytes via an mTOR-dependent pathway as determined 
by use of rapamycin (Roh et al., 2003). Glutamine was also identified as a nutrient 
regulator of cardiac gene expression mediated through both PKA and mTOR signalling 
pathways (Xia et al., 2003). So although the complete amino acid mixture is optimal for 
stimulating the mTOR pathway, the individual effects of leucine and other branched 
chain amino acids (BCAA) at stimulating mTOR signalling suggest they have an 
important regulatory role.
The importance of leucine and other BCAA e.g. isoleucine and valine, has been 
extended to whole animal studies. In rat skeletal muscle, only leucine was able to 
stimulate protein synthesis; furthermore it was the most effective at increasing 
phosphorylation of 4E-BP1 and S6K1 (T389) in a rapamycin sensitive manner (Anthony 
et al., 2000). Similarly, in rat hepatocytes, BCAA induced increased phosphorylation of 
4E-BP1 and S6K1 (T389) and again leucine was most potent (Anthony et al., 2001; 
Krause, 2002). Though BCAA did not induce a difference in total protein synthesis 
rates in hepatocytes, leucine was effective in promoting the association of ribosomal 
protein mRNA with polysomes in the liver; this correlates to S6K1 phosphorylation and 
is distinct from total protein synthesis rates (Anthony et al., 2001). This suggests tissue 
specific regulation of mTOR signalling by leucine. In support of this, chronic 
leucine/norleucine supplementation induces a tissue specific increase in the rate of 
protein synthesis in adipose tissue, liver and skeletal muscle but not heart or kidney 
(Lynch et al., 2002). These findings indicate that in vivo, leucine can stimulate 
tissue/cell type specific translation initiation via a rapamycin sensitive pathway and 
leucine is important for translation of ribosomal mRNA. However, global protein 
synthesis is most likely to require additional factors such as complete amino acids.
In addition, leucine can influence pathways independent of mTOR. Glucose uptake in 
soleus muscle can be stimulated by leucine in a rapamycin insensitive manner (Nishitani 
et al., 2002). In C2C12 myotubes withdrawal of leucine promoted autophagy but did
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not affect S6 phosphorylation, suggesting leucine regulation of translation via an 
mTOR-independent pathway in myotubes (Mordier et al., 2000).
1.7.2.2 mTOR detection of amino acid levels
How mTOR senses changes in amino acid availability is uncertain. tRNA 
aminoacylation was a mechanism considered for amino acid regulation of mTOR and its 
downstream effectors. In Jurkat cells, the activation of S6K1 and phosphorylation of 
4E-BP1 is dependent on amino acid availability and is inhibited by rapamycin (Iiboshi et 
al., 1999). Treatment of Jurkat cells with amino acid alcohols inhibits corresponding 
tRNA synthetases by preventing aminoacyl-tRNA formation, whereby a reduction of 
intracellular aminoacyl-tRNA levels leads to inhibition of S6K1 (Iiboshi et al., 1999). 
However, in freshly isolated rat adipocytes, the regulation of S6K1 and 4E-BP1 is 
sensitive to rapamycin but not to amino acid alcohols such as L-leucinol or L-histinol 
(Pham et al., 2000). Therefore, aminoacylated tRNA regulation of mTOR may be cell 
line or cell type dependent. In HEK293 cells, amino acid deprivation inhibits S6K1 
activity but does not affect total amounts of aminoacylated tRNA (Dennis et al., 2001). 
This suggests that mTOR is regulated by intracellular pools of amino acids rather than 
charged tRNA. Moreover, inhibition of protein synthesis in CHO-K1 cells with 
cycloheximide, emetine or anisomycin causes an increase in intracellular levels of amino 
acids and permits insulin stimulated activation of S6K1 and phosphorylation of 4E-BP1, 
even after amino acid deprivation (Beugnet et al., 2003). However, inhibition of 
autophagy prevents insulin activation of S6K1 and phosphorylation of 4E-BP1 in the 
absence of amino acids (Beugnet et al., 2003; Shigemitsu et al., 1999). This would be 
consistent with mTOR regulation by intracellular levels of amino acids; however, 
amino-acylated tRNA may still be involved. The mechanism by which mTOR can sense 
changes in amino acid availability remains to be determined.
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1.7.2.3 Leucine regulation of mTOR
In addition to speculation regarding the mode of amino acid signalling to mTOR, the 
essential amino acid leucine has been of particular interest because of all the amino 
acids, it is the most potent at stimulating S6K1 and 4E-BP1 phosphorylation (see above). 
The mechanism of leucine signalling has also been investigated. The method by which 
leucine exerts its effects on mTOR is unclear as there is no evidence of a ‘leucine 
receptor’. Mitochondrial metabolism of leucine has been considered as having 
signalling potential to the mTOR pathway. mTOR has been found to associate with 
outer mitochondrial membranes (Desai et al., 2002), so its physical location would be 
ideal for mitochondrial signals. Leucine is metabolised in mitochondria by oxidative 
decarboxylation. Firstly, in a reversible step, leucine is converted to a-ketoisocaproate 
(KIC) by branched chain aminotransferase (BCAT). Secondly, KIC is oxidised and 
decarboxylated by the multi-enzyme complex branched-chain a-keto acid 
dehydrogenase (BCKD) to form NADH and isovaleryl-CoA which can be further 
metabolised to acetyl-CoA for entry into the Krebs cycle (Voet and Voet, 1995). 
BCKD-kinase phosphorylates S293 of the Ela-subunit of BCKD to inactivate it (Zhao 
et al., 1994). In the RINm5F pancreatic P-cell line, leucine but not isoleucine or valine 
stimulates phosphorylation of S6K1 in a rapamycin and wortmannin sensitive manner 
(Patti et al., 1998; Xu et al., 2001). The leucine metabolite KIC is also effective in 
activating S6K1 (Xu et al., 2001) and stimulating phosphorylation of 4E-BP1 (Fox et 
al.9 1998) in several different cell types. Inhibition of mitochondrial function with azide 
inhibits leucine activation of S6K1 and this was not a cytotoxic effect because inhibition 
was reversible after removal of azide (Xu et al., 2001). This suggests that in p-cells, 
leucine may stimulate S6K1 phosphorylation via the mTOR signalling pathway by 
acting as mitochondrial fuel. In contrast, Lynch et al., (2003) assessed the role of 
leucine metabolism in adipose tissue by using a phospho-S293 antibody to assess the 
activity of BCKD. In nutrient deprived adipose tissue, BCKD was highly 
phosphorylated and inactive but when rats were orally administered a diet rich in 
leucine, circulating levels of leucine were accordingly raised and BCKD was 
dephosphorylated (active) in adipose tissue. Therefore, BCKD is also dependent on
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changes in leucine availability. However, much higher doses of leucine were required to 
elicit BCKD dephosphorylation compared to S6K1 T389 phosphorylation in adipose 
tissue. This implies that BCKD regulates leucine metabolism but this may not be 
required for stimulation of the mTOR pathway and suggests that leucine itself is the 
most effective at stimulating the mTOR signalling pathway.
1.7.3 Cytoplasmic nuclear shuttling of mTOR
mTOR is associated with membrane fractions distributed in the cytoplasm (Sabatini et 
al., 1999; Withers et al., 1997). mTOR has been located at the endoplasmic reticulum 
(ER) and Golgi apparatus (Drenan et al., 2004) and with the outer mitochondrial 
membrane (Desai et al., 2002). Localisation to these particular compartments 
presumably aids mTOR function. However, mTOR is found to be predominantly 
located in the nucleus of cells expressing the HIV-1 envelope glycoprotein (Castedo et 
al., 2001) and in human malignant cell lines, human fibroblasts and mouse myoblasts 
but was found to be excluded from the nucleus in HEK293 cells (Zhang et al., 2002). 
No identifiable nuclear import/export sequence is located in mTOR yet treatment of 
cells with leptomycin B (LMB), a specific inhibitor of nuclear export receptor Crml, 
specifically retains mTOR in the nuclear fraction and inhibits activation of S6K1 and 
phosphorylation of 4E-BP1. In addition, mTOR is reported to shuttle between the 
nucleus and the cytoplasm without affecting mTOR kinase activity (Kim and Chen,
2000). Addition of a nuclear localisation sequence (NLS) to mTOR enhances activation 
of nuclear localised S6K2 (Park et al., 2002) and also enhances activation of S6K1 and 
phosphorylation of 4E-BP1 which are cytoplasmic (Chen, 2004). Conversely, addition 
of a nuclear export signal (NES) reduces activation of S6K2 and S6K1 and reduces 
phosphorylation of 4E-BP1. This implies that nuclear localisation of mTOR may 
convey some regulatory mechanism. So far, the upstream signalling elements required 
for nuclear shuttling of mTOR are unknown and shuttling may be cell type specific 
(Chen, 2004). The importance of mTOR shuttling is unclear but may implicate mTOR 
in the regulation of nuclear proteins or in relaying nuclear signals to cytoplasmic 
proteins.
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1.7.4 Phosphatidic acid mediated mTOR signalling
Levels of the lipid second messenger phosphatidic acid (PA) are rapidly increased upon 
mitogenic stimulation via activation of phospholipase D (PLD) and have been linked to 
mTOR signalling (Chen, 2004; Chen and Fang, 2002; Fang et al., 2001). Extracellular 
PA is rapidly incorporated into the cell to mediate cellular signalling and was shown to 
stimulate activation of S6K1 and phosphorylation of 4E-BP1 in a rapamycin and amino 
acid sensitive manner (Fang et al., 2001). Moreover, serum stimulation rapidly 
increased cellular levels of PA which was concomitant to activation of S6K2 (Park et 
al., 2002), S6K1 and 4E-BP1 phosphorylation (Fang et al., 2001). Addition of the 
alcohol 1-butanol inhibits PA production and inhibits the phosphorylation of S6K1 and 
4E-BP1; inhibition did not appear to be mediated by reduced signalling through PKB as 
PKB was not inhibited by 1-butanol (Fang et al., 2001). The stimulatory effects of PA 
may therefore be dependent on the amino acid sensory mechanism of mTOR but 
independent of PI3K signalling; this was confirmed with use of an S6K1 mutant 
resistant to rapamycin and sensitive to wortmannin (Weng et al., 1995) which was not 
inhibited by 1-butanol. PA did have direct electrostatic interaction with the FRB domain 
of mTOR which was fully competed by FKBP/rapamycin (Fang et al., 2001); the 
interaction is not important for mTOR activity because PA did not affect mTOR kinase 
activity in vivo or in vitro (Chen, 2004). The stimulatory effects of PA are a novel input 
into mTOR regulation and though mTOR does have direct interaction with PA the 
signalling potential mediated by PA requires further examination.
1.7.5 mTOR regulation by ATP levels
mTOR has been described as a sensory protein which detects cellular levels of ATP 
(Dennis et al., 2001). The glycolytic inhibitor 2-deoxy glucose causes a decrease in 
intracellular levels of ATP which induces inhibition of mTOR-mediated S6K1 activation 
and 4E-BP1 phosphorylation but not PKB activation (Dennis et al., 2001), suggesting a
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specific ATP sensory system within the mTOR signalling pathway. As described above, 
mTOR is regulated by intracellular amino acids and regulation is via a mechanism 
independent of detection of intracellular ATP levels because ATP depletion does not 
affect cellular amino acid pools and vice versa (Dennis et al., 2001). mTOR has a high 
Km (Michaelis constant) for ATP at ~lmM, which is considerably higher than most 
other protein kinases. Dennis et al., (2001) used lOOmM 2-deoxy glucose to elicit the 
described effects, an extremely high concentration which translates to an extreme 
depletion of cellular ATP that would have multiple metabolic effects in vivo; mTOR 
may therefore be a sensory molecule for intracellular ATP levels only during extreme 
ATP depletion. Sensitivity to ATP levels via an mTOR dependent signalling pathway 
has been demonstrated in vivo; ethionine treatment of rats induces rapid depletion of 
hepatic ATP levels which causes de-phosphorylation of 4E-BP1 and S6K1 (Yoshizawa 
et al., 2002). Additionally, mTOR has been localised to the outer mitochondrial 
membrane and this may allow it to detect changes in ATP levels through association 
with components of mitochondrial permeability pores (PTP), which include adenine 
nucleotide transporters (ANT) that transport ATP generated in mitochondria to the 
cytosol (Desai et al., 2002). Therefore, an ATP sensory mechanism may exist in mTOR 
that occurs indirectly via an intermediate ATP sensing protein, possibly AMP-activated 
protein kinase (AMPK).
1.7.5.1 Interplay between mTOR and AMPK
AMPK is an established energy sensing/signalling protein that responds to the cellular 
ATP/AMP ratio of the cell (Carling, 2004; Hardie et al., 1998). AMPK is a 
heterotrimeric complex comprising a catalytic (a) subunit and two regulatory subunits (P 
and y) and is structurally and functionally related to a protein kinase complex in S. 
cerivisiae termed SNF1 (sucrose non-fermenting). Increasing cellular AMP levels 
activates AMPK allosterically via phosphorylation of the a-catalytic subunit (T172) by 
AMPK-kinase (AMPKK). AMPK activation promotes the production of ATP by 
stimulating glucose uptake and fatty acid oxidation while inhibiting energy consuming 
biosynthetic pathways (Hardie et al., 1998; Kemp et al., 1999). 5-aminoimidazole-4-
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carboxamideribonucleoside (AICAR) is a specific activator of AMPK (Corton et al., 
1995); AICAR injection of rats significantly decreases skeletal muscle protein synthesis 
via 4E-BP1 and S6K1 (Bolster et al., 2002). Activation of AMPK with AICAR also 
abrogates amino acid induced activation of S6K1, a process mediated through mTOR 
(Dubbelhuis and Meijer, 2002; Krause et al., 2002). AICAR may have cellular effects 
aside from AMPK activation in vivo (Kemp et al., 1999) but similar studies in which 
AMPK was activated by glucose withdrawal or 2-deoxyglucose substitution also 
inhibited S6K1 activity by an mTOR-dependent signalling pathway (Inoki et al., 2003b; 
Kimura et al., 2003). This supports the theory that AMPK signals energy changes to 
mTOR which in turn mediates signals to its downstream effectors.
1.7.6 TSC
The tuberous sclerosis complex (TSC) is an inherited human genetic disorder, occurring 
in 1:6000 newborns. TSC is an autosomal dominant disorder characterised by benign 
tumour development (hamartomas) in a variety of organs including most commonly the 
brain, kidney and heart (Young and Povey, 1998). Mutations in either the TSC1 or 
TSC2 tumour suppressor genes cause the TSC phenotype (Young and Povey, 1998). 
The TSC1 gene is located on chromosome 9q34 (Slegtenhorst et al., 1997) and encodes 
the 130kDa protein TSC1 (also known as hamartin) which contains a potential N- 
terminal transmembrane domain and a predicted coiled-coil domain but no obvious 
catalytic domain (Slegtenhorst et al., 1997). TSC1 is also involved in adhesion and 
Rho-dependent signalling for actin fibre stress formation (Lamb et al., 2000). The TSC2 
gene is located on chromosome 16pl3 (Consortium, 1993) and encodes the 200kDa 
protein TSC2 (also known as tuberin) which also has a coiled-coil domain and a carboxy 
terminal which shares homology to the catalytic domain of murine GTPase -activating 
protein (GAP) and human GAP3 (Consortium, 1993). TSC2 demonstrates in vitro GAP 
activity toward Rapl (Wienecke et al., 1995) and Rab5 (Xiao et al., 1997) and may also 
have a role in endo/exocytosis (Kleymenova et al., 2001; Xiao et al., 1997)). TSC1 and 
TSC2 interact to form a functional complex (herein, TSC denotes TSC1-TSC2 complex) 
(Potter et al., 2001), attributed to occur in a number of ways: via the TSC1 coiled coil
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domain (Slegtenhorst et al., 1998); through the N-terminus of both proteins (Hodges et 
al., 2001); by tyrosine phosphorylation of TSC2 (Aicher et al., 2001); and/or by 
phosphorylation of both proteins (Nellist et al., 2001). The TSC1 and TSC2 association 
occurs rapidly after protein synthesis, co-localising the complex into the cytoplasmic 
fraction (Nellist et al., 1999). Both TSC1 and TSC2 are required for reciprocal 
stabilization; uncomplexed TSC2 is heavily ubiquinated and targeted for proteasome- 
dependent degradation which is prevented by TSC1 association (Benvenuto et al.,
2000); in return TSC2 acts as a chaperone to TSC1 to prevent TSC1 self-aggregation 
(Nellist et al., 1999; Nellist et al., 2001). Missense or point mutations of either gene, as 
found in TSC patients, can abrogate TSC function and/or interaction (Aicher et al., 
2001; Hodges et al., 2001; Nellist et al., 2001) and thus their tumour suppressor 
function.
1.7.6.1 TSC and the mTOR signalling pathway
In Drosophila, mutation of either dTscl or dTsc2 increases cell size and proliferation, 
whereas over-expression of either gene reduces cell size and proliferation, suggesting a 
negative regulatory role for TSC (Tapon et al., 2001). Epistatic studies in Drosophila 
showed that TSC functioned in parallel to the insulin signalling pathway, converging at 
dAkt (dPKB) and upstream of dS6K (Gao and Pan, 2001; Potter et al., 2001) and in 
parallel or upstream of dTOR (Gao et al., 2002). Signalling in mammalian cells is 
predicted to be the same as that in Drosophila. Thus far, biochemical and bioinformatic 
techniques have identified TSC2 as a physiological substrate of PKB primarily at S939 
and T1462 (Dan et al., 2002; Manning et al., 2002). Phosphorylation of these sites does 
not affect association with TSC1 (Dan et al., 2002; Manning et al., 2002) but may 
promote degradation of existing complexes (Dan et al., 2002). The analogous PKB 
phosphorylation in Drosophila S924 and T1518 (Manning et al., 2002) does disrupt 
TSC complex formation and the sub-cellular localization of the complex (Potter et al.,
2002). TSC2 can also be phosphorylated by AMPK at T1227 and SI345 (Inoki et al., 
2003b); activation of AMPK mediates phosphorylation of TSC2 and decreases 
signalling through the mTOR pathway.
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Loss of TSC function results in the constitutive activation of S6K1 (Gao et al., 2002; 
Inoki et al., 2002; Jaeschke et al., 2002; Kwiatkowski et al., 2002; Zhang et al., 2003a) 
which remains sensitive to rapamycin (Gao et al., 2002; Kwiatkowski et al., 2002; 
Zhang et al., 2003a). Over-expression of TSC inhibits phosphorylation at the T389 site 
of S6K1 (Inoki et al., 2002) but not at the P421 or S424 sites suggesting a negative 
regulatory role for TSC which is specific to the T389 rapamycin sensitive site. Co­
expression of TSC inhibits insulin-stimulated phosphorylation of 4E-BP1 leading to 
repression of Cap-dependent translation (Tee et al., 2002). Evidence is consistent with 
TSC negatively regulating the mTOR pathway. dTOR was found to interact strongly 
with dTsc2 (Gao et al., 2002) but there is no evidence of physical interaction between 
mTOR and TSC (Gao et al., 2002; Zhang et al., 2003a). Instead TSC was found to 
interact with 14-3-3y, a phospho-serine/threonine-binding protein (Zhang et al., 2003a).
In CHO-IR cells amino acid deprivation induces rapid dephosphorylation and 
deactivation of S6K1 (Hara et al., 1998). This was also observed in mouse embryonic 
fibroblasts (MEFs) that were TSC2-null and p53-null, in which amino acid withdrawal 
reduces S6K1 activity (Zhang et al., 2003a). In insect S2 cells, amino acid withdrawal 
causes a 90% reduction in S6K1 activity after 15min and activity was abolished after 
30min (Gao et al., 2002). However, in contrast to Zhang et al., (2003), S6K1 activity 
was resistant to amino acid starvation when TSC1 and TSC2 expression was inhibited in 
S2 cells by RNA interference (RNAi) (Gao et al., 2002). S6K1 activity was only 
reduced by 39% after 30min and even after 6 hours amino acid starvation there was 
residual S6K1 activity and S6K1 activity remained rapamycin sensitive. This implies 
that TSC is not only a negative regulator of S6K1 but is also a component of amino acid 
signalling, given that resistance to amino acid starvation is a phenotype associated with 
loss of TSC. The conflicting evidence between Zhang et al., (2003) and Gao et al., 
(2002) may be accounted for by the use of different cell types and the method used to 
knock-out TSC2 expression. Though evidence places mTOR as a mediator between the 
TSC complex and S6K1 (Inoki et al., 2002; Tee et al., 2002), the use of an alternative 
rapamycin resistant S6K1 mutant (Dennis et al., 2001) in a study by Jaeschke et al.,
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(2002) suggested that TSC inhibits S6K1 via PI3K but independently of mTOR. 
Nevertheless, TSC may operate in both an mTOR-dependent and mTOR-independent 
pathway and may play a part in integrating metabolic and nutrient signals to mTOR.
1.7.6.2 TSC2 GAP activity may regulate mTOR
As mentioned above, TSC2 displays GAP (GTPase-activating protein) homology 
(Consortium, 1993), demonstrating in vitro GAP activity toward Rapl (Wienecke et al., 
1995) and Rab5 (Xiao et a l , 1997). TSC also possesses GAP activity toward the small 
G-protein, Ras homologue enriched in brain (Rheb) (Yamagata et al., 1994), which is 
related to the Ras, Rap and Ral super family of small GTP binding proteins (Reuther and 
Der, 2000). GAPs down-regulate activated small GTP-bound proteins by accelerating 
GTP hydrolysis to produce the inactive GDP bound form (Donavan et al., 2002). 
Evidence suggests that the GAP activity of TSC2 is specific for Rheb and this may 
contribute to regulation of mTOR signalling (Castro et al., 2003; Inoki et al., 2003a; Li 
et al., 2004; Tee et al., 2003). Studies in Drosophila implicate Rheb in the insulin 
signalling cascade downstream of dTSC and upstream of dTOR and dS6K (Saucedo et 
al., 2003; Stocker et al., 2003; Zhang et al., 2003b). Moreover, Rheb-GTP may be a 
positive regulator of the mTOR signalling pathway (Castro et al., 2003; Inoki et al., 
2003a; Tee et al., 2003) and contribute to the amino acid and energy sensing capabilities 
of mTOR. Over-expression of Rheb can promote S6K1 phosphorylation even in the 
absence of amino acids (Inoki et al., 2003a; Tee et al., 2003) or during energy depletion 
(Inoki et al., 2003a). Furthermore, Rheb is membrane associated by famesylation and 
this feature seems to be important for activation of mTOR signalling (Tee et al., 2003), 
possibly through co-localisation of Rheb and mTOR at membrane surfaces as mTOR is 
also membrane associated (Sabatini et al., 1999; Withers et al., 1997). Overall, the GAP 
activity of TSC2 in complex with TSC1 negatively regulates the positive signalling 
instigated through Rheb and mTOR (Castro et al., 2003; Inoki et al., 2003a; Tee et al.,
2003). A putative model for TSC contribution to the mTOR-dependent signalling 
pathway is shown in Fig. 1.7 (see Tee et al., 2003).
61
Chapter 1 Introduction
PI3K Wortmannin
•Am ino ac id s  
•E nergy  a v a ila b ility .
PKB
SC1ITSC2
Active
Rheb
GTP R heb-
GEFGDP GTP
Inactive
Rheb
•GDP
Rapamycin  1 I mTOR
/  \
S6K1 | 4E-BP1
elF4E
Figure 1.7 Putative model for TSC signalling via the mTOR-dependent signalling 
pathway
TSC GAP activity hydrolyses Rheb-GTP to the inactive GDP bound state and reduces 
signalling through mTOR. Upon activation of the PI3K signalling, PKB phosphorylates 
and inactivates the TSC GAP activity, and a Rheb-GEF (GTP exchange factor) activates 
Rheb by GDP/GTP exchange. Rheb-GTP can activate the mTOR signalling pathway 
through activation of S6K1 and phosphorylation of 4E-BP1. Schematic modified from 
Tee et al., 2003. mTOR and TSC may also have additional sensory capabilities for 
nutrient and energy availability.
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1.8 Role for mTOR in oncogenesis
The checkpoint properties of mTOR in the regulation of protein synthesis also extend to 
control of cellular growth and cell cycle progression, processes which are dependent on 
the energy and nutrient status of the cell. Therefore, it is not surprising that mTOR is 
also implicated in the control of cell cycle regulatory proteins, indicating that mTOR 
may be involved in tumorigenesis and be a viable target for cancer therapy.
1.8.1 mTOR and regulation of cell growth
In Drosophila, dTOR is important for regulating growth during larval development by 
integrating growth factor signalling and nutrient availability (Oldham et al., 2000; Zhang 
et al., 2000). dTOR mutants have a cellular phenotype normally associated with amino 
acid deprivation where cells are smaller than wildtype dTOR cells (Oldham et al., 2000; 
Zhang et al., 2000) and growth is arrested at the second instar larval stage (Zhang et al.,
2000). Lack of dPTEN {Drosophila orthologue: Phosphatase and tensin homolog 
deleted on chromosome 10), a tumour suppressor, increases cell growth (Huang et al., 
1999). Cells null for both dPTEN and dTOR were of reduced cell size and accumulated 
in the Gi phase, a phenotype indistinguishable from cells null for dTOR alone (Zhang et 
al., 2000). This indicates that growth stimulation by the PI3K pathway requires dTOR 
(Zhang et al., 2000). Similarly, mTOR is required for embryonic development and cell 
proliferation in a mouse model (Hentges et al., 2001). A mutation of mTOR in a mouse 
model (termed flat top) inhibited phosphorylation of S6K1 and 4E-BP1 but did not cause 
a reduction in cell size, as observed in Drosophila. In contrast, in U20S osteosarcoma 
cells, rapamycin reduces cell size especially during the Gi phase (Fingar et al., 2002) but 
expression of a rapamycin resistant mTOR mutant (S2035I) rescues cells from reduced 
cell size. Thus, mTOR regulation of cell size may be cell-type dependent. Aside from 
regulating cell growth via S6K1 and 4E-BP1 (Fingar et al., 2002; Hentges et al., 2001), 
another mechanism may be through regulation of nutrient uptake. In the interleukin-3 
dependent cell line FL5.12, growth factor withdrawal reduces cell size and causes 
downregulation of cell surface receptors for glucose and amino acids; over-expression of
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activated PKB maintains these cell surface receptors via an mTOR dependent pathway 
as determined by use of rapamycin (Edinger and Thompson, 2002).
1.8.2 mTOR and cell cycle progression
The downstream effector S6K1 has also implicated mTOR in the control of cell cycle 
progression. In cancerous pancreatic p-cell lines, S6K1 is constitutively phosphorylated 
but treatment by rapamycin inhibited S6K1 phosphorylation and induced Go-Gi arrest 
(Shah et al., 2001). Moreover, S6K1'7' murine embryonic stem cells are characterised by 
retarded proliferation that is sensitive to rapamycin and having an elevated level of cells 
in Go-Gi arrest (Kawasame et al., 1998). This implies that mTOR/S6Kl signalling is 
important for Gi to S phase progression. Similarly, in yeast, TOR is required for 
activating Cap-dependent translation and Gi progression in response to nutrients by 
regulating yeast Gi-cyclin CLN3 (Barbet et al., 1996). In mammalian cells, mTOR can 
also modulate translation of mRNAs which encode proteins involved in cell cycle 
progression. These include: cyclins, cyclin-dependent kinases (cdks) and cyclin- 
dependent kinase inhibitors, cdks are ser/thr kinases that regulate the cell cycle and are 
activated when complexed with cyclins, which are sequentially expressed during the Gi 
phase in response to growth factors (Pines, 1993). Possible cdk/cyclin combinations 
include: D-type cyclins complexed with cdk4 or cdk2 and cyclin E in complex with 
cdk2 (Pines, 1993). Cip/Kip (kinase inhibitor family) is a class of cyclin-dependent 
kinase inhibitors that include p21Waf*1 and p27Kipl which are down-regulated by 
mitogenic stimulation and can bind and inactivate cyclin/cdk2 complexes (Dai and 
Grant, 2003; Ho and Dowdy, 2002). The G2 to M transition is mediated by 
phosphorylation of the cdk2 complex and this is inhibited by rapamycin which arrests 
cells in transition without affecting p21Waf_1 and p27Kipl availability (Shah et al., 2001). 
In contrast, in D10 T-cells stimulated with interleukin-2 (IL-2), p27Kipl was eliminated. 
Rapamycin prevented p27Klpl elimination making it available for association with cyclin 
E/cdk2 complexes and inhibition of cell cycle progression (Nourse et al., 1994). 
Similarly in 3T3 fibroblasts, rapamycin increased association of p27Kipl with cdk2 
(Hashemolhosseini et al., 1998). Furthermore, rapamycin inhibits Gi to S phase cell
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cycle progression by destabilising and promoting degradation of cyclin D1 mRNA and 
protein. Inhibition of mitogen induced cyclin D1 expression causes a decrease in cdk4 
activity due to deficiency of cyclin D1 (Hashemolhosseini et al., 1998). This indicates 
that mTOR is involved in cell cycle progression, not only through S6K1 and 4E-BP1 but 
also through regulation of cell cycle proteins.
1.8.3 mTOR and cell survival
p53 is a tumour suppressor which regulates cell cycle progression and apoptosis; 
inactivation of p53 leads to tumorigenesis (Kaelin, 1999; Vousden, 2000). p53 primarily 
acts as a transcription factor and exerts control over specific mRNAs which include: the 
cyclin dependent kinase inhibitor p21Wafl (Gorospe et al., 1998) and cyclin dependent 
kinase 4 (cdk4) (Miller et al., 2000). Activation of p53 leads to a rapid decrease in 
translation initiation, correlating with an increase in 4E-BP1 de-phosphorylation, 
inhibition of S6K1 and increased expression of p21Wafl which inhibits cell cycle 
progression (Horton et al., 2002). p53 suppression of mTOR signalling may occur via c- 
Abl, a growth inhibitory non-receptor tyrosine kinase which is activated by DNA 
damage (Kharbanda et al., 1997; Kharbanda et al., 1995). c-Abl binds to p53 in vitro 
and enhances p53 dependent transcription (Goga et al., 1995). Mutation of c-Abl 
renders it unable to bind p53 and p53 transcriptional activity is not enhanced; moreover 
cell growth is not suppressed (Goga et al., 1995). c-Abl can also bind to the C-terminal 
domain of mTOR and mediate tyr-phosphorylation of mTOR in vivo and in vitro 
(Kumar et al., 2000b). Tyrosine phosphorylated mTOR demonstrated reduced activity 
towards both S6K1 and 4E-BP1. Furthermore c-Abl also negatively regulates PI3K 
(Yuan et al., 1997). Therefore, c-Abl activation could negatively regulate PI3K and 
translation via mTOR to induce GI arrest in response to DNA damage.
Rhabdomyosarcoma (RMS) cells lack functional p53 and rapamycin treatment of RMS 
cells induces GI arrest and apoptosis, implicating mTOR in apoptosis (Hosoi et al., 
1999; Huang et al., 2001). This indicates rapamycin induced apoptosis is independent 
of p53 because expression of a rapamycin resistant form of mTOR (S2035I) can rescue
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cells from apoptosis, demonstrating the importance of mTOR in cell survival (Hosoi et 
al., 1999). However, in syncytia (fusion) of cells expressing the human 
immunodeficiency virus-1 (HIV-1) encoded envelope glycoprotein complex (Env) and 
cells expressing CD4/CXCR4, apoptosis is induced via mTOR and p53 (Castedo et al., 
2001; Castedo et al., 2002). mTOR could associate with p53 from syncytial cells but 
not single cells; furthermore, delineation of the apoptotic pathway in syncytial cells 
showed that the initial step leading to apoptosis involved translocation of mTOR to the 
nucleus where it mediates p53 phosphorylation at S15 (Castedo et al., 2001; Castedo et 
al., 2002). Apoptosis of syncytial cells was inhibited by rapamycin (Castedo et al., 
2001; Castedo et al., 2002), suggesting that mTOR regulation of apoptosis is dependent 
on p53. The involvement of mTOR in these apoptotic pathways requires further 
investigation.
1.8.4 mTOR and Cancer
The phosphoinositide 3’ phosphatase, PTEN (Phosphatase and tensin homolog deleted 
on chromosome 10) is a tumour suppressor which is mutated in a variety of cancers 
(Cantley and Neel, 1999; Li et al., 1997). It functions as a negative regulator of 
PI3K/PKB signalling and loss of PTEN function results in increased levels of Ptdlns (3, 
4, 5)P3 and PtdIns-3, 4 -P2 (Stambolic et al., 1998) corresponding to enhanced activation 
of PKB (Maehama and Dixon, 1999; Mayo and Donner, 2002). In Drosophila, PI3K 
signalling is important for growth and development (Leevers et al., 1996). Loss of 
PTEN increases cell growth and over-expression of PTEN inhibits cell growth in 
Drosophila (Huang et al., 1999) and mouse models (Stambolic et al., 1998).
As established earlier, mTOR/S6Kl signalling is involved in progression to the S phase 
of the cell cycle (Shah et al., 2001) and mTOR is also involved in tumours with 
activated PI3K signalling. In chicken embryo fibroblasts (CEF) transformed by class la 
PI3K and PKB, constitutive phosphorylation of S6K1 and 4E-BP1 is observed (Aoki et 
al., 2001). The transforming activities of PI3K and PKB are specifically sensitive to 
rapamycin as other oncoproteins such as Src and Abl, were not affected by rapamycin.
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However, rapamycin did enhance the transforming activity of the Myc oncogene (Aoki 
et al., 2001). Similarly in human neuroblastoma cells, rapamycin potently inhibited 
mTOR dependent cell proliferation but did not inhibit Myc oncogene expression or the 
MAPK pathway (Misawa et al., 2003). Inhibition of mTOR by rapamycin can therefore 
specifically inhibit the oncogenic properties induced by PI3K and PKB transformation. 
In the heterozygote PTEN*7' tumour mouse model, PTEN expression is reduced or 
absent and accompanied by increased phosphorylation of PKB and S6K1 (Podsypanina 
et al., 2001), suggesting that the mTOR pathway is up-regulated in PTEN*7' tumours. 
The ester derivative of rapamycin, cell cycle inhibitor-779 (CCI-779), reduces neoplasia 
and normalises S6K1 activity without affecting PKB activation (Podsypanina et al.,
2001). Similarly, in human tumour cells deficient for PTEN (PTEN'7'), 4E-BP1 is highly 
phosphorylated and S6K1 is constitutively activated; both are sensitive to CCI-779 
(Neshat et al., 2001). PKB is also constitutively phosphorylated in the PTEN'7' cells but 
is insensitive to CCI-779. In addition, PTEN'7' cells had enhanced sensitivity to CCI- 
779 compared to the wildtype PTEN*7* cells. However, when wildtype PTEN*7* cells 
were transfected with activated PKB and transferred to severe combined 
immunodeficient (SCDD) mice, tumour growth rate increased but tumours were highly 
sensitive to CCI-779, compared to PTEN*7* cells lacking activated PKB (Neshat et al.,
2001). This supports mTOR being downstream of PI3K/PKB as previously 
demonstrated (Nave et al., 1999; Sekulic et al., 2000) and suggests that deregulation of 
mTOR signalling may contribute to tumours arising from loss of PTEN and enhanced 
PI3K and PKB signalling.
1.8.5 Rapamycin therapy
As mTOR is involved in activated PI3K (Aoki et al., 2001) and loss of PTEN mediated 
oncogenesis (Neshat et al., 2001; Podsypanina et al., 2001), it is an attractive target for 
chemotherapy because its inhibition can specifically govern translation which is a 
requirement for cell growth. Moreover, mTOR is specifically inhibited by rapamycin 
and the high specificity of inhibition makes mTOR a good target for cancer therapy 
(Davies et al., 2000). Rapamycin was discovered as an antifungal and
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immunosuppressant which also had potential as an anti-cancer agent (Abraham and 
Wiederrecht, 1996; Dilling et al., 1994). Rapamycin is a potent inhibitor in the growth 
of childhood rhabdomyosarcoma (RMS) cells (IC50 ~4000 ng/ml) via inhibition of the 
insulin-like growth factor-1 (IGF-1) receptor signalling pathway, a requirement for 
signalling in RMS cells (Dilling et al., 1994; Hosoi et al., 1998). Though rapamycin 
was effective at inhibiting RMS and some neuroblastoma and glioblastoma cell lines, 
S6K1 remained inactive in some rapamycin resistant cancer cell lines, suggesting 
redundancy or inactivation of S6K1 via an mTOR independent pathway (Hosoi et al., 
1998). Nevertheless, rapamycin or analogues of rapamycin may provide therapeutic 
efficacy as anti-cancer agents. Cell cycle inhibitor-779 (CCI-779) by Wyeth-Aycrst 
(PA, USA) and RAD001 by Novartis AG (Basel, Switzerland) are derivatives of 
rapamycin with anti-cancer properties and improved pharmaceutical qualities e.g. 
stability in solution. CCI-779 has demonstrated inhibition of tumour growth in vivo 
(Neshat et al., 2001; Podsypanina et al., 2001) and has been used in pre-clinical trials for 
chemotherapy of breast cancer (Yu et al., 2001). Currently, both CCI-779 and RADOOl 
are in phase I-III clinical trials and show efficacy in tumour regression (Hidalgo and 
Rowinsky, 2000; Houghton and Huang, 2004; Huang and Houghton, 2003). So far, only 
mild side effects were reported from phase I trials of CCI-779 (Hidalgo and Rowinsky, 
2000)
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Protein translation involves complex signalling networks which have implicated mTOR 
both directly and indirectly. Rapamycin has increased our understanding of pathways 
which involve mTOR and it is now clear that mTOR plays an important role in 
regulating cellular homeostasis in response to mitogens, energy and nutrient availability. 
Although mTOR is a convergence point for insulin signalling and amino acid sensing, 
the mechanisms by which mTOR is regulated are still not well understood.
The current studies were aimed at characterisation of a novel mTOR phosphorylation 
site and understanding the role of phosphorylation in the regulation of mTOR. Further, 
we examined the effects of other signal transduction pathways which have been linked 
to mTOR signalling.
An outline of the studies performed is summarized below:
I. Identification and characterisation of a novel mTOR phosphorylation site and 
assessment of pathways which lead to mTOR phosphorylation.
II. Investigation of the role of mTOR phosphorylation by mutational analysis and 
whether mTOR regulation is via phosphorylation of mutually exclusive phosphorylation 
sites.
III. Investigation of the involvement of TSC in upstream signalling to mTOR
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2 Materials and Methods
2.1 Materials
2.1.1 General Reagents
Tissue culture media, phosphate-buffered saline, trypsin, and fetal calf serum, were 
obtained from Sigma. Phosphoinositides, agarose conjugated protein A and agarose 
conjugated anti-mouse IgG were purchased from Sigma. [y-32P]ATP (specific activity: 
lOmCi/ml) was from NEN. Protein-G agarose was purchased from Santa Cruz. 
PD98059 was purchased from Cell Signalling Technologies. Rapamycin, puromycin 
and okadaic acid were obtained from Calbiochem. Activated recombinant ERK1 and 
CK2 was from Upstate Biotechnology. DNA sequencing was performed and peptides 
were generated by the Wolfson Institute for Biomedical Research (University College 
London). All chemicals were from Sigma unless stated otherwise and sources of other 
reagents or facilities are stated in the text.
2.1.2 Antibodies
Lab generated antibodies included: R27 mTOR antibody raised against the HEAT 
domain (Withers et al., 1997) and phospho-mTOR -S2448 and corresponding de- 
phospho-S2448 (Nave et al., 1999). Other antibodies used were as follows: - 
monoclonal FLAG-M2 and HA-tag antibody was purchased from Sigma. Polyclonal 
total mTOR antibody, phospho-mTOR -S2442 and -T2446 and corresponding de- 
phospho-antibodies were generated as described in Methods. aTOR antibody raised 
against the C-terminal portion of mTOR (a.a. 2433-2450) (Heesom and Denton, 1999) 
and total 4E-BP1 were kindly provided by Prof. R. Denton (University of Bristol, UK). 
hTOR, a mouse monoclonal antibody raised against a peptide corresponding to residues
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230-240 of human mTOR was purchased from Oncogene (CN Biosciences) and Anti- 
FRAP polyclonal antibody raised against a peptide corresponding to residues 2524-2538 
in rat mTOR that is conserved in the human sequence was from Calbiochem. Phospho- 
AMPK (T172), total AMPK, phospho-PKB (S473) and phospho-S6K (T389) antibodies 
were purchased from Cell Signalling Technologies. Total S6K and PKC-^ antibodies 
were purchased from Santa Cruz. Phospho-ERK and total ERK was purchased from 
New England Biolabs (Beverly, MA, USA). Total PKB antibody against the C-terminus 
of PKB was kindly provided by Dr D. Alessi (University of Dundee). Phospho-4E-BPl 
at positions T37, S65 or T70 antibodies (equivalent to rat numbering T36, S64 and T69 
respectively) were kindly provided by Dr J. C. Lawrence, Jr. (University of Virginia, 
USA)
2.1.3 Additional gift reagents
The following reagents were also kindly provided through collaboration:
• Activated recombinant S6K1, Glu-Glu tagged S6KlaII and Glu-Glu tag antibody 
were provided by Dr Ivan Gout (Ludwig Institute for Cancer Research, University 
College London, UK).
• Recombinant AMPK, AMPK resin and H2K lysates were provided by Dr David 
Carling (Cellular Stress Group, MRC Clinical Sciences Centre, Imperial School of 
Medicine, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK).
• Control and TSC2"/_ MEFs were provided by Dr Richard Lamb (Cancer Research 
UK Centre for Cell and Molecular Biology, The Institute of Cancer Research, 237 
Fulham Road, London).
• Min6 extracts were provided by Dr Guy Rutter (Department of Biochemistry, School 
of Medical Sciences, University of Bristol, BS8 1TD).
• HA tagged human 4E-BP1 in the vector pACTAG-2 was a gift from Dr A.-C. 
Gingras (McGill University, Canada).
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2.2 Methods
2.2.1 Nucleic acid manipulation
2.2.1.1 Polymerase Chain Reaction
PCR amplifications were performed in 50pl reaction volume containing lx Cloned 
PfuTurbo DNA polymerase reaction buffer (20mM Tris-HCl, pH 8.8, 2mM MgS04, 
lOmM KC1, lOmM (NH4)2 S04, 0.1% Triton X-100, 1 mg/ml nuclease-free BSA), 
200pM each dNTP, lOng template DNA, 20pmol primers and 2.5U Pfu Turbo 
polymerase (all purchased from Stratagene). Amplifications were performed in a 
Techne Progene thermo-cycler. Cycling parameters were as follows: A single 2min 
denaturing step at 95 °C followed by 30 cycles of 30s denaturation at 95 °C, 30s 
annealing at 5°C below the lowest primer melting temperature and lmin per kb of 
the target extension at 72°C. Annealing temperatures were calculated for each 
primer using the equation:
Tm (°C) = 2(NA+NT) + 4(NG+NC), where N equals the number of primer adenine 
(A), thymine (T), guanine (G), or cytosine (C) bases.
PCR products were resolved on a 1.5% agarose gel to check for yield and specificity 
of amplification. The amplified DNA was concentrated by ethanol precipitation and 
further purified by agarose gel electrophoresis, excision of the DNA band and 
extraction of DNA using a QIAquick® Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instructions.
2.2.1.2 Ethanol precipitation of DNA
0.1 volumes of 3M sodium acetate (pH 5.2) was added to DNA samples which were 
then precipitated with 3 volumes of ice cold 100% ethanol, then centrifuged at 
14,000# for 15min at 4°C. The supernatant was discarded and the DNA pellet was 
flushed with 200pl ice cold 70% ethanol, then centrifuged at 14,000# for 15min at
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4°C. The supernatant was discarded and the DNA pellet was air dried then re­
suspended in deionised water (ddH2<3) or appropriate buffer.
2.2.1.3 Restriction enzyme digestion of DNA
All restriction enzymes and reaction buffers used were purchased from New England 
Biolabs (NEB). Restriction digestions were performed in a reaction volume of 20pl 
containing 0.5pg of plasmid DNA and 10U of enzyme. Reactions were incubated at 
37°C for one hour.
2.2.1.4 Electrophoresis of DNA fragments
Agarose (Gibco/BRL) was dissolved in lx TAE buffer (40mM Tris-acetate, ImM 
EDTA) by heating and ethidum bromide at a concentration of lpg/ml was added 
when cooled, prior to the gel being cast. DNA fragments of less than 1Kb in size 
were resolved on 1% (w/v) agarose gels; fragments of greater than 1Kb were 
resolved on 0.7% (w/v) agarose gels. 6x gel loading buffer (0.25% (w/v) 
bromophenol blue, 30% glycerol dissolved in water) was added to DNA samples, 
which were electrophoresed in 1 x TAE buffer at 60mA. For the determination of the 
fragment size, 1Kb DNA ladder (Gibco/ BRL) was electrophoresed simultaneously. 
DNA bands were visualised by illuminating the gel on a UV light box.
2.2.1.5 Ligation of DNA fragments
Ligations were performed in a lOpl reaction volume containing lx ligation buffer 
(50mM Tris-HCl pH 7.5, lOmM MgCl2, lOmM DTT, ImM ATP and 25pg/ml BSA) 
and 1(4,1 T4 DNA ligase. lOOng total DNA was used containing a 3-fold molar excess 
of insert DNA relative to plasmid DNA. Reactions were incubated at 16°C for 16h.
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2.2.1.6 Transformation of competent Escherichia coli cells
Competent cells were purchased from Stratagene: XLl-Blue competent cells were 
used for plasmid DNA and XL 10-Gold ultra-competent cells for ligation products. 
Transformation of cells was achieved by mixing either lOOng plasmid DNA or 2pl of 
ligation reaction with 1 OOpil of freshly thawed competent cells and heat-pulsing at 
42°C for 45s, followed by 2min incubation on ice. Cells were allowed to recover by 
adding 0.9ml of NZY1’ broth (per litre of LB: lOg tryptone, 5g yeast extract, lOg 
NaCl made up to 11 with ddftO, pH 7.5 and autoclaved. For NZY^ broth, LB was 
supplemented with a final concentration of 125mM MgCh, 125mM MgSC>4 and 
20mM sterile glucose). Cells were shaken for lh at 37°C at 220rpm then spread on 
agar plates containing lOOpg/ml ampicillin. Per litre LB: 20g agar was added, pH 7, 
and autoclaved. Filter-sterilised ampicillin was added to cooled LB-agar at a final 
concentration of 100jig/ml, prior to pouring into plates; plates were incubated 
overnight at 37°C.
2.2.2 Propagation and purification of plasmid DNA
2.2.2.1 Miniprep plasmid purification
This procedure was used predominantly to screen bacterial colonies for recombinant 
DNA plasmids. 5ml LB supplemented with ampicillin (100pg/ml), inoculated with a 
single colony isolated from a freshly streaked ampicillin plate, was incubated with 
shaking at 37°C overnight and cells harvested by centrifugation at 4000g for 5min. 
The cell pellet was further processed using a QIAprep® Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions.
2.2.2.2 Maxiprep plasmid purification
This method was applied to produce plasmid DNA which was predominantly used 
for transfections. A 5ml starter culture was inoculated with a single colony isolated 
from a freshly streaked agar plate (containing lOOjig/ml ampicillin) and incubated 
with shaking for 8h at 37 °C. The starter culture was used to inoculate a 200ml
75
Chapter 2 Materials and Methods
culture and incubated overnight at 37°C with shaking. Cells were harvested by 
centrifugation at 10,000g for 15min at 4°C. Pelleted cells were further processed 
using a QIAfilter TM Plasmid Maxi Kit (Qiagen) according to the manufacturer’s 
instructions. Purified plasmid DNA was suitable for downstream applications, such 
as DNA sequencing, in vitro transcription/translation or transfection experiments.
2.2.2.3 Determination of DNA concentration
DNA concentration was determined spectrophotometrically by measuring OD at 
260nm. Concentration was then calculated from the equation:
Aod260 x50 xdilution factor = concentration of double stranded DNA (fig/ml)
2.2.3 Plasmid Constructs
2.2.3.1 Generation of point mutations by site-directed mutagenesis
Point mutations were generated by site directed mutagenesis using the 
QuikChange™ Site Directed Mutagenesis Kit (Stratagene) according to the 
manufacturer’s instructions. Primers containing the desired mutation were used in a 
PCR reaction to generate nicked circular plasmid DNA bearing the desired mutation. 
PCR reactions were performed as described in Section 2.2.1.1, using a range of 
plasmid concentrations (5, 10, 20, 50ng of plasmid DNA template). Following 
amplification, the parental methylated DNA was digested with 10U of Dpn I for lh 
at 37°C. After digestion with Dpn I, lpl of the PCR reaction was used to transform 
Epicurian Coli® XLl-Blue supercompetent cells (Stratagene). Transformed cells 
were then selected on agar plates containing lOOpg/ml ampicillin. Plasmid DNA 
was purified from colonies (Section 2.2.2.1) and sequenced.
2.2.3.2 Construction of rapamycin resistant mTOR mutants
Wildtype mTOR in N-terminal FLAG-tagged PBJ5.1 (Peterson et al., 2000) was first 
digested with SacI which cleaves within the coding sequence of mTOR. This
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removed a 3.8Kb fragment to create a smaller wildtype mTOR plasmid termed 
AmTOR (~8Kb) to improve efficiency of mutagenesis. A series of point mutations 
were generated within the AmTOR construct to convert each of the following sites: 
S2442; T2446 and S2448 into either alanine or glutamic acid. The aim was to 
reconstitute the point mutations into a rapamycin resistant (S2035T) sequence rather 
than the wild-type sequence. Each AmTOR construct containing a point mutated 
sequence was digested with Notl and BspEI. Full length mTOR containing the 
rapamycin resistant S2035T mutation (termed Ml) was also digested with Notl and 
BspEI and the fragment containing the rapamycin resistance mutation was ligated 
into ATOR in place of the wild-type sequence (Fig. 2.1). The accuracy of the 
mutations was verified by DNA sequencing.
2.2.3.3 Construction of GST-mTOR-HEAT chimera
The region between amino acids 668 and 939 of the mTOR sequence corresponding 
to the HEAT domain was amplified by PCR to incorporate a 5’ EcoRI site and a 3’ 
Xhol restriction site. The HEAT-mTOR fragment and the pGEX4T-l vector 
(Pharmacia) were digested with EcoRI and Xhol, then separated and purified from a 
1% agarose gel. The HEAT-mTOR fragment was ligated into pGEX4T-l and the 
accuracy of construction was verified by DNA sequencing.
2.2.3.4 Construction of His-tag a4 chimera
a4 construct in pUC18 (Inui et al., 1995) was cloned into a modified pTri-ex vector 
(Novagen), cloning out the a4 STOP codon to incorporate the pTri-ex HSV and His 
tag at the C-terminus. Positive clones were selected and sequenced; a correct clone 
was selected to transform XL-1 blue bacterial cells in an attempt to produce 
recombinant a4.
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Figure 2.1 Schematic representation of the construction of mTOR rapamycin 
resistant mutants
Wildtype FLAG-tagged mTOR in pBJ5.1 was mutated at sites S2442, T2446 and 
S2448 into A or E, then reconstituted to full length with the rapamycin resistant 
mutant as detailed in the figure above and described in the text. ‘Rap11’ denotes 
rapamycin resistance and ‘wt’ denotes wild-type.
78
Chapter 2 Materials and Methods
2.2.4 Cell Culture
All procedures were carried out in a laminar flow hood using aseptic technique. All 
surfaces were disinfected with 70% ethanol before and after any manipulation. 
Medium for mammalian cell culture was pre-warmed to 37°C before use.
2.2.4.1 Cryo-preservation of cells
80% confluent cell monolayers were trypsinised and 10ml of culture medium 
containing 10% foetal calf serum (FCS) was added. The cell suspensions were 
transferred to a sterile 15ml tube and spun at 150g for 5min at 4°C. The supernatant 
was aspirated and the cell pellet re-suspended in ice-cold freezing medium (culture 
medium containing 20% FCS and 10% DMSO). 1ml aliquots of the suspension were 
transferred to sterile cryo-vials, which were frozen slowly in an insulated polystyrene 
box at -80°C overnight. The following day, cells were transferred to liquid nitrogen 
for long-term storage.
2.2.4.1.1 To revive frozen cells
Aliquots were removed from storage and thawed quickly in a 37°C water bath before 
transfer to a tissue culture flask containing pre-warmed culture medium (containing 
10% FCS). Following overnight incubation in a 37°C humidified incubator with 5% 
CO2 , the medium was changed to remove traces of the cryo-preservation medium.
2.2.4.2 Mammalian cell culture
2.2.4.2.1 Maintenance of HEK 293, MEFs and CHO-IR cells
Human embryonic kidney (HEK 293) and control mouse embryonic fibroblasts 
(MEFs) [p53+/+ TSC2+/+] and TSC2'/- cells [p53v‘ TSC2'A] were cultured in 
Dulbecco’s Modified Eagle’s Essential Medium (DMEM) and Chinese hamster ovary 
cells stably expressing the human insulin receptor (CHO-IR) cells were cultured in 
nutrient medium FI2 (Ham). Medium was supplemented with 10% fetal calf serum
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and 1% antibiotic-antimycotic solution (lOOx: 10,000U/ml penicillin, lOmg/ml 
streptomycin sulfate, 25pg/ml amphotericin B); this will be referred to as complete 
media. Cells were grown at 37°C in a humidified incubator with 5% CO2 . For 
further propagation, cells were trypsynised when 80-90% confluent; culture medium 
was removed and the monolayer briefly rinsed with phosphate buffered saline (PBS) 
(without calcium or magnesium). Trypsin/EDTA solution was added to just cover 
the monolayer then incubated at 37°C for 2min. The culture vessel was tapped 
gently to dislodge cells, which were then re-suspended in medium and plated at a 
density of approximately 60% of confluence.
2.2.4.2.2 Calcium Phosphate transfection
HEK 293 cells were transfected using the calcium phosphate precipitation method 
(Invitrogen). Briefly, the medium was changed lh prior to transfection to remove 
traces of trypsin. For co-transfections: 5pg of mTOR and 3pg of S6K1 or 5pg of 
mTOR and 5pg 4E-BP1 plasmid DNA were co-transfected per 6cm tissue culture 
dish; or lOpg mTOR plasmid DNA was transfected per 10cm tissue culture dish as 
indicated. 500pl 2X HBS (280mM NaCl, 50mM HEPES, 750mM NaH2P04, 
750mM Na2HP0 4 , pH 7.0) was added to a solution containing plasmid DNA and 
200mM CaCl2, in 500jnl ddH20. The mix was left to stand for 30min at room 
temperature to form the precipitate. The precipitate was added drop-wise to the cell 
monolayer. Following an 18h incubation in a 37°C incubator maintained with 5% 
C02, the cells were washed twice with PBS (without calcium or magnesium) and 
fresh complete medium was added. Protein expression of the transfected DNA was 
found to be optimal if cells were allowed to recover in this medium for 24h.
2.2.4.2.3 LipofectAmine transfection
CHO-IR cells were transfected using LipofectAMINE (Invitrogen). Briefly, 90% 
confluent CHO-IR cells were trypsinised and re-plated at a dilution of 1:10 in 6cm 
plates and grown overnight. Cell monolayers were rinsed the following day with 
PBS and 2ml fresh F12 medium (without FCS) was added. For co-transfections, 5pg 
of mTOR and 3pg of S6K1, or 5pg of mTOR and 5pg 4E-BPlplasmid DNA (per
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6cm tissue culture dish) and 5-1 Opl LipofectAMINE reagent were each diluted in 
250|il F12 medium (without FCS). The media containing DNA and LipofectAMINE 
were mixed together (500pl total) and following a 30min incubation at room 
temperature, the mix was added dropwise to the monolayer. Cells were incubated 
with transfection mixture for 5 hours before the addition of 2.5ml F12 containing 
20% FCS and 1% antibiotic-antimycotic solution (final 10% serum including 
transfection mix). Cells were incubated overnight in a 37°C incubator maintained 
with 5% CO2, then washed twice with PBS (without calcium or magnesium) and 
complete medium was added as required. Protein expression from the transfected 
plasmids was found to be optimal 36h post-transfection, as determined by 
transfection with green fluorescent protein (GFP).
2.2.5 Large scale protein purification
2.2.5.1 Ribosomal purification
Six littermate rats, each weighted at 200-220g, were obtained and maintained at UCL 
Animal House. These were starved for 24 hours with water only, then anaesthetized 
by subcutaneous injection with Pentobarbitol 35mg/kg, prior to liver extraction. The 
livers were extracted and washed several times in ice-cold buffer A (20mM Tris- 
HC1, lOOmM KC1, 5mM MgCl2 ImM DTT, 200mM sucrose with a cocktail of 
protease inhibitors), weighed, then homogenised with a Teflon homogeniser in 2x 
weight volumes of buffer A. The homogenate was centrifuged at 10,000g for 30min 
at 4°C in a Sorvall centrifuge. The supematent was centrifuged at 10,000g for 15min 
at 4°C then filtered through a nylon membrane before application to a sucrose 
gradient.
Six Ti45 tubes were used to prepare discontinuous sucrose gradients comprising 
10ml buffer B (buffer A with 1.6M sucrose and 0.5M KC1), overlaid with 10ml 
buffer C (buffer A with 0.7M sucrose). These gradients were topped with the filtered 
liver extracts and balanced weight for weight to within 0.0 lg for ultracentrifugation 
at 38,000g overnight at 4°C in a Beckman ultracentrifuge with a Ti45 rotor.
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Supematents were aspirated and the pellets re-suspended in a total of 5ml buffer D 
(buffer A with 0.5M KC1) then incubated at 37°C for 30min, after which 0.65 
volumes of ethanol and a final concentration of lOmM MgCh was added. This was 
centrifuged at 15,000g for 2min at room temperature. The buffer D wash and 
centrifugation step was repeated and the pellet re-suspended in buffer E (buffer A 
with 0.7M KC1 and 2mM puromycin) then incubated at 37°C for 30min, after which 
0.65 volumes of ethanol was added and centrifuged at 13,000g for 2min at room 
temperature. The pellet was re-suspended in buffer E without puromycin then 
incubated at 37°C for 30min, after which 0.65 volumes of ethanol was added and 
centrifuged at 13,000g for 2min at room temperature. The pellet was then re­
suspended in storage buffer (20mM MOPS, ImM EGTA, ImM DTT) and the 
protein concentration measured.
2.2.6 Immunological Methods
2.2.6.1 Generation of mTOR HEAT domain antibodies, phospho- 
specific S2442 and phospho-specific T2446 antibodies
Polyclonal antibody against the HEAT domain of mTOR (as described in Withers et 
al, 1997) was generated by immunising rabbits with a chimeric protein, 
corresponding to the region between amino acids 668 and 939 of the mTOR 
sequence fused to glutathione-S-transferase (GST). Phospho-mTOR S2442 was 
raised in rabbit using the phospho-peptide CGNKRS*(P)RTRT, corresponding to 
amino acids G2438-T2446 and phospho-mTOR T2446 was raised in rabbit using the 
phospho-peptide CSRTRT*(P)DSYS, corresponding to amino acids S2442-S2450 of 
the human mTOR sequence, with *(P) representing the phosphorylated residue. 
Peptides were conjugated to keyhole limpet hemocyanin (KLH) using m- 
maleimidobenzoyl-N-hydroxysuccinimide ester according to protocols described 
elsewhere (Harlow and Lane, 1988). All immunisations were carried out by 
Eurogentec (Belgium).
Total immunoglobulins from the HEAT mTOR antiserum were purified by passing 
through an affinity column made by coupling the GST-mTOR-HEAT chimera to
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Actigel (Sterogene). The flow-through was re-run through the column, and then the 
column was washed twice with PBS (0.5M NaCl) and once with PBS.
Affinity columns for the purification of the phospho-S2442 and phospho-T2446 
antiserum were made by coupling the relative peptides to SulfoLink resin (Pierce) 
according to the manufacturer’s instructions. The antiserum was purified by affinity 
chromatography, first through a column of the corresponding dephospho-peptide to 
remove clones reacting with non-phosphorylated -S2442 or -T2446. The flow­
through was further purified by passing through a second column made of the 
phospho-peptide coupled to SulfoLink. Bound immunoglobulins from both the 
dephospho-peptide (termed dephospho-S2442 or dephospho-T2446 antibodies) and 
phospho-peptide (termed phospho-S2442 or phospho-T2446 antibodies) columns 
were eluted.
In all cases, bound immunoglobulins were eluted with lOOmM glycine pH 2.5, 
150mM NaCl. The eluate was immediately neutralised by addition of 1M Tris pH 
8.0 then concentrated using spin filters and dialysed against PBS. 
Polyethyleneglycol was added at 50% final concentration to the purified antibodies 
and the final preparation was aliquoted and stored at -20°C. The purified antibody 
preparation was characterised by immuno-blotting lysates of cell extracts.
2.2.6.2 Expression and purification of GST fusion proteins
pGEX4T-l plasmid containing the region between amino acids 668 and 939 of the 
mTOR sequence was constructed as described above. The construct was used to 
transform competent E.coli XL 1-Blue cells. After selection on ampicillin-containing 
agar plates, a single colony was used to inoculate a 5ml starter culture in LB medium 
containing lOOpg/ml ampicillin. This was grown overnight with shaking at 37°C 
and the next day used to inoculate a 500ml culture in LB medium supplemented with 
lOOpg/ml ampicillin. The culture was grown at 37°C with shaking until it reached an 
A od600 of 0.6. Expression of the plasmid was induced by addition of IPTG to a final 
concentration of 0.2mM, followed by incubation overnight at 20°C with shaking. 
Bacterial cells were pelleted at 10,000g, 4°C, for 10 minutes. Pelleted cells were
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resuspended in 10 volumes (v/w cell pellet) ice-cold lysis buffer (50mM Tris-HCl 
pH 7.5, 1% Triton X-100 and ImM PMSF). The suspension was sonicated on ice by 
applying five rounds of 10s pulses, with 10s intervals between pulses. The lysate 
was centrifuged at 10,000g for 15 minutes to remove cell debris. Protein was 
isolated from the lysate by rotating with Glutathione-Sepharose 4B (Pharmacia) in a 
15ml Falcon tube at 4°C. Sepharose beads with bound GST fusion proteins were 
washed three times in lysis buffer, followed by three washes with 50mM Tris-HCl 
pH 8.0 and then bound GST fusion proteins were eluted by incubating with lOmM 
reduced glutathione. The eluate was concentrated using Vivaspin-20 filters 
(Sartorius), dialysed three times against PBS, aliquoted then snap-frozen in liquid 
nitrogen and stored at -80°C.
2.2.6.3 Protein Assay
Determination of protein concentration was performed using the BCA method 
(Pierce) according to the manufacturer’s instructions. BSA was used as a standard.
2.2.6.4 Immunoprecipitation
Cell monolayers were washed once with ice cold D-PBS and lysed at 4°C in lysis 
buffer A [50 mM Tris/HCl (pH 8.0), 120 mM NaCl, 20mM NaF, 20mM P- 
glycerophosphate, ImM EDTA, 6mM EGTA, 1% (v/v) NP40, ImM DTT, 5mM 
benzamidine, ImM PMSF, 0.25mM Na3VC>4 , 2pg/ml aprotinin, lpg/ml pepstatin, 
lpg/ml leupeptin]. 0.5ml of lysis buffer was used per 10cm dish, 0.3ml of lysis 
buffer was used per 6cm dish. Lysates were clarified from insoluble material by 
centrifugation at 14,000g for lOmin at 4°C. Immunoprecipitations were performed 
from the detergent-soluble fraction using the indicated antibodies at the appropriate 
dilution. Lysates were incubated with the antibody for 2h at 4°C under rotation 
followed by the addition of protein A- or protein G-agarose beads (30pi of 1:2 
slurry), then incubated for a further 45min under rotation. Immune complexes were 
washed three times with “high salt” buffer, followed by washes with kinase assay 
buffer and further processed as described for each assay.
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2.2.6.5 Tris-glycine-SDS-polyacrylamide gel electrophoresis
SDS-polyacrylamide gel electrophoresis was performed according to the method of 
Laemmli (Laemmli, 1970). Vertical slab gels were prepared using either a Hoeffer 
gel apparatus or BioRad mini gel apparatus. Samples were denatured by addition of 
electrophoresis sample buffer (4x concentrated: 50% glycerol, 10% SDS, 500mM 
DTT, 500mM Tris-HCl pH 6.8) and heating at 95°C for 5min. Electrophoresis was 
performed under constant voltage of 200V for 3 hours in the Hoeffer gel system or 
150V for 90min for the BioRad apparatus. Gels were then either processed for 
Western blotting, stained with Coomassie blue or fixed, dried and exposed to 
autoradiographic film.
2.2.6.6 Tris-tricine-SDS-polyacrylamide gel electrophoresis
This system is suitable for resolving polypeptides in the range from 5 to 20 kDa. This 
is achieved by use of tricine rather than glycine in the electrophoresis buffer, and 
lowering the pH of the gel. Here, it was used for the electrophoretic analysis of low 
molecular weight proteins or peptides. Gels were prepared according to the method 
of Schagger and von Jagow (Schagger and Jagow, 1987). The BioRad mini gel 
apparatus was used. 15% resolving gels were made up containing 12% glycerol, 15% 
acrylamide-0.5% bisacrylamide, 0.3% SDS, 0.1% ammonium persulphate, 0.2% 
TEMED in 0.125M Tris-HCl pH 8.45. Stacking gels were made to a final 
concentration of 4% acrylamide in 0.1M Tris-HCl pH 8.45, 0.1% ammonium 
persulphate, 0.05% TEMED. The anode buffer consisted of 200mM Tris-HCl pH 8.9 
and the cathode buffer of lOOmM Tris, lOOmM Tricine and 0.1% SDS. 
Electrophoresis was performed under constant voltage of 80V. Following 
electrophoresis the gels were processed for western blotting, stained with Coomassie 
or fixed, dried and exposed to a phosphorimager screen.
2.2.6.7 Coomassie staining of acrylamide gels
Following electrophoresis, the gel was submerged in a solution of 40% (v/v) 
methanol, 10% (v/v) acetic acid, 0.3% (w/v) Coomassie brilliant blue R250 and
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incubated under constant agitation for lh at room temperature. Protein bands were 
visualised by washing the gel in destaining solution (20% (v/v) methanol, 10% (v/v) 
glacial acetic acid). Several changes of the destaining solution were required to 
completely destain the background.
2.2.6.8 Autoradiographic exposure of acrylamide gels
Following electrophoresis, the gel was submerged in fixing solution (20% (v/v) 
ethanol, 10% (v/v) glacial acetic acid) and incubated under constant agitation for lh 
at room temperature in order to fix proteins into the gel. The gel was dried under 
vacuum then exposed to a phosphorimager screen. Images of radiolabelled protein 
bands were acquired using a Fuji FLA-2000 phosphorimager and analysed with Fuji 
Image Gauge software.
2.2.6.9 Western blotting and immunodetection of transferred 
proteins
Proteins separated by electrophoresis, as described in Section 2.2.6.5 and 22.6.6, 
were transferred onto Immobilon-P polyvinylidene fluoride (PVDF) membrane 
(Millipore) using a Bio-Rad Trans-Blot Cell. The membrane was soaked in methanol 
briefly and then rinsed in water for 2min. Both gel and membrane were equilibrated 
in transfer buffer (25mM Tris, 192mM glycine, 20% (v/v) methanol) for 5min. The 
transfer stack was assembled immersed in transfer buffer. To assemble the transfer 
stack a foam pad was placed on one side of the transfer cassette and one sheet of 
3MM filter paper was placed on top. The gel was then placed on top of the filter 
paper and the membrane on top of the gel. One sheet of 3MM filter paper was then 
placed on top of the membrane and a foam pad was put on top of the filter paper to 
complete the stack. The transfer cassette was closed and placed in the transfer tank 
containing transfer buffer such that the gel faced the cathode. The transfer was run at 
20V overnight for large gels or 100V for lhour for small gels. Following transfer to 
PVDF membranes, the membrane was first incubated in blocking buffer (5% (w/v) 
dried skimmed milk in 0.1% (v/v) Tween 20 in phosphate buffered saline (PBS-T)) 
for 1 hour at room temperature to saturate the binding sites on the membrane. For
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immunoblotting using phosphospecific antibodies, bovine serum albumin (BSA) and 
Tris-buffered saline (TBS) substituted the use of skimmed milk and PBS, 
respectively, throughout the procedure.
The primary antibody was then added at the appropriate dilution in 20ml of 1% (w/v) 
dried milk powder in TBS-T and incubated with the membrane on a rocking platform 
at room temperature for lh or at 4°C overnight. The membrane was then washed 
with TBS-T (three times for 5min). The secondary antibody, conjugated to 
horseradish peroxidase (HRP), was diluted at 1:2000 in 20ml of 1% milk in PBS-T 
and incubated with the membrane for 45min at room temperature. The membrane 
was then washed in TBS-T (three times for 5min). Antibody-antigen complexes 
were detected by Enhanced Chemiluminescence (KPL) according to the 
manufacturer’s instructions. Images were captured by a Fuji LAS-1000 Luminescent 
Image Analyser and analysed with Fuji Image Gauge software.
2.2.7 Kinase assays
2.2.7.1 Peptide assays
Confluent CHO-IR cells were serum-starved overnight with FI2 (Ham) containing 
1% antibiotic-antimycotic solution. Cells were stimulated with lOOnM insulin for 
lOmin then lysed in PKB lysis buffer [50mM HEPES, 0.2mM EDTA, 2.2mM 
EGTA, lOOmM KC1, 1% (v/v) Triton X-100, 10% (v/v) glycerol, ImM DTT, 
lOpg/ml aprotinin, lOpg/ml leupeptin, 20nM okadaic acid]. Following lysate 
clarification, supernatants were pooled and equal volumes were immuno-precipitated 
with anti-C-terminal PKB (provided by Dr D. Alessi, Protein Phosphorylation Unit, 
University of Dundee) for 2h. Immuno-complexes were then incubated with Protein 
G-agarose (Santa Cruz) for 45min. Cells stimulated with 1 pM PMA for 10 min were 
lysed as described above then immunoprecipitated with anti-PKC<£ (Santa Cruz) with 
protein A-agarose. Immunoprecipitates were washed and assayed as described in 
(Moule et al., 1997). The reactions with recombinant enzyme (AMPK, S6K1) and 
immunoprecipitates were incubated with ImM peptide (peptides were generated by 
the Wolfson Institute for Biomedical Research (UCL), see Table 3.1), and reactions
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were initiated with: lpM PKI, 20 mM MgCl2, 100 pM unlabelled ATP, 
5(iCi/reaction [y-32P] ATP in assay buffer [20mM MOPS (pH 7.0), ImM EDTA, 
ImM EGTA, 0.01% Triton X-100, 5% (v/v) glycerol] (AMPK samples also 
contained ImM AMP) in a final reaction volume of 30pl. Reactions were incubated 
at 30°C for 15min with agitation then stopped by spotting all the reaction mixture 
onto p81 grade phospho-cellulose paper (Whatman), and washed five times in 75mM 
ortho-phosphoric acid. Papers were dried and transferred to scintillation vials for 
liquid scintillation counting (Beckman).
2.2.7.2 PI 3-kinase lipid kinase assays
Cell extracts were lysed and processed as described in Section 2.2.6.4. p85, Py-99 or 
IRS-1 were used for immunoprecipitations then assayed for PI 3-kinase lipid kinase 
activity. Reactions were performed in a final volume of 50pl in a buffer containing 
50mM HEPES pH 7.4, lOOmM NaCl, ImM DTT, 5mM MgCl2, lOOpM ATP (plus 
0.1 pCi of [y-32P] ATP/assay) using 200pg/ml phosphatidylinositol or 
phosphatidylinositol-4,5-bisphosphate as a substrate. Reactions were initiated by 
adding a mix of the ATP and Mg2+ and incubated at 25 °C for 20min. Reactions were 
terminated by the addition of lOOpl 0.1M HC1. 200pl of a 1:1 (v/v) mixture of 
chloroform and methanol was added. The mixture was vortexed and the phases 
separated by centrifugation at 10,000g for 2min. The aqueous phase was discarded 
and the lower organic phase was washed with 80pl of a 1:1 (v/v) mixture of 
methanol and 1M HC1. After centrifugation at 10,000g for 2min, the aqueous phase 
was discarded and the lower organic phase was vacuum dried. The dried lipids were 
re-suspended in 30pl of chloroform: methanol (4:1) and spotted on to thin layer 
Silica Gel-60 plates (Merck), pre-treated with 1% oxalic acid, ImM EDTA in water: 
methanol (6:4). TLC plates were developed in chloroform: methanol: 4M ammonia 
(9:7:4) for analysis of phosphatidylinositol-3-phosphate; or n-propanol: 2M acetic 
acid (13: 7) for analysis of phosphatidylinositol-3,4,5-trisphosphate. After 
completion of the separation, the plates were dried and exposed to phosphorimager 
film. Images of radio-labelled lipid products were acquired using a Fuji FLA-2000 
phosphorimager and analysed with Fuji Image Gauge software.
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2.2.7.3 mTOR autokinase assay
Cells were lysed in lysis buffer containing lOmM Tris-HCl pH 7.6, 5mM EDTA, 
50mM NaCl, 50mM NaF, 30mM sodium pyrophosphate, 1% NP40, lOOpM sodium 
vanadate, ImM PMSF, lOpg/ml aprotinin and lOpg/ml leupeptin. Lysates were 
immunoprecipitated with mTOR antibody as specified then washed four times with 
lysis buffer, once with wash buffer [0.5M LiCl, 50mM Tris pH 7.6 and ImM DTT] 
and then once with reaction buffer [25mM HEPES pH 7.7, 50mM KC1, lOmM 
MgCh, 0.1% NP40, 20% glycerol, ImM DTT]. Reactions were initiated by the 
addition of lOOpM ATP plus 0.3 pCi/reaction [y-32P] ATP in assay buffer in a final 
reaction volume of 30pl. Reactions were incubated at 30°C for 30min with agitation 
and stopped with lOpl 4x sample buffer then separated by 7.5% SDS-PAGE. The 
gel was fixed, dried and exposed to phosphorimager film. Images were acquired 
using a Fuji FLA-2000 phosphorimager and analysed with Fuji Image Gauge 
software.
2.2.7.4 S6K1 assay
Cells were lysed as described in Section 2.2.6.4. 50% of the lysate was used to 
immunoprecipitate transfected S6K1 with Glu-Glu antibody. The 
immunoprecipitates were washed twice in lysis buffer A (Section 2.2.6.4) containing 
0.5M NaCl and three times with 20mM MOPS (pH 7.4), lOmM P-glycerophosphate, 
ImM DTT and ImM PMSF. 20pg of 80S ribosomes were added to each 
immunoprecipitate and mixed gently. Reactions were initiated by the addition of 
2.5 pM PKI, 50mM MgCl2, lOpM ATP plus 0.3pCi/reaction [y-32P] ATP in assay 
buffer [50mM MOPS (pH 7.4), 2mM EGTA, lOmM p-glycerophosphate and ImM 
DTT] in a final reaction volume of 30pl. Reactions were incubated at 30°C for 
30min with agitation then stopped by addition of 4x sample buffer; samples were 
then boiled at 95°C for 5min and proteins were separated by 10% SDS-PAGE. The 
gel was cut at the 46kDa marker, the upper half containing 70kDa S6K1 was 
transferred to PVDF membrane to blot total S6K and the lower half was fixed, dried 
and exposed to a phosphorimager screen. Images of radiolabelled protein bands
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were acquired using a Fuji FLA-2000 phosphorimager and analysed with Fuji Image 
Gauge software. Activity was normalised to total S6K determined by immuno-blot.
2.2.7.5 4E-BP1 assay
Two methods were used for comparison (Brunn et ah, 1997a; Mothe-Satney et al., 
2000a).
The first method was as described in Brunn et ah, (1997a). Briefly, cells were lysed 
in lysis buffer containing 50mM P-glycerophosphate, 1.5mM EGTA, 1% Triton X- 
100, ImM DTT, 20nM okadaic acid, 0.2mM PMSF, 5pg/ml aprotinin, 5pg/ml 
pepstatin and lOpg/ml leupeptin. mTOR was immunoprecipitated then washed twice 
with TGN buffer [50mM Tris-HCl, 50mM p-glycerophosphate, lOOmM NaCl, 10% 
glycerol, 20nM okadaic acid, 5pg/ml aprotinin, 5pg/ml pepstatin and lOpg/ml 
leupeptin, 600pM PMSF], once with high salt buffer [lOOmM Tris-HCl pH 7.4, 
500mM LiCl] then twice with kinase buffer [lOmM HEPES pH 7.4, 50mM P- 
glycerophosphate, 50mM NaCl, 20nM okadaic acid, 5pg/ml aprotinin, 5pg/ml 
pepstatin and lOpg/ml leupeptin, 600pM PMSF]. The reaction was started with 
kinase assay buffer containing lOmM MnCL, 200pM ATP plus 0.3 pCi/reaction [y- 
32P] ATP and 0.5pg recombinant 4E-BP1 (purchased from Upstate Biotechnology) 
in a final reaction volume of 30pl. The reaction was incubated at 30°C for 30min 
with agitation and stopped with lOpl 4x sample buffer, then separated by 12% 
tris/tricine SDS-PAGE. The gel was fixed, dried and exposed to a phosphorimager 
screen.
The second method was as described in Mothe-Satney et al., (2000a). Briefly, cell 
monolayers were rinsed twice in buffer 1 [150mM NaCl, 50mM Tris-HCl pH 7.4], 
then lysed in lysis buffer 2 [50mM NaF, ImM EDTA, ImM EGTA, 0.5% Triton X- 
100, lOmM potassium phosphate , 50mM p-glycerophosphate, 2.5mM MgCl2 , ImM 
DTT, lOnM okadaic acid, 0.5mM PMSF, lOpg/ml aprotinin, lOpg/ml pepstatin]. 
mTOR was immunoprecipitated then washed twice with buffer 2, twice with buffer 2 
[containing 0.5M NaCl], twice with buffer 3 [ImM EDTA, ImM EGTA, 50mM 
Tris-HCl pH 7.4] and twice with buffer 4 [50mM NaCl, O.lmM EGTA, ImM DTT, 
20nM okadaic acid, lOmM HEPES, 50mM P-glycerophosphate]. The reaction was
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started with kinase assay buffer containing lOmM MnCh, lOOpM ATP plus 
0.6 pCi/reaction [y-32P] ATP and 0.5 pg recombinant 4E-BP1 (purchased from 
Upstate Biotechnology) in a final reaction volume of 30pl. The reaction was 
incubated at 30°C for 30min with agitation then stopped with lOpl 4x sample buffer 
and separated by 12% tris/tricine SDS-PAGE. The gel was fixed, dried and exposed 
to a phosphorimager screen.
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3 Identification and characterisation of 
a novel mTOR phosphorylation site
3.1 Summary
A key regulator of translation is the mammalian target of rapamycin (mTOR) which 
is dually regulated by growth factors and nutrient availability. A previous study 
from this lab, subsequently confirmed by others, identified S2448 as a nutrient 
regulated phosphorylation site located at the C-terminus of the mTOR catalytic 
domain. Studies have shown that insulin stimulated phosphorylation of S2448 via 
PKB and phosphorylation was abrogated by nutrient deprivation. Here, a novel 
nutrient responsive mTOR phosphorylation site was identified at T2446. In contrast 
to S2448 phosphorylation; T2446 is de-phosphorylated when CHO-IR cells are 
insulin stimulated and phosphorylated when cells are nutrient deprived. Similarly, 
the AMP-activated kinase (AMPK) is activated under conditions of nutrient 
deprivation and was hypothesised to be involved in the regulation of T2446 
phosphorylation. Subsequent studies in cultured murine myotubes treated with 5’- 
aminoimidazole-4-carboxamide ribonucleoside (AICAR) or di-nitrophenol (DNP) 
showed activation of AMPK and a concomitant increase in mTOR T2446 
phosphorylation, paralleled by a decrease in S6K1 phosphorylation. In vitro kinase 
assays were employed to assess which kinases were capable of phosphorylating 
mTOR peptides based on the sequence of amino acids 2440-2551, this incorporating 
both the T2446 and S2448 phosphorylation sites. Data showed that both PKB and 
AMPK are able to differentially phosphorylate sites in this region, PKB 
phosphorylation of the phospho-mimic T2446E peptide was restricted. Conversely, 
AMPK mediated phosphorylation was reduced with the phospho-S2448 peptide. 
Interestingly PKC£ mediated phosphorylation was completely inhibited with the 
S2448A and phospho-S2448 peptide. These data suggest that T2446 and S2448 
phosphorylation is mutually exclusive and their differential phosphorylation may be
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a mechanism to integrate signals from growth factors and nutrient status to control 
the regulation of protein translation.
3.2 Introduction
Though the domains of mTOR have been defined and interacting proteins, such as 
Raptor, have been identified it remains unclear exactly how these factors interact and 
how mTOR itself is regulated. A region of mTOR which is of regulatory interest is 
the catalytic domain at the C-terminus. The antibody mTAbl is directed to the C- 
terminus of mTOR (residues 2433-2450) (Brunn et al., 1997b) and can bind to and 
activate mTOR protein kinase activity towards 4E-BP1; additionally deletion of the 
C-terminus residues 2430-2450 significantly increases the basal protein activity 
(Sekulic et al., 2000). PKB was found to directly phosphorylate the C-terminus of 
mTOR suggesting regulatory importance (Burgering and Coffer, 1995; Gingras et 
al., 1998; Scott et al., 1998). Nave et al., (1999) and subsequently others (Bolster et 
al., 2002; Reynolds et al., 2002; Sekulic et al., 2000) developed a phospho-specific 
antibody that identified S2448 as a phosphorylation site in mTOR. Phosphorylation 
at S2448 was mediated by PKB and confirmed to be wortmannin-sensitive but 
rapamycin-insensitive (Nave et al., 1999). Phosphorylation of S2448 increased with 
insulin stimulation and was directly related to amino acid availability and regulated 
by amino acid status (Nave et al., 1999; Reynolds et al., 2002). Evidence also shows 
that mTOR can act independently of amino acid availability by responding as a 
sensor of cellular ATP levels (Dennis et al., 2001). More recently it has been 
suggested that the nutrient effect on mTOR might be via AMPK which is a well 
established energy sensing/signalling protein that is responsive to the ATP/AMP 
ratio of the cell (Hardie et al., 1998). Increasing cellular AMP activates AMPK 
allosterically by phosphorylation of the a-catalytic subunit (T172) by AMPK-kinase 
(AMPKK) which leads to preservation of ATP levels by increasing glucose uptake 
and fatty acid oxidation (Hardie et al., 1998). It has been shown that the AMPK 
activator AICAR significantly decreased skeletal muscle protein synthesis via 4E- 
BP1 and S6K1: both downstream targets of mTOR. These events were accompanied 
by down-regulation of PKB activity and subsequently S2448 phosphorylation 
(Bolster et al., 2002). mTOR S2448 phosphorylation is hypothesised to be a positive
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regulatory site since phosphorylation is mediated by mitogenic stimuli (Bolster et 
al., 2002; Nave et al., 1999; Reynolds et al., 2002; Sekulic et al., 2000) which results 
in increased protein synthesis. Since activation of AMPK results in reduced 
signalling through mTOR and its downstream targets (Bolster et al., 2002; Kimura 
et al., 2003), S2448 phosphorylation might be important for controlling the activity 
and function of mTOR and the energy sensing protein AMPK may play a role in this 
process.
The attenuation of S2448 phosphorylation by nutrient deprivation (Nave et al., 1999) 
raised the possibility that this may be due to phosphorylation of an adjacent site 
which prevented insulin stimulated phosphorylation via PKB. We hypothesised that 
the vicinity of S2448 had potential to include other regulatory phosphorylation 
events since the catalytic domain of mTOR which contains S2448 is 100% conserved 
in all mammalian sequences for mTOR. Scansite analysis (Obenauer et al., 2003) 
showed that this region contained a number of serine (S) and threonine (T) residues 
which may be phosphorylation sites. The most evident site of interest was T2446 
which not only overlapped the S2448 site but had a loose consensus to the 
PKB phosphorylation motif R-X-R-Y-Z-S/T-hvd: where X is any small amino acid, 
Y and Z are any amino acid and ‘hyd’ is a hydrophobic amino acid (Alessi et al., 
1996). Another proximal site of interest was S2442 which is in a SXXR motif that is 
recognised by human interferon induced double stranded RNA activated protein 
kinase (PKR), a member of a family of structurally related ser/thr kinases that have 
effects on protein translation via S51 phosphorylation of eIF2a. PKR is a negative 
regulator of cell growth, activated by human interferon and viral double-stranded 
RNA (Proud, 1995) and although S2442 falls in a PKR motif, studies show that 
recognition of S51 in eIF2a is determined by flanking sequences (Kawagishi- 
Kobayashi et al., 1997) which are not present in the mTOR sequence. Nevertheless 
S2442 was of interest because members of the same enzyme family are regulated by 
availability of a limiting factor e.g. haem regulated eIF2a kinase (HRI) and the yeast 
general control nondepressible 2 enzyme (GCN2) which are regulated by levels of 
haem and amino acids respectively (Wek, 1994).
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In this study, we investigated whether S2442 and T2446 were in vivo 
phosphorylation sites. There was no evidence that S2442 was phosphorylated in vivo 
with the reagents generated; however, we identified T2446 to be a novel mTOR 
phosphorylation site. T2446 phosphorylation is attenuated by growth factor 
stimulation and activated by amino acid deprivation and factors which also activate 
AMPK. Further evidence is provided that phosphorylation at T2446 and S2448 are 
mutually exclusive, indicating that these sites may act antagonistically to integrate 
the counteracting signals of growth factors and nutrient deprivation.
3.3 Results
3.3.1 Characterisation of mTOR antibody
Total mTOR protein blots were performed with R27, an antiserum produced by 
Withers et al., (1997) against residues 668-939 of mTOR incorporating the HEAT 
domain of mTOR. A new polyclonal mTOR antibody was raised against the same 
region as described by Withers et al., (1997) and affinity purified as described in 
Materials and Methods (Section 2.2.6.1). The purified antibody was tested against 
FLAG immunoprecipitates of mTOR (from HEK cells transfected with FLAG- 
tagged wild-type mTOR) and HEK whole cell lysate. The new antibody reacted with 
an identical band at the correct molecular weight as the existing mTOR antibody 
(R27) (Fig. 3.1 A). The new mTOR antibody was identified as ‘total mTOR’ and was 
used in subsequent experiments. The new total mTOR antibody was further tested 
with another cell line. Min6 (a mouse P-cell line) whole cell lysates were blotted 
with various mTOR antibodies which were specific to different regions of mTOR 
(Fig. 3.IB). The antibodies included:- ‘total mTOR’ (Fig. 3.1 A); R27 antibody 
(Withers et al.9 1997); aTOR, raised against the C-terminal portion of mTOR 
(residues 2433-2450) (Heesom and Denton, 1999); hTOR, a mouse monoclonal 
antibody raised against a peptide corresponding to residues 230-240 of human 
mTOR (Hosoi et al., 1998) (Oncogene); de-phospho-T2446 antibody (eluted from 
the fraction of immunoglobulin retained from the de-phospho peptide column during 
phospho-T2446 antibody purification - see Materials and Methods, Section 2.2.6.1) 
and de-phospho-S2448 antibody, eluted from the de-phospho peptide column during
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phospho-S2448 purification from Nave et al., (1998). hTOR did not react with a 
band corresponding to mTOR which may be due to lack of sensitivity. Although the 
cell line was derived from mouse, the hTOR antibody is raised to a region (residues 
230-240) conserved between human and mouse. Total mTOR, R27 and aTOR all 
identified a doublet corresponding to mTOR from the Min6 cell line; interestingly 
de-phospho-T2446 antibody reacted to the lower band of the doublet while de- 
phospho-S2448 reacted to the upper band of the doublet. The mTOR doublet 
identified by the various antibodies suggests that mTOR may have in vivo 
modifications which cause different migrating forms.
3.3.2 Characterisation of phospho-T2446 and phospho- 
S2442 mTOR antibody
Based on the hypothesis that S2442 and T2446 are potential phosphorylation sites 
adjacent to the existing mTOR S2448 phosphorylation site antisera were generated to 
specific phospho-peptides containing phosphorylation at the S2442 or T2446 site. 
The phospho-T2446 and phospho-S2442 antibody were affinity purified as described 
in Materials and Methods (Section 2.2.6.1) and used to study the in vivo 
phosphorylation states of T2446 and S2442 in CHO-IR cell lysates which had been 
nutrient fed or deprived. The phospho-T2446 antibody reacted with a band which 
showed differential reactivity to the nutrient status of the cell and was the same size 
as that detected by total mTOR; reactivity of phospho-T2446 was fully competed by 
the corresponding phospho-peptide (Fig. 3.2A). The phospho-S2442 antibody 
detected no signal from the membrane despite confirming the presence of mTOR 
with total mTOR antibody (Fig. 3.2B). CHO-IR and HEK cell lysates from different 
treatments were subsequently used to test the phospho-S2442 antibody in western 
blots though no signal was detected despite being able to blot total mTOR protein 
(data not shown). It is possible that S2442 is not phosphorylated in vivo or that 
functional antiserum was not produced. For this reason use of the phospho-S2442 
antibody was abandoned.
97
Chapter 3 Results
IB: Blotting antibody:
mTOR Existing mTOR (R27) 1:500
FLAG iP HEK lysate
mTOR Purified total mTOR 1:50
FLAG IP HEK lysate
B
IB:
■"* " *  Total mTOR
Blotting Total R27 aTOR De-phos De-phos
Antibody: mTOR mTOR T2446 S2448
Figure 3.1 Characterisation of mTOR antibody
(A) HEK cells were transfected with wildtype mTOR using the calcium phosphate 
method. Cells were lysed and immunoprecipitated with the FLAG-tag antibody. 
Immunoprecipitates and cell lysate were subjected to SDS-PAGE then wet 
transferred and probed first with the existing mTOR antibody (termed R27), then 
stripped and re-probed with the newly developed and purified ‘total mTOR’ 
antibody. Dilution of the antibody is as indicated.
(B) Min 6 cell whole cell lysates were separated by SDS/PAGE, wet transferred to 
PVDF then probed with various mTOR antibodies, including total mTOR, R27, 
aTOR antibody, hTOR (Oncogene), dephospho T2446 and dephospho S2448 
antibody. ‘De-phos’ denotes dephospho antibody and ‘IB’ denotes immuno-blot.
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Figure 3.2 Characterisation of phospho-T2446 and phospho-S2442 mTOR 
antibody
CHO-IR cells were fed with F I2 (Ham) supplemented with 10% fetal calf serum or 
nutrient starved in D-PBS for lhr then lysed. Lysates were separated by SDS/PAGE, 
wet transferred to PVDF then probed with: (A) purified phospho-T2446 and; (B) 
phospho-S2442 mTOR antibody or the equivalent antibody pre-blocked with ImM 
of the relevant phospho-peptide, all in 1% BSA in TBS/0.01% Tween20. The same 
blots were then stripped and re-probed for total mTOR as shown. Lanes are in 
duplicate.
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3.3.3 An inverse relationship exists between 
phosphorylation of T2446 and S2448 on mTOR
It was previously shown that nutrient deprivation caused a time-dependent decrease 
in phosphorylation of S2448 in HEK293 cells, as shown by reduced reactivity of 
mTOR to a phospho-specific S2448 antibody (Nave et al., 1999). This observation 
was extended here in CHO-IR cells to assess T2446 phosphorylation under the same 
parameters. Nutrient deprivation caused an increase in reactivity to the phospho- 
T2446 antibody concomitant with a decrease in reactivity to the phospho-S2448 
antibody under the same starvation conditions (Fig. 3.3A). Total levels of mTOR 
remained unchanged. The reverse was observed when CHO-IR cells were stimulated 
with insulin: a decrease in reactivity of mTOR with the phospho-T2446 antibody was 
observed. Prolonged insulin stimulation of CHO-IR cells corresponded to an 
increase in reactivity to the phospho-S2448 antibody without a change in total 
mTOR (Fig. 3.3B). S2448 has been established as a nutrient sensitive site (Nave et 
al., 1999) and here T2446 is also confirmed to be nutrient sensitive. These results 
demonstrate that conditions supporting T2446 phosphorylation are converse to those 
required for S2448 phosphorylation suggesting that phosphorylation at these sites 
may be mutually exclusive.
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Figure 3.3 An inverse relationship exists between phosphorylation of T2446 and 
S2448 on mTOR
(A) Effects of nutrient starvation; CHO-IR cells were fed with F I2 (Ham) 
supplemented with 10% fetal calf serum or nutrient starved in D-PBS for the times 
indicated above. (B) Effects of insulin stimulation; CHO-IR cells were serum- 
starved overnight in F12 (Ham) media, then stimulated with lOOnM insulin for the 
times indicated. In all cases cells were lysed and lysates were separated by 
SDS/PAGE, wet transferred to PVDF and probed with the phospho-antibodies as 
shown. The same blots were stripped and re-probed for total mTOR as shown. 
Similar results were obtained in three independent experiments.
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3.3.4 Effects of various inhibitors on mTOR T2446 
phosphorylation compared to S2448 phosphorylation in 
CHO-IR
To examine the signalling pathways involved in T2446 phosphorylation several, well 
characterised inhibitors were used to investigate their effects on phosphorylation of 
T2446 in the presence or absence of nutrients (Fig. 3.4). Wortmannin, a specific 
inhibitor of PI3K, can cause a block in PKB activation, and has been shown to inhibit 
PKB dependent S2448 phosphorylation in HEK cells (Nave et al., 1999). As seen in 
Fig. 3.4B, wortmannin treatment also decreased S2448 phosphorylation under 
nutrient fed conditions in CHO-IR cells. In contrast wortmannin did not inhibit the 
phosphorylation of T2446 under nutrient deprivation (Fig. 3.4A). Thus 
phosphorylation of T2446 is independent of PI3K and PKB activation. Protein 
phosphatase 2A (PP2A) is a major ser/thr phosphatase involved in the regulation of 
many signalling pathways and has been shown to be a downstream target of mTOR 
(Peterson et al., 1999). Here, okadaic acid was used as an inhibitor of PP2A to 
examine whether it played a part in the regulation of T2446 phosphorylation. 
Okadaic acid induced no appreciable difference in reactivity to the phospho-T2446 
or phospho-S2448 antibody compared to lysates from non-treated cells indicating 
that an okadaic acid sensitive protein phosphatase may not be involved in regulating 
phosphorylation at mTOR-T2446. To assess the possible involvement of the MAP 
kinase cascade in the regulation of T2446 phosphorylation, PD98059 was used. 
PD98059 is a highly selective inhibitor of in vivo MEK1 and MEK5 activation and 
thus blocks activation of the ERK kinase cascade. PD98059 did not inhibit S2448 
phosphorylation in the presence of nutrients nor did it inhibit T2446 phosphorylation 
under nutrient deprivation thus excluding the MAP kinase pathway in the regulation 
of T2446 phosphorylation. Finally, treatment with rapamycin also did not affect 
T2446 phosphorylation in the presence or absence of nutrients (Fig. 3.4A), excluding 
mTOR itself from regulation of T2446 phosphorylation.
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Figure 3.4 Effects of various inhibitors on mTOR T2446 phosphorylation 
compared to S2448 phosphorylation in CHO-IR
CHO-IR cells were incubated with lOOnM wortmannin, 250nM okadaic acid, 50pM 
PD98059 (denoted as PD) or 50nM rapamycin for lhour in the presence of nutrients 
[FI2 (Ham) media] or absence of nutrients [D-PBS]. Cells were lysed and lysates 
were separated by SDS/PAGE, wet transferred to PVDF then probed with (A) 
phospho-T2446 or (B) phospho-S2448 antibodies as shown then stripped and re­
probed for total mTOR. Similar results were obtained in three independent 
experiments.
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3.3.5 PMA stimulates phosphorylation of S2448 on 
mTOR
The phorbol ester PMA (phorbol-12-myristate- 13-acetate) is a potent mouse skin 
tumour promoter and is used to activate the protein kinase C (PKC) family of ser/thr 
protein kinases in vivo and in vitro (Newton, 2001); here it was used to analyse its 
effects on mTOR phosphorylation. CHO-IR cells were serum starved overnight then 
stimulated with insulin or PMA for 10 minutes. As observed earlier, T2446 is 
basally phosphorylated and insulin caused de-phosphorylation of this site (Fig. 3.5). 
Similarly PMA also caused T2446 dephosphorylation (Fig. 3.5). In contrast, S2448 
phosphorylation was stimulated by insulin and also by PMA. The same effect was 
also observed in mouse myotubes (data not shown). PMA stimulated S2448 
phosphorylation has also been demonstrated previously (Iijima et al., 2002). It 
seems that T2446 and S2448 phosphorylation in response to PMA remains mutually 
exclusive. Since PMA activates PKC in vivo, PKC itself may directly cause the 
increase in S2448 phosphorylation by phosphorylating mTOR; however scansite 
analysis of mTOR does not identify S2448 as a potential PKC phosphorylation site. 
Therefore, the increase in S2448 phosphorylation may actually be indirect because 
PMA treatment can induce an increase in cellular levels of Ptdlns (3,4, 5)P3 (Nave et 
al., 1996). By increasing cellular levels of Ptdlns (3, 4, 5)P3, PDK1 and its 
downstream effector PKB would be activated and thus in vivo, the observed increase 
in S2448 phosphorylation by PMA treatment could still be via PKB. Insulin and 
PMA also stimulated T389 phosphorylation of S6K1 (Fig. 3.5), a downstream target 
of mTOR, indicating that PMA stimulation of mTOR induces normal activation of 
S6K1.
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Figure 3.5 PMA stimulates phosphorylation of S2448 on mTOR
CHO-IR cells were serum starved overnight then stimulated for lOmin with lOOnM 
insulin or lpM  PMA (phorbol-12-myristate-13-acetate) as indicated. Cells were 
lysed and lysates were separated by SDS/PAGE, wet transferred to PVDF then 
probed with the phospho-antibodies as shown, before being stripped and re-probed 
for total protein. Similar results were obtained in three independent experiments.
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3.3.6 cAMP and isoprenaline do not regulate mTOR- 
T2446 or S2448 phosphorylation
Previous findings indicated that increasing intracellular cAMP attenuated mTOR 
activity (Scott and Lawrence, 1998). Here, CPT-cAMP (a cell permeable cAMP 
analogue) and isoprenaline were used to assess the involvement of PKA in T2446 
phosphorylation. CHO-IR cells were serum starved overnight before stimulation 
with lOOpM CPT-cAMP or lOpM isoprenaline. Results show that neither CPT- 
cAMP nor isoprenaline stimulated a change in the phosphorylation state of T2446 or 
S2448 compared to basal levels, as determined by their respective phospho-antibody 
(Fig. 3.6). Both the phospho-T2446 and -S2448 antibody identified mTOR as a 
doublet at the correct molecular weight for mTOR; however this may be an artefact 
since the total blot only identifies a single band corresponding to mTOR (Fig. 3.6). 
The evidence here also excludes the involvement of PKA in the regulation of T2446 
phosphorylation.
3.3.7 Effect of various serum/nutrients combinations on 
mTOR T2446 phosphorylation
Having not identified a regulatory pathway for T2446 phosphorylation by use of 
inhibitors, the effect of nutrients on T2446 phosphorylation was further investigated 
in CHO-IR cells by incubation with different nutrient combinations (Fig. 3.7A). 
Presence of 10% serum media complete with all nutrients namely glucose (3mM) 
and amino acids (at the standard concentration in media) did not induce 
phosphorylation at T2446. In contrast, cells incubated with any combination of the 
nutrient elements absent, induced T2446 phosphorylation to similar levels. Cells 
incubated in the absence of all nutrients (D-PBS) induced maximal stimulation of 
phosphorylation: approximately 2 fold more reactivity to the phospho-T2446 
antibody than any of the other nutrient combinations (Fig. 3.7B). This suggests that 
T2446 phosphorylation is a general nutrient sensing site since loss of all nutrients 
results in maximal phosphorylation and addition of any one nutrient reduces 
phosphorylation to a basal level. Interestingly, the level of mTOR-T2446
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phosphorylation was at a similar level whether serum starved for 1 hour or overnight, 
suggesting that withdrawal of some constituent in foetal calf serum is enough to 
stimulate basal T2446 phosphorylation. As described in Chapter 1: Introduction 
(Section 1.7.5.1), AMPK has been implicated in mTOR signalling; therefore the 
effects of nutrient deprivation on AMPK activation were assessed in parallel with 
T2446 phosphorylation. AMPK kinase (AMPKK) activates AMPK by 
phosphorylation at T172 in response to elevated AMP: ATP ratio due to cellular and 
environmental stress (Hardie et al., 1998). The general trend in AMPK T172 
phosphorylation was similar to the profile observed for T2446 phosphorylation (Fig. 
3.7A) except where glucose was present in D-PBS which appeared to prevent AMPK 
phosphorylation. It seems that AMPK is more sensitive to glucose levels and this is 
unsurprising since glucose starvation elevates the AMP: ATP ratio (Hardie et al., 
1998); the presence of glucose would counteract this and thus inactivate AMPK. 
Nevertheless, loss of all nutrients also induced the highest AMPK activation and the 
overall similarities between T2446 and AMPK phosphorylation in response to 
different nutrient conditions suggests they lie in the same or parallel nutrient sensing 
pathways. ERK phosphorylation was induced by growth stimuli and was inactivated 
only during initial serum withdrawal and loss of all nutrients or glucose (Fig. 3.7A). 
As established earlier with the MEK1 inhibitor PD98059 (Section 3.3.4), the MAPK 
pathway does not seem to be involved in T2446 phosphorylation.
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Figure 3.6 cAMP and Isoprenaline do not regulate mTOR-T2446 or S2448 
phosphorylation
CHO-IR cells were serum starved overnight in serum free F12 (Ham) media before 
treatment with lOOpM CPT-cAMP or lOpM isoprenaline for the indicated time 
points. Cells were lysed and lysates were separated by SDS/PAGE, wet transferred 
to PVDF then blotted with the phospho-antibodies as shown then stripped and re­
probed for total mTOR. Similar results were obtained in three independent 
experiments.
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Figure 3.7 Effect of various serum and nutrient combinations on mTOR T2446 
phosphorylation
CHO-IR cells with nutrients were incubated in F12 media either with 10% serum, 
without serum for lhr (-lhr) or serum starved overnight (-o/n) as indicated. Cells in 
the absence of nutrients were incubated in D-PBS supplemented with 1.802g/l 
glucose [3mM], 10% serum or both for lhr. Cells were lysed and lysates were 
separated by SDS/PAGE, wet transferred to PVDF and probed with the phospho- 
antibodies as shown then stripped and re-probed for the total protein (A). Similar 
results were obtained in three independent experiments. The level of mTOR-T2446 
phosphorylation detected from the western blot was quantitated and plotted in (B).
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3.3.8 Effect of AMPK activators on T2446 
phosphorylation in H2K cells
As established in Section 3.3.7, AMPK phosphorylation and mTOR phosphorylation 
at T2446 are similarly induced by nutrient deprivation. Therefore to determine the 
physiological significance of nutrient status in regulating mTOR T2446 
phosphorylation in relation to AMPK activation, mouse H2K myotubes were treated 
with AMPK activators and the effects on T2446 phosphorylation and AMPK activity 
were assessed. Myotubes were treated with the metabolic inhibitor Dinitrophenol 
(DNP) which acts to rapidly decrease cellular ATP level or with AICAR riboside, a 
cell permeable compound that in some cell types (including H2K) is degraded to 
ZMP, a nucleotide which mimics the effects of 5’AMP and is capable of activating 
AMPK directly without altering cellular concentrations of ATP, ADP and AMP 
(Corton et a l, 1995). mTOR S2448, ERK and also S6K1 (T389) phosphorylation 
were increased only in the presence of insulin even when in combination with 
AICAR (Fig. 3.8A). In contrast, insulin did not stimulate T2446 phosphorylation but 
DNP did cause an acute increase in T2446 phosphorylation even in the presence of 
insulin. Treatment with DNP also increased AMPK T172 phosphorylation (Fig. 
3.8A) and activity of AMPK (Fig. 3.8B). AICAR had similar effects to DNP 
treatment on T2446 and AMPK phosphorylation though it was less potent in 
activation of AMPK. In accordance with results presented earlier where the 
phosphorylation of AMPK was increased following withdrawal of amino acids in 
CHO-IR cells (Fig. 3.7A), data here suggest that mTOR T2446 phosphorylation and 
AMPK activation (as indicated by T172 phosphorylation and activity data) are 
similarly regulated and possibly within the same pathway.
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Figure 3.8 Effect of AMPK activators on T2446 phosphorylation in H2K cells
H2K cells were incubated in DMEM [0.5% serum] overnight, which was replaced 
with HEPES buffered saline [containing 5mM glucose] for 30min treatments with 
either lOOnM insulin, 0.5mM DNP or 0.5mM AICAR as indicated. Where the 
legend is labelled 1st and 2nd, cells were first stimulated with lOOnM insulin for 
30min followed by treatment with 0.5M AICAR for 30min or vice versa. Cells were 
harvested and AMPK was immunoprecipitated using a pan p-subunit AMPK 
antibody and used to assay AMPK activity against SAMS peptide (B). The 
remaining lysates were separated by SDS/PAGE, wet transferred to PVDF then 
probed with the phospho-antibodies as shown in (A), stripped and re-probed for the 
total protein. Similar results were obtained in three independent experiments. 
[Experiment performed in collaboration with co-workers in Cheng et al., 2004].
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3.3.9 In vitro kinase assays with mTOR peptides
Evidence that T2446 phosphorylation and AMPK activation were similarly regulated 
raised the possibility that AMPK could phosphorylate mTOR at T2446. To 
investigate this hypothesis and identify potential kinases which may phosphorylate 
the T2446 region of mTOR, in vitro kinase assays were performed using a series of 
mTOR peptides based on residues 2440-2551. The peptide series included residue 
changes to alanine and glutamic acid at the S2448 or T2446 positions (Table 3.1). 
The kinases which were used in the peptide assays included: PKB, AMPK, PKC£ 
and S6K1.
PKB is well documented as a kinase which can directly phosphorylate mTOR and 
was used here to assess the effect of T2446 phosphorylation on PKB mediated 
phosphorylation of S2448. PKB was immunoprecipitated from CHO-IR cells 
stimulated with insulin. Data presented in Fig. 3.9A shows that PKB mediated 
maximal phosphorylation of the wildtype peptide from PKB immunoprecipitates 
obtained after insulin stimulation, demonstrating that the wildtype peptide was a 
suitable substrate. PKB has been shown to directly phosphorylate mTOR at S2448 
(Nave et al., 1999). Evidence presented here shows phosphorylation of the phospho- 
mimic T2446E peptide by PKB was at a low level compared to phosphorylation of 
both the wild type peptide and the T2446A peptide (Fig. 3.9B), suggesting that 
phosphorylation at T2446 prevents S2448 phosphorylation and supporting the 
hypothesis that phosphorylation of these two sites is mutually exclusive. In addition, 
PKB phosphorylated the phospho-S2448 and S2448A peptides at approximately 20% 
and 40% respectively of the phosphorylation observed with the wild type peptide, 
suggesting that some level of T2446 phosphorylation may be possible by PKB in 
vitro. Since T2446 has a loose consensus to the PKB phosphorylation motif, R-X-R- 
Y-Z-S/T-hvd (Alessi et al., 1996), it is unsurprising that PKB has some ability to 
phosphorylate T2446, though this data suggests that T2446 is not a major site of 
PKB phosphorylation.
To investigate whether AMPK could phosphorylate the mTOR peptides, 
constitutively active recombinant AMPK was used, comprising His-tagged-
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aiT172D, pi and yi subunits - gift from Dr D. Carling (Hammersmith Hospital, 
London) (Stein et al., 2000). AMPK phosphorylates the motif hyd-(X, bas)-X-X- 
S/T-X-X-X-hvd where X is any amino acid; hyd is a hydrophobic residue; bas is a 
basic residue; S/T is the phosphorylatable residue at position zero (P=0). Hence, the 
P-5 and P+4 positions are occupied by a bulky hydrophobic residue with either the P- 
4 or P-3 position occupied by a basic residue (Dale et al., 1995). The ai isoform of 
the AMPK catalytic subunit which was used in these experiments is less selective for 
the phosphorylation motif than other AMPK isoforms; a hydrophobic residue at P+4 
is not essential while a basic residue at P-6 is beneficial for phosphorylation (Dale et 
al., 1995). The wildtype mTOR peptide had a basic residue at P-6 and P-4, so 
fulfilled requirements for AMPK recognition (see Table 3.1) and AMPK was able to 
phosphorylate this peptide fully. In contrast, phosphorylation of the T2446E and 
T2446A peptide was greatly reduced to approximately 20% and 50% respectively of 
the phosphorylation observed with the wildtype peptide, consistent with the mutated 
T2446 site being unrecognisable by AMPK (Fig. 3.9C). Changes at the S2448 
position also reduced the ability of AMPK to phosphorylate the peptides (Fig. 3.9C). 
It is possible that the phospho-S2448 and S2448A peptide prevents T2446 
phosphorylation by preventing AMPK recognition and phosphorylation.
As shown in Fig. 3.5, PMA stimulates S2448 phosphorylation which may be 
mediated by a PKC isoform. To determine whether an isoform of PKC could 
phosphorylate the mTOR peptides, PKC£, an atypical PKC isofrom was used. PKC£ 
does not bind phorbol esters (Newton, 2001); here however PMA did stimulate 
PKC£ activition (Fig. 3.9A). This was most likely via PMA activation of PDK1 
which phosphorylates and activates PKC£ in vitro (Good et al., 1998). The optimal 
peptide sequence for PKC phosphorylation is an XRXXS motif where X is any 
amino acid (Newton, 2001); S2448 is in a XRXXS motif. Here, PKC£ was able to 
phosphorylate the S6 control peptide and the T2446A and E peptide to the same level 
of phosphorylation observed with the wildtype peptide. Phosphorylation did not 
occur when the phospho-S2448 and S2448A peptides were used (Fig. 3.9D), 
suggesting that PKC£ is capable of phosphorylating the S2448 site in vitro or that 
abrogation of this site prevents phosphorylation of an alternative residue within the 
peptide sequence. This data does not necessarily imply in vivo phosphorylation of
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mTOR by PKC£, since theoretically any peptide containing the XRXXS motif is 
capable of phosphorylation by PKC£, as demonstrated by the S6 control peptide. In 
vivo tests would determine the significance of these observations.
The S6K1 phosphorylation motif is K/RXRXX-S/T-hyd, where X is any amino acid 
and ‘hyd’ is a hydrophobic residue (Pinna and Ruzzene, 1996). Scansite analysis 
revealed that T2446 is a potential S6K1 phosphorylation site. Fig. 3.9A presents 
data showing that S6K1 immunoprecipitated from CHO-IR cells had maximal 
activity towards the wildtype peptide after insulin stimulation, thus demonstrating 
that the wildtype peptide was a suitable substrate for S6K1. Assays with S6K1 
immunoprecipitates from insulin stimulated CHO-IR cells showed that S6K1 could 
phosphorylate all the mTOR peptides to between 50% and 200% of the 
phosphorylation observed with the wildtype peptide (Fig. 3.9E), suggesting general 
peptide phosphorylation by S6K1 which was not dependent on the status of T2446 or 
S2448 phosphorylation. Constitutively active recombinant S6K1 was able to 
phosphorylate the T2446E peptide to approximately 80% of the phosphorylation 
observed with the wildtype peptide (Fig. 3.9E), suggesting that S6K1 is able to 
phosphorylate alternative residues to T2446 within the T2446E peptide and 
supporting the conclusion that S6K1 phosphorylates the mTOR peptides non- 
specifically. It is possible that the difference between recombinant and 
immunoprecipitated S6K1 phosphorylation of the mTOR peptides may be from 
contaminating kinase activity associated with the S6K1 immunoprecipitate.
A truncated PKR construct in pGEX-4T-2 (courtesy of Dr T. Dever, National 
Institute of Health, USA), which was reported as constitutively active in vitro (Ung 
et al., 2001) was obtained to investigate the possibility that PKR could phosphorylate 
mTOR. Unfortunately, repeated attempts to express the GST-PKR construct failed 
and the question of whether PKR could mediate phosphorylation of the mTOR 
peptides could not be addressed.
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Peptide Sequence
Wild-type KKRSRTRTDSYSA
T2446E KKRSRTREDSYSA
T2446A KKRSRTRADSYSA
Phospho-S2448 KKRSRTRTDS*YSA
S2448A KKRS RTRTDAYSA
Table 3.1 Peptides used as substrates in kinase assays
Peptides used in the peptide assays are shown above. Sequences were based on 
twelve residues in the mTOR sequence from K2440-A2451 with an additional K 
residue at the N-terminal to increase the charge for binding to p81 paper. E and A 
denotes the mutated residue and S* denotes a phosphorylated serine residue.
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Figure 3.9 In vitro kinase assays using mTOR peptides as the substrates
See legend overleaf.
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Figure 3.9 In vitro kinase assays using mTOR peptides as the substrates
CHO-IR cells were stimulated with insulin or PMA, lysed and immunoprecipitated 
for PKB and S6K or PKC£ respectively. The immunoprecipitates or recombinant 
AMPK and S6K1 were subjected to in vitro kinase assay against all the peptides 
shown in Table 3.1. Assays were conducted in the presence of [y-32 P] ATP and 
Mg2+. % phosphorylation of each peptide was determined relative to
phosphorylation of the wildtype peptide. The activity o f PKB, PKC£ and S6K 
immunoprecipitates from basal or stimulated cells against the wildtype peptide is 
shown in (A). The activities of various kinases towards each peptide in Table 3.1 are 
presented in (B) PKB, (C) AMPK, (D) PKC£, (E) S6K1. Results shown are n=3 in 
triplicate ± SEM
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3.3.10 Recombinant AMPK is unable to phosphorylate 
mTOR in vitro
Based on the data obtained from AMPK activators and the peptide assays, 
recombinant AMPK (aiT172D, Pi and yi subunits) was used in an in vitro kinase 
assay to assess its ability to phosphorylate full-length mTOR immunoprecipitated 
from cells. HEK cells were incubated in the absence and presence of amino acids 
then lysed and endogenous mTOR was immunoprecipitated with aTOR. The 
immunoprecipitates were subjected to an in vitro kinase assay with recombinant 
AMPK and no phosphorylation of mTOR was observed (Fig. 3.10A). To increase 
the quantity of mTOR immunoprecipitated, HEK cells were transfected with 
wildtype mTOR and the assay was repeated with FLAG immunoprecipitates of 
mTOR (Fig. 3.1 OB); there was no noticeable phosphorylation of mTOR by AMPK 
and a background level of phosphorylation was observed even in the absence of 
recombinant AMPK. The background phosphorylation observed with FLAG 
immunoprecipitates may be from a contaminating kinase activity or mTOR 
autokinase activity (Fig. 3.1 OB).
The in vitro kinase assay was extended to immunoprecipitates of mTOR mutants 
which substituted T2446 or S2448 with non phosphorylatable alanine or phospho- 
mimetic glutamic acid (Section 2.2.3.2). The mutants were transfected into HEK 
cells and isolated by FLAG immunoprecipitation. Again, there was no appreciable 
difference in AMPK mediated phosphorylation of each mutant and a background 
level of phosphorylation was observed even in the absence of recombinant AMPK; 
the background level of phosphorylation was unchanged in the presence of AMPK 
(Fig. 3.10C). Results here suggest that AMPK does not phosphorylate mTOR in 
vitro though it is possible that immunoprecipitating mTOR with antibody blocks the 
accessibility to AMPK mediated phosphorylation or that mTOR exists in a complex 
in which an intermediate kinase may be involved between activation of AMPK and 
T2446 phosphorylation.
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Figure 3.10 Recombinant AMPK is unable to phosphorylate mTOR in vitro
HEK293 cells were transfected with wildtype mTOR (B) or mTOR mutant 
constructs (C) using the calcium phosphate method of transfection. Non-transfected 
(A) and wild-type transfected (B) cells were incubated with amino acids [DMEM] or 
amino acid starved in D-PBS supplemented with 5mM glucose for lhr. Mutant 
constructs were incubated in DMEM for lhr. All were lysed then 
immunoprecipitated with aTOR (A) or FLAG (B and C) as indicated; bead only 
represents immunoprecipitation with protein A (A) or mouse IgG (B, C) in the 
absence o f antibody. The immunoprecipitates were washed then subjected to an in 
vitro kinase assay with recombinant AMPK in the presence of [y-32P] ATP and Mg2+. 
Reaction products were analysed by SDS-PAGE and autoradiography. Results are 
shown in duplicate and similar results were obtained in another experiment.
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3.4 Discussion
The present study supports the notion that the AMPK and mTOR signalling 
pathways are linked. Previous evidence indicates that the C-terminus region of 
mTOR is of regulatory importance (Brunn et al., 1997b, Sekulic et al., 2000, 
Peterson et al., 2000) and results presented here provide evidence that T2446 is a 
novel mTOR phosphorylation site within this region. Factors which promote 
phosphorylation at T2446 cause dephosphorylation of the previously identified PKB 
mTOR phosphorylation site S2448 (Nave et al., 1999). The evidence suggests that 
T2446 phosphorylation may have negative regulatory effects on mTOR activation 
since phosphorylation of T2446 is acutely stimulated by nutrient deprivation, a 
condition associated with reduced signalling through mTOR. Moreover T2446 
phosphorylation correlates with an attenuation of insulin-stimulated phosphorylation 
of S6K1.
Evidence from the peptide assays shows that PKB can phosphorylate at the mTOR- 
T2446 position since phosphorylation of the S2448A and phospho-S2448 peptides 
was observed at approximately 50% of the phosphorylation observed with the 
wildtype peptide. This is not surprising because it weakly fits the PKB consensus 
sequence. However, T2446 is unlikely to be a major PKB target site. Sekulic et al., 
(2000), reported that expression of a S2448A mTOR mutant with activated PKB still 
gave rise to residual T2446 phosphorylation, as shown by increased reactivity to a 
double phospho-T2446/S2448 antibody termed a-mTORp2. Interestingly the 
authors also produced a phospho-T2446 antibody though no findings were reported 
with it. Data presented here suggests that phosphorylation of T2446 and S2448 are 
mutually exclusive in vitro because phosphorylation of the S2448 position is 
inhibited with use of the mTOR T2446E phospho-mimetic peptide but 
phosphorylation is normal when T2446 is changed to alanine. Furthermore, in-vivo 
studies in CHO-IR cells show that wortmannin, which blocks activation of PKB and 
S2448 phosphorylation, does not reduce phosphorylation at T2446, indicating that 
phosphorylation of this site is independent of PKB activation. The use of selective 
inhibitors showed that phosphorylation of T2446 is also independent of an okadaic 
acid-sensitive protein phosphatase activity, the MAP kinase pathway, and even of
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mTOR itself. Additionally, the phorbol ester PMA did not stimulate phosphorylation 
of T2446 and peptide data support the exclusion of PKCs from the regulation of 
T2446 phosphorylation. However, PMA did stimulate S2448 phosphorylation and 
also downstream S6K1 activation (indicated by T389 phosphorylation), previously 
described by Iijima et al., (2002). Iijima et al., (2002) proposed that PMA stimulated 
phosphorylation of mTOR-S2448 via the PKC mediated c-Raf/MEK/ERK signalling 
pathway which was not critical during insulin stimulation of cardiomyocytes: this 
pathway may also operate in CHO-IR cells. The mechanisms of c-Raf/MEK/ERK 
mediated S2448 phosphorylation have not been demonstrated and the activation of 
mTOR S2448 phosphorylation observed here could be indirect, as PMA can increase 
cellular levels of Ptdlns (3, 4, 5)P3 (Nave et al., 1996) and thus activation of PDK1 
and PKB. However in vitro kinase assays show that the PKC£ isoform had the 
capability to phosphorylate the wildtype, T2446A and T2446E peptides 
indiscriminately; it could not phosphorylate the S2448A or phospho-S2448 peptides. 
This may be because the S2448 site is within a PKC phosphorylation motif and 
changing the S2448 position with either alanine or phospho- prevents peptide 
phosphorylation. Phosphorylation of mTOR-S2448 by PKC£ would be a novel 
observation; however, in vitro kinase data may not truly reflect the actual 
phosphorylation of S2448 by PKC isoforms in-vivo. mTOR has been implicated in 
down-regulation of IRS-1 signalling (Haruta et al., 2000) and in the sub-cellular 
redistribution of IRS-1 (Takano et al., 2001); PKC£ can also associate and 
phosphorylate serine residues of IRS-1 in an insulin dependent manner 
(Ravichandron et al., 2001). It will be of interest to determine whether mTOR and 
atypical PKCs (which includes PKCQ are recruited together for down-regulation of 
IRS-1. Although upstream involvement of PKC in mTOR regulation must be 
considered, there is evidence that places the novel PKC isoforms (8 and e) 
downstream of mTOR (Kumar et al., 2000a; Parekh et al., 1999). Both isoforms 
were identified as operating via an mTOR dependent pathway as determined by 
inhibition of PKC8 and PKCe phosphorylation in the presence of rapamycin or with 
amino acid starvation (Parekh et al., 1999); moreover, PKCS was found to associate 
with mTOR and was required for phosphorylation and inactivation of 4E-BP1 
(Kumar et al., 2000a). Further in-vivo testing is needed to clarify which and how the 
PKC isoforms are involved in mTOR signalling, whether upstream or downstream.
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The data discussed above suggest that phosphorylation of T2446 and S2448 is 
mutually exclusive since conditions which promote T2446 phosphorylation act to 
decrease S2448 phosphorylation and vice versa, an event which would require co­
ordinate regulation of the kinases involved.
Recent evidence implicates AMPK in the mTOR pathway (Bolster et al., 2002; 
Kimura et al., 2003) and results here suggest that AMPK is likely to be involved in 
regulating phosphorylation at T2446. Two lines of evidence support this: nutrient 
deprivation, DNP and AICAR all activate AMPK and also stimulate phosphorylation 
of T2446 and; AMPK can directly phosphorylate the wildtype mTOR peptide 
(residues 2440-2551). Although AMPK is able to phosphorylate the wildtype mTOR 
peptide, it also phosphorylates both the T2446A and S2448A peptides at 
approximately 20% and both the T2446E and phospho-S2448 peptides at 
approximately 60% of that observed with the wildtype peptide. Furthermore, 
experiments designed to demonstrate AMPK phosphorylation of full length mTOR 
were inconclusive. From this data it is not possible to confirm the direct 
phosphorylation of mTOR by AMPK. Although recent data has been published 
indicating that the y subunit of AMPK can interact with the C-terminal portion of 
mTOR, again highlighting the importance of this region, no interaction was observed 
with full length mTOR (Kimura et al., 2003). It seems more likely that AMPK is 
indirectly involved in T2446 phosphorylation. A recent study showed that AMPK 
interacted with TSC2, and AMPK was able to directly phosphorylate TSC2 at T1227 
and SI345 to downregulate translation and reduce cell size under energy starved 
conditions (Inoki et al., 2003b). The findings of Inoki et al., (2003) suggest that TSC 
integrates signals of energy availability via AMPK leading to inhibition of mTOR 
signalling to S6K1 and 4E-BP1.
Though AMPK may not regulate mTOR by direct phosphorylation, the mutually 
exclusive phosphorylation of T2446 and S2448 is likely to be due to phosphorylation 
of one site which then affects the substrate recognition sequence for subsequent 
phosphorylation by another kinase. However, the kinase responsible for T2446 
phosphorylation remains to be identified.
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Additionally, increasing intracellular cAMP has been reported as attenuating mTOR 
activity (Scott and Lawrence, 1998) but here cAMP treatment did not affect basal 
T2446 or S2448 phosphorylation. However, conditions did not include CPT-cAMP 
treatment in conjunction with insulin, which was shown to decrease mTOR 
phosphorylation by increased reactivity to the mTAbl antibody (mTOR 2433-2450) 
which is not specific to T2246 or S2448 phosphorylation (Brunn et al., 1997b). 
Therefore, it would be speculation to assume the status of mTOR phosphorylation in 
the presence of cAMP used in conjunction with insulin. Although cAMP inhibited 
insulin stimulated mTOR activity, this combination of treatment did not attenuate 
activation of PKB; thus S2448 may still be phosphorylated (Scott and Lawrence, 
1998). In addition, the mTAbl antibody epitope encompasses both mTOR 
phosphorylation sites and includes other phosphorylatable serine and threonine 
residues. It was unfortunate that the cAMP + insulin treatment was not included in 
this investigation, as this would have provided a more conclusive answer as to 
exactly which mTOR site is phosphorylated.
In summary, T2446 has been identified as a novel phosphorylation site in mTOR 
which may also be regulated by AMPK signalling. Phosphorylation of T2446 is 
increased by low nutrient conditions which are normally associated with the negative 
regulation of mTOR. Phosphorylation at T2446 limits phosphorylation at S2448 and 
vice versa suggesting that phosphorylation of these sites is mutually exclusive and 
might act as a switch in controlling the positive and negative signals which regulate 
protein translation via mTOR.
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4 Investigating the role of 
phosphorylation in mTOR by mutational 
analysis
4.1 Summary
The mammalian target of rapamycin (mTOR) integrates growth factor signalling and 
nutrient availability, culminating with an increase in the rate of translation of specific 
sub-sets of mRNA. The precise mechanism of mTOR regulation is not clear though 
identification of nutrient sensitive phosphorylation sites within the mTOR catalytic 
domain suggested a level of regulation by phosphorylation. Based on this 
hypothesis, mutants of mTOR were constructed at sites S2442, T2446 and S2448, 
substituting each site with non-phosphorylatable alanine (A) or phospho-mimetic 
glutamic acid (E). To allow discrimination between the effects of endogenous 
mTOR and that of each mTOR site mutant, an additional rapamycin resistance 
mutation (S2035T) was cloned into each mutant construct. S6K1 activation and 4E- 
BP1 phosphorylation are regulated via mTOR in response to insulin or nutrient 
deprivation and were used here as readouts of the effects of the mutant mTOR. The 
best characterised mTOR phosphorylation site is S2448, which is phosphorylated by 
PKB when cells are stimulated with insulin and dephosphorylated in response to 
nutrient deprivation. Results from transfection assays show that the alanine mutation 
of the S2448 site did not have a dominant negative effect on insulin stimulated S6K1 
activity when compared to an mTOR construct with rapamycin resistance but 
wildtype C-terminal sequence. Likewise, the S2442 and T2446 mutants had no 
overall effect on insulin stimulated S6K1 activation. Similarly, none of the mutants 
were able to sustain S6K1 activity in the absence of nutrients. These results suggest 
that although phosphorylation of T2446 and S2448 is mutually exclusive in response 
to growth factors and nutrients, their individual phosphorylation may not be enough 
to have a direct effect on downstream S6K1 activity.
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4.2 Introduction
The mTOR catalytic domain is a member of a family of phosphatidylinositol kinase 
(PIK)-related kinases which share homology to the pi 10 catalytic subunit of PI-3 
kinase (Abraham, 1996). The C-terminal catalytic domain of mTOR exhibits protein 
kinase (as discussed below) and autokinase activity (Brown et al., 1995; Withers et 
al., 1997) but lacks lipid kinase activity (Brown et al., 1995). The mechanisms 
which regulate mTOR protein kinase activity remain undefined. Evidence of the 
regulatory potential of the mTOR catalytic domain was augmented by identification 
of the S2448 phosphorylation site. Nutrients and insulin stimulate the 
phosphorylation at S2448 by PKB (Nave et al., 1999; Reynolds et al., 2002; Sekulic 
et al., 2000) and the identification of the T2446 phosphorylation site described in the 
previous chapter suggests that phosphorylation of mTOR is not restricted to a single 
site. Moreover, the antibody mTAbl has an epitope directed to residues 2433-2450 
and has been used as an mTOR activating antibody (Brunn et al., 1997b). 
Phosphorylation of S2448 is associated with conditions that also activate mTOR 
kinase activity (Reynolds et al., 2002; Bolster et al., 2002), though exactly how 
phosphorylation affects mTOR kinase activity remains unresolved. Thus far, the 
highly specific mTOR inhibitor, rapamycin, has been extremely useful for 
identifying pathways which are under the control of mTOR. Two major downstream 
targets of mTOR were identified both of which are involved in the regulation of 
translation. One target identified was S6K1 (also known as p70 S6 kinase), which is 
stimulated by mitogens and phosphorylates the S6 protein of the 40S ribosomal 
subunit to initiate translation of transcripts containing 5’ oligopyrimidine tracts 
(5’TOP); these mainly include ribosomal mRNAs (Volarevic et al., 2000). 
Rapamycin caused the rapid de-phosphorylation and inactivation of S6K1 (Chung et 
al., 1992; Kuo et al., 1992) and mTOR was subsequently identified as the rapamycin 
sensitive upstream regulator of S6K1 (Brown et al., 1995; Hara et al., 1997). Amino 
acid availability was also a major factor in S6K1 regulation, as nutrient deprivation 
mirrored the effects of rapamycin treatment (Hara et al., 1998; Shigemitsu et al., 
1999; Wang et al., 1998; Xu et al., 1998a). Though S6K1 can be activated via an 
mTOR independent pathway (Alessi et al., 1997b; Balendran et al., 1999; Pullen et 
al., 1998), studies showed that mTOR was able to directly phosphorylate S6K1 in
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vitro in a rapamycin sensitive manner at T389, a site flanked by bulky hydrobobic 
residues (Burnett et al., 1998; Isotani et al., 1999); phosphorylation at T389 is 
probably important in S6K1 activation.
The second major target of mTOR identified was the eIF4E binding protein (4E- 
BP1). Under translationally repressive conditions, such as nutrient deprivation, 
eIF4E is bound to hypo-phosphorylated 4E-BP1 to inhibit CAP-dependent 
translation. Upon growth factor stimulation and nutrient availability, 4E-BP1 
becomes phosphorylated on at least six sites (T37, T46, S65, T70, S83 and SI 12) 
causing the release of eIF4E which is then able to bind eIF4G; binding of eIF4E to 
eIF4G is the first step in formation of the eIF4F complex which facilitates Cap- 
dependent translation to progress (Proud, 2002a). Unlike the S6K1 mTOR 
phosphorylation motif, the 4E-BP1 phosphorylation sites are all proline directed 
(S/T-P). However, phosphorylation of 4E-BP1 was also shown to be rapamycin 
sensitive (Beretta et al., 1996; Brunn et al., 1997a, 1997b; Fadden et al., 1997) and 
mTOR has been shown to directly phosphorylate 4E-BP1 in vitro (Brunn et al., 
1997a, 1997b; Burnett et al., 1998; Fadden et al., 1997) and by an mTOR-associated 
kinase (Heesom and Denton, 1999); however the multi-site phosphorylation of 4E- 
BP1 is considered to occur in an ordered hierarchal manner (Gingras et al., 2001a).
The differences in the S6K1 and 4E-BP1 phosphorylation motifs have led to 
suggestions that mTOR activity is directed to a protein phosphatase. Studies have 
shown that mTOR is capable of phosphorylating protein phosphatase 2A (PP2A) 
with a greater affinity than 4E-BP1 (Peterson et al., 1999). The yeast TOR signalling 
cascade introduced the nutrient and rapamycin sensitive Sit4/PP2A-catalytic subunit 
and Tap42 effecter complex (DiComo and Arndt, 1996) (Section 1.6.1). The 
mammalian homologue of the regulatory Tap42 protein was subsequently identified 
and termed a4 (Kuwahara et al., 1994) which was able to bind to PP2A; PP2A 
activity and a4 association were shown to be sensitive to rapamycin treatment (Inui 
et al., 1998), again implicating mTOR. There is also evidence which suggests that 
mTOR controls S6K1 activity via downregulation of PP2A/a4 (Parrott and 
Templeton, 1999).
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As described above, a range of conditions regulate mTOR which in turn acts as a 
crucial intermediate in the regulation of cell growth; however, the mechanisms 
involved in the regulation of mTOR activity remain an important issue. In this 
chapter, the functionality of the S2448 PKB phosphorylation site was assessed in 
parallel to the novel mTOR phosphorylation site at T2446 by site directed 
mutagenesis. Additionally, S2442 was assessed as a potential PKR phosphorylation 
site (Section 3.2). Using the Stratagene QuikChange™ site directed mutagenesis kit, 
wildtype mTOR was mutated at each site to generate mTOR constructs substituted 
with glutamic acid as a phospho-mimetic mutant or site-substitued with alanine as a 
non-phosphorylatable mutant. All the mTOR mutants were constructed in a FLAG- 
tagged vector with a rapamycin resistant backbone which bore the S2035T 
rapamycin resistance mutation (Chen et al., 1995; Lorenz and Heitman, 1995). The 
rapamycin resistance mutation was integral in assessing the in vivo effects of mutant 
mTOR. Rapamycin would inhibit endogenous mTOR activity, without blocking the 
activity of the mutant forms of mTOR which were introduced by transfection. As a 
proven target of mTOR protein kinase activity, S6K1 activation was used as readout 
of mTOR activity; additionally the effects on 4E-BP1 phosphorylation were 
explored.
The present studies suggest that phosphorylation at S2442, T2446 or S2448 is not 
sufficient to have an affect on S6K1 activation with respect to growth factor 
stimulation or nutrient availability. The results suggest that phosphorylation at these 
sites may not directly control mTOR activity per se. Additional attempts were made 
to assess the in vivo effects of the mutant mTOR towards 4E-BP1 phosphorylation 
but in vitro mTOR activity could not be consistently attained.
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4.3 Results
4.3.1 Testing the integrity of expressed mTOR mutants
with phospho-specific antibodies
The mTOR mutant constructs as described in Section 4.2, were made using the 
Stratagene Quik Change mutagenesis kit as described in Section 2.2.3.2. The 
accuracy of each mutation was analysed by sequencing; additionally each of the 
T2446A, T2446E, S2448A and S2448E plasmids were transfected into HEK cells to 
test the integrity of the mTOR mutants. mTOR expressed from the transgene was 
immunoprecipitated with FLAG, separated by SDS PAGE, transferred then probed 
with the phospho-mTOR (S2448) antibody. Under fed conditions, the phospho- 
S2448 antibody reacted with a band corresponding to the T2446A mutant (Fig. 4.1), 
suggesting that the T2446A mutant allows phosphorylation at S2448. The phospho- 
S2448 antibody also reacted faintly with the phospho-mimetic T2446E mutant. 
Ordinarily conditions promoting phosphorylation of the T2446 site inhibit 
phosphorylation of the S2448 site and vice versa (Section 3). Partial phosphorylation 
of S2448 may exist with the phospho-mimetic T2446E mutant, possibly because 
T2446E does not fully mimic the in vivo phosphorylation of endogenous wildtype 
mTOR. Nevertheless, the phospho-S2448 antibody was unable to recognise the 
epitope from both of the S2448 mutants, suggesting successful mutation of all the 
sites.
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Figure 4.1 Testing the integrity of expressed mTOR mutants with phospho- 
S2448 antibody
HEK cells were transfected with mutant mTOR constructs as indicated, using the 
calcium phosphate method of transfection. After 36h, cells were lysed and equal 
amounts o f protein were immunoprecipitated with the FLAG antibody. 
Immunoprecipitates were subjected to 7.5% SDS-PAGE, wet transferred then probed 
with the phospho-S2448-antibody. (‘IB’ denotes immuno-blot).
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4.3.2 Variable insulin response from different cell lines
During the development and optimisation of the co-transfection experiments, HEK 
cells were extensively used since they were relatively easy to transfect with the 
calcium phosphate transfection method (Section 2.2.42.2) and expressed large 
amounts of protein from the transfected plasmid. However, during the S6K assay 
optimisation stage it became clear that the HEK cells had a high basal activity, even 
after 16-28h serum starvation, which depressed the level of insulin stimulation 
observed (data not shown). Therefore HEK cells were tested against CHO-IR cells 
which stably expressed the insulin receptor. Three HEK cell lines within the 
laboratory, but obtained from different sources, were tested using phosphorylation of 
PKB (S473) as a read-out of insulin stimulation. CHO-IR cells had significantly 
lower basal PKB (S473) phosphorylation than HEK cells and insulin stimulation was 
almost double that observed in all three HEK cell lines (Fig. 4.2). Subsequent co­
transfections with mutant mTOR and S6K1 were performed in CHO-IR cells.
4.3.3 Insulin stimulated S6K1 activity in the presence of 
mTOR mutants
As described in Section 1.5.2, the S6 kinases are encoded by two genes designated 
S6K1 (or S6Kla) and S6K2 (or S6K2p) (Duftier and Thomas, 1999). The isoform 
used in transfection experiments described here was 70kDa glu-glu tagged S6KlaII 
(denoted as S6K1 in all subsequent experimental descriptions), a gift from Dr I. Gout 
(Ludwig Institute for Cancer Research, London). S6KlaII was used because it is 
cytoplasmic and more sensitive to rapamycin and nutrient deprivation than the S6K2 
isoforms (Gout et al., 1998; Minami et al., 2001). To assess the effect of the mTOR 
mutants on S6K1 activity, the mTOR constructs (excluding the FLAG tagged 
wildtype), were made in a rapamycin resistant backbone containing the S2035T 
mutation (Section 2.2.3.2 and 4.2). The influence of each mutant could only be 
assessed by suppression of endogenous mTOR which was achieved by treatment 
with rapamycin prior to insulin stimulation.
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CHO-IR cells were co-transfected with glu-glu tagged wildtype S6K1 and FLAG 
tagged mTOR and were treated as described in the Fig. 4.3 legend; cells were lysed 
and half the lysate was used in a FLAG immunoprecipitation, which was subjected to 
SDS-PAGE, wet transferred and probed back for mTOR. The other half of the lysate 
was used in glu-glu immunoprecipitation for S6K1 which was used in an in vitro 
kinase assay in the presence of [y-32 P] ATP and Mg2+ with 80S ribosomes as 
substrate. Assay products were subjected to SDS-PAGE and the gel cut at the 46kDa 
marker; the upper portion was wet transferred and probed for S6K1. Activity was 
determined from the lower portion of the gel which was fixed, dried and exposed to 
radiographic film. An example of a western blot showing total mTOR and total 
S6K1 with the 80S autoradiograph from a co-transfection of S6K1 with wildtype or 
Ml (rapamycin resistant) mTOR, in the absence and presence of rapamycin, is 
shown in Fig. 4.3A. Within each experiment, control western blots were performed 
to check mTOR transfection efficiency and mTOR was always equal as 
demonstrated in Fig. 4.3A. Total S6K1 was quantitated from the western blot to 
normalise S6K1 activity detected in the autoradiograph of phosphorylated 80S (Fig. 
4.3A). The activity data from the same co-transfections is shown in Fig. 4.3B. In 
these experiments rapamycin completely blocked insulin-stimulated activation of 
S6K1 in CHO-IR cells transfected with S6K1 and wildtype mTOR (Fig. 4.3B). Cells 
transfected with S6K1 and the Ml rapamycin resistant mTOR mutant maintained 2 
fold activation of S6K1 even after rapamycin treatment (Fig. 4.3B). This 
demonstrated that the effect of the Ml-rapamycin resistant mTOR on S6K1 activity 
was clearly separable from that of rapamycin sensitive wildtype mTOR.
The S6K1 activity when co-transfected with each mTOR mutant in the presence of 
rapamycin is presented in Fig. 4.3C. Within each experiment, the Ml mutant was 
used as the readout of ‘normal’ S6K1 activity in the presence of rapamycin because 
although containing the rapamycin resistant S2035T mutation, the rest of the mTOR 
construct was the same as wildtype mTOR. S2448 is normally phosphorylated with 
insulin stimulation (Nave et al., 1999) and would be expected to be an activating 
phosphorylation; however, the non-phosphorylatable S2448A mutant did not 
significantly decrease S6K1 activity compared to the Ml mutant. Similarly, the 
S2448E phospho-mimic did not increase basal S6K1 activity compared to both the
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Ml and S2448A mutants, suggesting that S2448 phosphorylation is not coupled to 
activation of mTOR or downstream S6K1 activity in response to insulin.
The T2446 mTOR phosphorylation site identified in Section 3 is not insulin 
stimulated and was hypothesized to be a negative regulatory site. Here, the T2446E 
phospho-mimetic mutant was expected to lower S6K1 activity as T2446 
phosphorylation was postulated to block insulin responsive S2448 phosphorylation. 
However, the T2446E mutant displayed similar activation of S6K1 as both the 
S2448A and S2448E mutants (Fig. 4.3C). Similarly the T2446A mutant was 
expected to allow more efficient phosphorylation at the S2448 position and increase 
S6K1 activity; however the T2446A mutant did not show an increase in basal S6K1 
activity. Therefore, phosphorylation of T2446 and S2448 may be mutually exclusive 
but their individual phosphorylation does not seem to considerably affect 
downstream S6K1 activity in response to insulin.
S2442 was not identified as an mTOR phosphorylation site but the proximity to both 
the T2446 and S2448 phosphorylation sites may be important for their regulation. 
However the S6K1 activity profile of both the S2442A and S2442E mutants was 
comparable to that observed when S6K1 was co-transfected with the Ml mutant 
(Fig. 4.3C) which also suggests that it is not important in regulation of S6K1 activity.
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Figure 4.2 Variable insulin response from different cell lines
Three HEK 293 cell-lines from different sources (shown as typel, 2 or 3) and CHO­
IR cells were serum starved overnight in DMEM and F12 (Hams) respectively. Cells 
were stimulated with lOOnM insulin for lOmin then lysed, the protein concentration 
was determined and equal amounts of protein were subjected to SDS-PAGE, wet 
transferred to PVDF then probed with phospho-PKB (S473) as shown (A). Relative 
fold over basal was determined for each cell type as presented in (B).
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See legend overleaf.
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Figure 4.3 Insulin stimulated S6K1 activity in the presence of mTOR mutants
CHO-IR cells were co-transfected with 5pg FLAG-tagged mTOR mutants and 3pg 
glu-glu tagged S6KlaII (denoted in figures as S6K1) using the lipofectamine method 
of transfection. Cells were serum starved overnight in F I2 medium then pre­
incubated with 50nM rapamycin or vehicle for 30min, followed by insulin 
stimulation for 1 Omin. Cells were lysed and the lysate split: half the lysate was used 
in FLAG immunoprecipitation, which was subjected to 7.5% SDS-PAGE, wet 
transferred and probed for mTOR; the other half was used in glu-glu 
immunoprecipitation for S6K1 which was used in an in vitro kinase assay in the 
presence of [y-32 P] ATP and Mg2+ with 80S ribosomes as substrate. The assay 
products were subjected to 10% SDS-PAGE and the gel cut at the 46kDa marker; the 
lower portion was fixed, dried and exposed to radiographic film. The upper portion 
was wet transferred and probed for S6K1 for normalisation of S6K1 activity.
An example of a western blot showing total mTOR and total S6K with the 80S 
autoradiograph (autorad) from a co-transfection of S6K1 with wildtype (wt) or M l 
(rapamycin resistant) mTOR, in the absence and presence o f rapamycin, is shown in 
(A); the activity data from the same co-transfections is shown in (B). The S6K1 
activity when co-transfected with each mTOR mutant in the presence o f rapamycin is 
presented in (C). All data is expressed as fold over basal ± SEM. n=3 in duplicate
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4.3.4 Effect of mTOR mutants on the regulation of S6K1 
activity by nutrient availability
The effect of the mTOR mutants in response to nutrient availability was assessed 
with the same principal of co-transfecting CHO-IR cells with glu-glu tagged 
wildtype S6KlaII (S6K1) and FLAG tagged mTOR, using rapamycin to inhibit 
endogenous mTOR in the presence or absence of nutrients. Cells were lysed and half 
the lysate was used in a FLAG immunoprecipitation for SDS-PAGE and western 
blotting for the presence of mTOR. As described above the other half of the lysate 
was used in glu-glu immunoprecipitation for S6K1 which was used in an in vitro 
kinase assay in the presence of [y-32 P] ATP and Mg2+ with 80S ribosomes as 
substrate. Assay products were analysed as described above. An example of a 
western blot showing total mTOR and total S6K1 with the 80S autoradiograph from 
a co-transfection of S6K1 with wildtype or Ml (rapamycin resistant) mTOR, in the 
absence and presence of rapamycin, is shown in Fig. 4.4A.
Within each experiment control western blots were always performed to check 
mTOR transfection efficiency and total mTOR was always equal as demonstrated in 
Fig. 4.4A. Total S6K1 was quantitated from the western blot to normalise S6K1 
activity detected in the autoradiograph of phosphorylated 80S (Fig. 4.4A). The 
activity data from the same co-transfections is shown in Fig. 4.4B; S6K1 activity was 
expressed relative to S6K1 activity when co-transfected with the Ml mutant. This 
was calculated by standardising S6K1 activity to S6K1 activity when co-transfected 
with the Ml mutant (in the absence of nutrients), which was used as the readout of 
‘normal’ S6K1 activity. The activity data from the same co-transfections is shown in 
Fig. 4.4B. In CHO-IR cells transfected with S6K1 and wildtype mTOR, there was a 
4 fold (relative to S6K1 co-transfection with Ml -nutrients) activation of S6K1 in the 
presence of nutrients; this was suppressed to basal in the absence of nutrients. The 
same profile was observed when S6K1 was co-transfected with the rapamycin 
resistant Ml mutant. This showed that the Ml-rapamycin resistant mTOR construct 
behaved like wildtype mTOR in the absence of nutrients.
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The S6K1 activity with each mTOR mutant in the presence of rapamycin is 
presented in (Fig. 4.4C). As mentioned previously, the Ml mutant was used as the 
readout of ‘normal’ S6K1 activity in the presence of rapamycin because although 
containing the rapamycin resistant mutation the remainder of the construct was 
wildtype mTOR. Under nutrient deprivation the S2448 phosphorylation site is 
dephosphorylated and this was hypothesized to negatively regulate mTOR (Nave et 
a l , 1999); therefore the phospho-mimetic S2448E mutant used here was expected to 
have an activating influence on downstream S6K1 activity. However, like the Ml 
mutant it could not sustain S6K1 activity in the absence of all nutrients. The non- 
phosphorylatable S2448A mutant also activated S6K1 activity in the presence of 
nutrients, suggesting that phosphorylation of S2448 is not essential for activation of 
mTOR or downstream S6K1 activity in response to nutrients.
The T2446 mTOR phosphorylation site identified in Chapter 3 is phosphorylated in 
response to nutrient deprivation so the T2446A mutant would be expected to 
promote S6K1 activity since it would allow S2448 phosphorylation. However, as 
established above, S2448 phosphorylation is not enough to enable S6K1 activity, 
and data from both T2446 mutants suggests likewise. So although phosphorylation 
of T2446 and S2448 is mutually exclusive in response to nutrients, their individual 
phosphorylation does not seem to affect downstream S6K1 activity.
The S6K1 activity profiles of S2442A and E were comparable to that observed in the 
Ml mutant (Fig. 4.4C) which suggests that this site is not important in regulation of 
S6K1 activity.
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Figure 4.4 Effect of mTOR mutants on the regulation of S6K1 activity by amino 
acid availability
See legend overleaf.
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Figure 4.4 Effect of mTOR mutants on the regulation of S6K1 activity by amino 
acid availability
CHO-IR cells were co-transfected with 5pg FLAG-tagged mTOR mutants and 3pg 
glu-glu tagged S6KlaII (denoted in figures as S6K1) using the lipofectamine method 
of transfection. Cells were incubated in F I2 medium containing 10% serum for 1 
hour or nutrient starved in D-PBS in the presence of vehicle (B) or 50nM rapamycin 
(C). Cells were lysed and the lysate split: half the lysate was used in FLAG 
immunoprecipitation, which was subjected to 7.5% SDS-PAGE, wet transferred and 
probed for mTOR; the other half was used in glu-glu immunoprecipitation for S6K1 
which was used in an in vitro kinase assay in the presence of [y- P] ATP and Mg 
with 80S ribosomes as substrate. The assay products were subjected to 10% SDS- 
PAGE and the gel cut at the 46kDa marker; the lower portion was fixed, dried and 
exposed to radiographic film. The upper portion was wet transferred and probed for 
S6K1 for normalisation of S6K1 activity.
An example o f a western blot showing mTOR and S6K with the 80S autoradiograph 
(autorad) from a co-transfection of S6K1 with wildtype (wt) or M l (rapamycin 
resistant) mTOR, in the absence rapamycin, is shown in (A); the activity data from 
the same co-transfections is shown in (B). The S6K1 activity when co-transfected 
with each mTOR mutant in the presence of rapamycin is presented in (C) ± SEM. 
Data is expressed as S6K1 activity relative to the activity of S6K1 when co­
transfected with the M l mutant (-nutrient sample) which was used as the readout of 
‘normal’ S6K1 activity. n=2 in duplicate.
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4.3.5 Blotting phospho-4E-BPl from co-transfection with 
T2446 mTOR mutants
As established in Section 1.5.1, 4E-BP1 has been reported as a substrate of mTOR 
and phosphorylation of 4E-BP1 has been used as readout of mTOR activity. 
Therefore in parallel to assessing the impact of the mutant mTOR on S6K1 activity, 
the effects of mutant mTOR on 4E-BP1 phosphorylation were also investigated using 
phospho-specific 4E-BP1 antibodies (Mothe-Satney et al., 2000a). HA tagged 
human 4E-BP1 (gift from A.-C. Gingras, McGill University, Canada) was used to 
transfect HEK cells. Cells were stimulated with insulin then immunoprecipitated 
with anti-HA antibody; the immunoprecipitates were blotted with phospho-4E-BPl 
at positions S65 or T70 (equivalent to rat numbering S64 and T69 respectively) 
antibodies (gift from J. C. Lawrence Jr., University of Virginia, USA) as shown in 
Fig. 4.5A. Insulin stimulates the phosphorylation of 4E-BP1 and here phospho-4E- 
BP1 S65 and T70 seemed able to detect an increase in 4E-BP1 phosphorylation in 
response to insulin stimulation. Both phospho-antibodies reacted with HA 
immunoprecipitates from non-transfected cells; the background signal was faintly 
insulin responsive and it is likely that the HA immunoprecipitation brought down a 
contaminating protein which was reactive to the phospho-antibody. Preliminary 
experiments were similar to the S6K1 co-transfections; FLAG-tagged mTOR 
mutants were co-transfected with HA-tagged wildtype 4E-BP1 in HEK cells. An 
example of a co-transfection with the Ml and T2446A and T2446E mutants is shown 
in Fig. 4.5B. Transfected HEK cells were serum starved overnight then treated with 
50nM rapamycin prior to insulin stimulation. Cells were lysed and 
immunoprecipitated with anti-HA; immunoprecipitates were subjected to 15% SDS- 
PAGE then transferred and sequentially probed with phospho-4E-BPl at S65 and 
T70. Cells transfected with wildtype 4E-BP1 were expected to be rapamycin 
sensitive in the absence of mutant mTOR. The phospho-antibodies detected a non 
insulin-responsive background, similar to the background from HA 
immunoprecipitates from non-transfected cells (Fig. 4.5). However, cells co­
transfected with 4E-BP1 and the Ml rapamycin resistant mutant were expected to 
support 4E-BP1 phosphorylation in the presence of rapamycin. However, neither 
phospho-antibody detected an insulin-stimulated increase in 4E-BP1
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phosphorylation. Similarly, no change in 4E-BP1 phosphorylation was detected 
when co-expressed with either T2446A or T2446E. This interpretation may not be 
accurate because of the background detected by both phospho-antibodies from HA 
immunoprecipitates from non transfected cells. The background from the phospho- 
specific antibodies made it difficult to interpret the effects of the mTOR mutants on 
4E-BP1 phosphorylation. This method was rejected in favour of a direct assay of 
mTOR activity with 4E-BP1 as substrate.
4.3.6 Assessment of 4E-BP1 phosphorylation in mTOR 
in vitro kinase assays at high ATP concentration
Dennis et al., (2001) previously reported that mTOR acted as a sensor of cellular 
levels of ATP and mTOR activity was dependent on the ATP concentration; their in 
vitro kinase assays were conducted using high ATP concentration, and this method 
was tested here in both radioactive and non-radioactive assays to assess assay 
sensitivity. HEK cells were transfected with FLAG-tagged wildtype mTOR and 
were treated in the presence or absence of nutrients (as described in Fig. 4.6 legend) 
to assess the effect on 4E-BP1 phosphorylation. Extracts were immunoprecipitated 
with anti-FLAG then subjected to an in vitro kinase assay with 3mM ATP and 4E- 
BP1 as substrate in the presence (Fig. 4.6 autoradiograph) or absence (Fig. 4.6 
western blots) of [y-32 P] ATP. Low level 4E-BP1 phosphorylation was detected in 
the autoradiograph, though no difference was observed in the presence or absence of 
nutrients. The low level phosphorylation seems more likely to be background 
phosphorylation since the ‘bead only’ (immunoprecipitation with anti-mouse IgG in 
the absence of FLAG antibody) negative control demonstrates the same level of 
phosphorylation and the level of phosphorylation detected is significantly lower than 
that of the positive control. The radioactive kinase assay uses high concentrations of 
unlabelled ATP and the specific activity of radio-labelled ATP is relatively low, to 
improve sensitivity of the assay a non radioactive approach, at high ATP 
concentration, was also used. 4E-BP1 was allowed to phosphorylate in the presence 
of mTOR immunoprecipitates and the level of phosphorylation was determined using 
phospho-4E-BPl antibody as described in Fig. 4.5. Western blot analysis showed 
that phospho-4E-BPl (S65) reacted to low level phosphorylation of 4E-BP1 which
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was indistinguishable from the background ‘bead only’ control. Again, the MAPK 
positive control showed strong phosphorylation of 4E-BP1 (S65) in the western blot 
which was clearly distinguishable from the background.
4.3.7 mTOR activity towards 4E-BP1 is dependent on the 
immunoprecipitating antibody
The inability to assay mTOR activity towards exogenous substrates even at high 
ATP concentration may stem from the method of assay or the immunoprecipitating 
mTOR antibody, given that mTOR activity has been found to be dependent on the 
antibody used to immunoprecipitate mTOR (Brunn et al., 1997b; Heesom and 
Denton, 1999). Therefore, three different in vitro kinase methods were used to assay 
mTOR activity. mTOR was immunoprecipitated with the following mTOR 
antibodies: aTOR; (Heesom and Denton, 1999) raised against the C-terminal portion 
of mTOR (a.a. 2433-2450) which has the identical epitope to the activating mTAbl 
antibody (Brunn et al., 1997b); anti-FRAP (Calbiochem) a polyclonal antibody 
raised against a peptide corresponding to residues 2524-2538 in rat mTOR which is 
conserved in the human sequence; or hTOR (Hosoi et al., 1998) (Oncogene) a mouse 
monoclonal antibody raised against a peptide corresponding to residues 230-240 of 
human mTOR, for endogenous mTOR. FLAG antibody was used for transfected 
wildtype mTOR. Assays were performed in the presence of [y- P] ATP and Mg 
using 0.5pg 4E-BP1 as substrate. The first method was previously used successfully 
in the laboratory to assay mTOR autokinase activity as described in Withers et al., 
(1997). The other two methods were as described in Brunn et al., (1997a) and 
Mothe-Satney et al., (2000a). Only the anti-FRAP antibody (Calbiochem) 
immunoprecipitated mTOR autokinase activity (Fig. 4.7A). In contrast, only the 
aTOR antibody (Heesom and Denton, 1999) was successful in immunoprecipitating 
activity towards 4E-BP1 using the Brunn and Mothe-Satney methods. Therefore, 
isolation of mTOR kinase activity is dependent on the antibody used in the 
immunoprecipitation. The aTOR epitope is identical to that of the mTAbl antibody 
(Brunn et al., 1997b) and encompasses the mTOR T2446 and S2448 phosphorylation 
sites.
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Figure 4.5 Blotting phospho-4E-BPl from co-transfection with T2446 mTOR 
mutants
(A) Non-transfected HEK cells (indicated as ‘N ’) and HEK cells transfected with 
5pg HA-tagged wildtype 4E-BP1 were serum starved overnight then stimulated with 
lOOnM insulin for lOmin. Cells were lysed and equal amounts of protein were 
immunoprecipitated with HA antibody. The immunoprecipitates were subjected to 
15% SDS-PAGE, wet transferred in SDS-ffee transfer buffer then probed 
sequentially with phospho-4E-BPl S65 or T70 and finally with anti-HA to check 
transfection efficiency.
(B) HEK cells were also co-transfected with 5pg HA-tagged wildtype 4E-BP1 and 
5pg FLAG tagged mTOR T2446 mutant as indicated using the calcium phosphate 
method of transfection. Cells were serum starved overnight then treated with 50nM 
rapamycin for 30min followed by stimulation with lOOnM insulin for lOmin. Cells 
were lysed and the lysates were used in HA immunoprecipitations which were 
subjected to 15% SDS-PAGE, wet transferred in SDS-free transfer buffer then 
blotted sequentially with phospho-4E-BPl S65, T70 and finally with anti-HA to 
check transfection efficiency.
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Figure 4.6 Assessment of 4E-BP1 phosphorylation in mTOR in vitro kinase 
assays at high ATP concentration
HEK cells were transfected with FLAG-tagged wildtype mTOR. Cells were treated 
in the presence or absence of nutrients for 1 hour as indicated. Lysates were 
immunoprecipitated with FLAG. ‘Bead only’ represents immunoprecipitation with 
mouse IgG in the absence of antibody. One set of FLAG immunoprecipitates was 
subjected to an in vitro kinase assay in the presence of 3mM ATP (Dennis et al.,
2001), [y-32 P] ATP and Mg2+ with 0.5 pg 4E-BP1 as substrate. Recombinant MAPK 
(500ng) was used as positive control. Another set of FLAG immunoprecipitates was 
subjected to a ‘cold’ in vitro kinase assay in the presence of 3mM ATP and Mg2+ 
with 0.5pg of recombinant 4E-BP1 as substrate. MAPK was again used as positive 
control. Reactions were stopped with 4x sample buffer then subjected to 12% 
Tris/tricine SDS-PAGE. Reaction products from the assay with [y-3 P] ATP were 
analysed by autoradiography as presented in the top panel. Reaction products from 
the assay without [y-32 P] ATP were wet transferred in SDS-free transfer buffer and 
probed with phospho-4E-BPl (S65), then stripped and re-probed for total 4E-BP1. 
Results are shown in duplicate.
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Figure 4.7 mTOR activity towards 4E-BP1 is dependent on the immuno­
precipitating antibody
Non-transfected CHO-IR cells or wildtype mTOR transfected (immunoprecipitated 
with FLAG) CHO-IR cells were lysed and immunoprecipitated with: aTOR antibody 
(Heesom and Denton, 1999), anti-FRAP (Calbiochem), or hTOR (Oncogene) for 
endogenous mTOR; or FLAG for transfected mTOR. Immunoprecipitates were 
processed and subjected to an in vitro kinase assay according to 3 published methods 
as described in Section 2.2.7.3 and 2.2.1.5. Assays were in the presence of [y-32 P] 
ATP and Mg2+ for the autokinase assay as presented in (A) or additionally with 
0.5pg 4E-BP1 as substrate (B); recombinant CK2 (500ng) was used as positive 
control in (B). All reactions were stopped with 4x sample buffer. Reaction products 
from the mTOR autokinase assay were subjected to 7.5% SDS-PAGE then fixed, 
dried and analysed by autoradiography as shown in (A). Reaction products from (B) 
were subjected to 12% Tris/tricine SDS-PAGE, processed as described above then 
analysed by autoradiography as indicated. Results are shown in duplicate.
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4.3.8 FKBP/rapamycin is unable to inhibit endogenous 
mTOR activity in vitro
By identifying the aTOR antibody as the most suitable for immunoprecipitating 
mTOR activity, it was clear that if mutant mTOR was transfected it would not be 
possible to isolate mTOR activity with the FLAG antibody. Inhibition of 
endogenous mTOR would have to be performed in vitro, since binding of the 
FKBP/rapamycin complex is not covalent and would be washed from wildtype 
mTOR during processing of aTOR immunoprecipitates. Therefore, the mTOR 
mutants were transfected and immunoprecipitated with aTOR, isolating both 
endogenous and transgene expressed mTOR. These immunoprecipitates were 
incubated with FKBP/rapamycin to isolate activity from the rapamycin resistant 
mutants only. In preliminary trials HEK (Fig. 4.8A) or CHO-IR (Fig. 4.8B) cells 
were lysed and immunoprecipitated with aTOR or transfected with the Ml mutant 
then lysed and immunoprecipitated with aTOR. Immunoprecipitates were processed 
according to the Mothe-Satney method (Mothe-Satney et al., 2000a). A fraction of 
each immunoprecipitate was extracted prior to the in vitro kinase assay to assess the 
level of mTOR in each sample (top panel Fig. 4.8 A & B). Immunoprecipitates were 
pre-incubated in assay buffer or with lOpM FKBP and lOpM rapamycin in assay 
buffer, for lhr at 25°C, to inhibit endogenous rapamycin sensitive mTOR, then 
assayed. The amount of mTOR immunoprecipitated was substantial in both cell 
types (top panel Fig. 4.8 A & B), although HEK cells seemed to express the 
recombinant gene more efficiently than CHO-IR cells. There only seemed to be a 
background level of 4E-BP1 phosphorylation detected by autoradiography (lower 
panel Fig. 4.8 A & B) when compared to the casein kinase II (CK2) positive control. 
The FKBP/rapamycin additions did not inhibit the aTOR immunoprecipitated from 
non-transfected cells in either cell type though this is unlikely to be from a defect in 
FKBP. It is likely that a contaminating kinase was co-immunoprecipitated with 
mTOR which had low level activity and was insensitive to FKBP/rapamycin, since 
the ‘bead only’ immunoprecipitation had the same background. In a similar 
experiment, CHO-IR cells were transfected with Ml (rapamycin resistant mTOR), 
the T2446A or the T2446E mutant, then immunoprecipitated and processed as 
described above, with or without FKBP/rapamycin in the assay. Non-transfected
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cells immunoprecipitated with aTOR brought down a background level of activity 
when compared to the positive control. The background level of phosphorylation 
was insensitive to FKBP/rapamycin treatment and was present in cells transfected 
with the Ml mutant. Although there seemed to be a negligible level of 
phosphorylation from samples with the T2446A or E mutant, this could have been 
due to transfection efficiency and results here are inconclusive because of the 
contaminating kinase activity from non-transfected cells. The inconsistency in 
isolating mTOR activity persisted despite refining conditions.
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Figure 4.8 FKBP/rapamycin is unable to inhibit endogenous mTOR activity in 
vitro
See legend overleaf.
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Figure 4.8 FKBP/rapamycin is unable to inhibit endogenous mTOR activity in 
vitro (legend)
Non-transfected (denoted by N) or Ml (rapamycin-resistant mTOR construct) 
transfected HEK (A) or CHO-IR (B) cells were lysed and immunoprecipitated with 
aTOR. ‘Bead only’ represents immunoprecipitation with protein A in the absence of 
antibody. A fraction of the mTOR immunoprecipitate was extracted for blotting with 
aTOR (top panel A & B). The remaining immunoprecipitate was incubated in assay 
buffer or with lOpM FKBP and lOpM rapamycin in assay buffer for lhr at 25°C 
with agitation at 300rpm. Immunoprecipitates were subjected to an in vitro kinase 
assay in the presence of [y-32 P] ATP and Mg2+ with 0.5pg 4E-BP1 as substrate. 
Recombinant CK2 (500ng) was used as a positive control. The assay method was as 
described by Mothe-Satney et al., (2000). Reactions were stopped with 4x sample 
buffer then subjected to 12% Tris/tricine SDS-PAGE. Gels were fixed, dried and 
analysed by autoradiography as shown in the bottom panel of (A) & (B). Results 
shown are in duplicate and representative of 2 independent experiments.
(C) CHO cells were transfected with Ml or T2446A or E mutant using the 
lipofectamine method of transfection. Equal amounts of protein were 
immunoprecipitated with aTOR then processed as described by Mothe-Satney et al., 
(2000). Immunoprecipitates were incubated in assay buffer or with 10pM FKBP and 
lOpM rapamycin in assay buffer for lhr at 25°C with agitation at 300rpm, then 
subjected to an in vitro kinase assay in the presence of [y-3 P] ATP and Mg2+ with 
0.5 pg 4E-BP1 as substrate. Recombinant CK2 (500ng) was used as a positive 
control. Reactions were stopped with 4x sample buffer then subjected to 12% 
Tris/tricine SDS-PAGE. Gels were fixed, dried and analysed by autoradiography. 
Results shown are in duplicate.
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4.4 Discussion
In the previous chapter evidence was presented which showed that S2448 and T2446 
are sites of reversible phosphorylation in the mTOR catalytic domain. An inverse 
relationship between these two phosphorylation sites was identified, which was 
dependent on growth factor and nutrient status, suggesting that phosphorylation at 
these sites had regulatory effects on mTOR function. The mechanisms by which the 
S2448 and T2446 phosphorylation affect downstream targets are unclear. The 
present study used mutational analysis to dissect the effects of phosphorylation at 
S2442, T2446 and S2448 on S6K1 activity. Evidence shows that none of the 
individual mutations caused a difference in S6K1 activity when compared with the 
Ml construct, which contained the rapamycin resistant S2035T mutation but had 
wildtype S2442, T2446 and S2448. The S2448 phosphorylation site was considered 
a likely activating site in mTOR since phosphorylation is mediated by mitogenic 
stimuli which activate the mTOR pathway (Nave et al., 1999; Reynolds et al., 2002; 
Sekulic et al., 2000). Here, the phospho-mimetic S2448E mutation did not increase 
basal S6K1 activity and neither did the non phosphorylatable S2448A mutant 
significantly decrease S6K1 activity compared to the rapamycin resistant Ml 
construct, or any of the mutant constructs as determined by 80S ribosome 
phosphorylation. The T2446 phosphorylation site, which is phosphorylated under 
conditions that normally reduce activity downstream of mTOR, was hypothesized as 
the mutually exclusive partner site to S2448 and thus considered as a negative 
regulatory site in response to insulin. Here, the T2446E mutant did not significantly 
reduce S6K1 activity and the T2446A mutant, which should allow better S2448 
phosphorylation, did not increase S6K1 activity. Furthermore, the adjacent S2442 
site mutations shared the same S6K1 activity profiles as the other mutants. These 
data suggest that mTOR phosphorylation does not directly affect S6K1 activity. 
These findings were confirmed by another group who used a similar approach in 
which they produced rapamycin resistant T2446A, S2448A and a double 
T2446A/S2448A mTOR mutant. When these mutants were co-transfected with 
S6K1, S6K1 activity was not affected (Sekulic et al., 2001).
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The effects of mutant mTOR in relation to nutrient availability were not assessed by 
Sekulic et al., (2000). Data presented here also suggest that each single mutation has 
no effect on downstream S6K1 activity in response to nutrients. As mentioned 
earlier the S2448 phosphorylation site is considered an activating phosphorylation. 
However, the S2448E phospho-mimetic mutant did not support S6K1 activity in the 
absence of nutrients. In fact none of the mutants could overcome nutrient starvation 
and S6K1 activity remained at a basal level in response to nutrient deprivation.
The data presented here does not support the hypothesis that phosphorylation of 
S2448 or T2446 are involved in regulation of mTOR activity towards S6K1 in cells. 
It is possible that the glutamic acid mutation does not fully mimic the phosphorylated 
form of mTOR. The effects of mTOR phosphorylation may be more subtle than 
having an effect on a downstream target and might instead act to regulate the 
signalling potential of factors associated with mTOR, as reports have suggested that 
mitogen stimulation does not modulate in vitro mTOR kinase activity towards either 
S6K1 or 4E-BP1 (Dennis et al., 2001; Hara et al., 1998).
As no effects of changes at S2448 or T2446 were detected in vivo, we sought to 
determine whether any effects could be detected using in vitro assays under defined 
conditions. However, it proved extremely difficult to develop a reliable method for 
consistently assaying mTOR protein kinase activity. mTAbl has been described and 
used as an activating mTOR antibody (Brunn et al., 1997b) and its epitope spans a 
repressor domain in mTOR (Sekulic et al., 2001). Deletion of this region 
corresponds with an increase in mTOR kinase activity, and relief of repression by 
mTAbl is thought to involve substrate presentation (Sekulic et al., 2001). The 
mTAbl antibody has been reproduced by several groups using the identical epitope 
spanning residues 2433-2450 of the mTOR catalytic domain (Sekulic et al 2001; 
Heesom and Denton, 1999). The epitope encompasses all the sites mutated here and 
it should be noted that the mTAbl antibody is not a phospho-antibody and recognises 
mTOR phosphorylation by reduced reactivity in western blot analysis (Scott and 
Lawrence, 1998). The aTOR antibody used here is identical to the mTAbl antibody, 
but we were unable to assay consistent mTOR activity. If actual mTOR kinase 
activity were to be attained, it is possible that aTOR or mTAbl may have different
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binding affinities for each mTOR mutant which may affect the mTOR activity 
observed. Heesom and Denton (1999) reported that aTOR (denoted Ab 1 in the 
reference) retrieved less mTOR by immunoprecipitation from insulin-treated cells 
because of in vivo mTOR phosphorylation within the antibody epitope (presumably 
S2448). Any ‘artificial’ activation of mTOR by mTAbl (or similar antibody) may 
override and mask the real effects of the mutants themselves. McMahon et al., 
(2002) also produced a S2448E mutant which did not affect in vitro phosphorylation 
of 4E-BP1 at T37/46 or T70 when activated with the mTAbl antibody. Sekulic et 
al., (2001) who also made the T2446 and S2448 point mutations did not test the 
mutant effect on 4E-BP1 phosphorylation; however, they did produce a deletion 
mutant (2430-2450) to identify the mTAbl epitope as a region forming a repressor 
domain. Taken together, I would expect the mutant mTOR produced here to have no 
global effect on 4E-BP1 phosphorylation in response to both growth factor 
stimulation and nutrient deprivation. It is likely that the S2448 phosphorylation 
(mimicked by the S2448E mutant) cannot relieve inhibition of this repressor domain 
as observed with the S6K1 data.
The difficulties in obtaining mTOR activity remain problematic as differences in 
isolation procedures affect the activities brought down in an mTOR 
immunoprecipitate; these could include mTOR associated kinase activities or other 
associated proteins which include Raptor. Isolation of mTOR with Raptor is 
detergent sensitive (Hara et al., 2002; Kim et al., 2002), and Raptor was required for 
in vitro mTOR activity towards 4E-BP1. Therefore, despite the negative data 
obtained from the mutants they may still prove a useful tool.
One factor which should be considered in the interpretation of these results is the 
actual principal of assessing the effect of mutant mTOR over endogenously 
expressed mTOR. The principal was to exploit the rapamycin resistant mutation that 
was cloned into each construct as S2035T. S2035 has long been identified as the site 
to mutate for rapamycin resistance (Chen et al., 1995; Lorenz and Heitman, 1995) 
and was always considered as a silent mutation until recent reports which indicated 
that mutation at this site affected mTOR substrate selectivity (McMahon et al.,
2002). Specifically, S2035I had a much lower mTOR kinase activity for
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phosphorylation of 4E-BP1 at T37 and T46 and a moderately lower activity for T70 
compared to wildtype mTOR; furthermore several other S2035 substitutions which 
include S2035T (also E, D and R mutations) affected mTOR kinase activity for 4E- 
BP1 and S6K1 and only the S2035W mutation was considered truly silent 
(McMahon et al., 2002). The S2035T mutation was used here and the Sekulic group 
(2000) used the S2035I mutation. Therefore, it is possible that the rapamycin 
resistant mutation affected the mutant mTOR activity towards its downstream targets 
and the effect of phosphorylation at T2446 and S2448 may still prove significant.
Additionally, the inability to achieve mTOR kinase activity sidelined plans to 
analyse mTOR and PP2A interaction and the effect of mutant mTOR kinase activity 
towards the PP2A associated phospho-protein a4. Initially, a4 was cloned into a 
modified pTri-ex vector to incorporate the pTri-ex -HSV and -His tag at the C- 
terminus; this construct was expressed in bacterial cells to produce recombinant a4 
(Section 2.2.3.4). An inducible protein was expressed with molecular weight 
~55kDa but could not be isolated sufficiently, possibly because the His-tag had been 
cleaved or the His-tag was not exposed. The pTri-ex-a4 construct was also used to 
transfect CHO-IR cells but a4 could not be clearly identified by western blot. 
Correspondence with Prof. D. Brautigan (Director of Cell Signalling, University of 
West Virginia, USA) indicated that his collaboration with J. C. Lawrence Jr. 
(University of Virginia, USA) showed that while mTOR could phosphorylate 4E- 
BP1, it could not phosphorylate GST-a4; neither had they seen co- 
immunoprecipitation of a4 with mTOR, or PP2A with mTOR which was also tried 
unsuccessfully (data not shown). Therefore, the studies with mTOR, PP2A and a4 
were abandoned.
Further, in collaboration with Dr I. Gout (Ludwig Institute for Cancer Research, 
London), a series of experiments were performed to identify whether CoA synthase 
(CoAsy) was regulated by mTOR. CoAsy is a 63kDa protein found to be weakly 
associated with S6K (Zhyvoloup et al., 2002). Initial studies showed no association 
between S6K1 and CoAsy or between mTOR and CoAsy even with less stringent 
washing of immunoprecipitates. Insulin did stimulate a 2 fold activation of CoAsy
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but this was not inhibited by rapamycin treatment, suggesting that mTOR was not 
involved and this was also not pursued further.
In summary, the established S2448 PKB phosphorylation site does not directly affect 
S6K1 activity and the mutually exclusive T2246 phosphorylation site does not 
negatively regulate S6K1 activity in response to growth factors. Moreover, neither 
alanine nor glutamic acid mutants at S2442, T2446 or S2448, within a rapamycin 
resistant backbone, were able to overcome the effects of nutrient deprivation on 
S6K1 activity. Evidence suggests that individual phosphorylation of these sites is 
insufficient to affect downstream S6K1 activity and the importance of differential 
phosphorylation at T2446 and S2448 remains to be determined.
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5 The involvement of TSC in upstream 
signalling of mTOR
5.1 Summary
The tuberous sclerosis complex (TSC) is an inherited human genetic disorder 
characterised by mutation of either the TSC1 or TSC2 gene. TSC1 and TSC2 interact 
to form a functional complex and epistatic studies in Drosophila indicate that TSC 
functions within the insulin signalling cascade upstream or parallel to the mammalian 
target of rapamycin (mTOR). PKB is able to directly phosphorylate TSC2 and 
further studies with TSC revealed that it acted as a negative regulator of two 
downstream effectors of translation, S6K1 and 4E-BP1, both of which are 
downstream targets of mTOR. Moreover, targeted disruption of TSC interaction 
caused constitutive activation of S6K1, suggesting deregulation of upstream 
signalling elements. To further understand the factors involved in TSC signalling, a 
mouse embryonic fibroblast cell line derived from mice deficient for TSC2 was used 
here to analyse defects in the insulin signalling cascade. The loss of TSC2 caused 
down-regulation of insulin stimulated PKB activation and consequently mTOR 
S2448 phosphorylation, while simultaneously displaying constitutive activation of 
S6K1. Moreover, the MAPK kinase pathway was down-regulated and IRS-1 levels 
were significantly reduced. Low levels of IRS-1 in TSC2 deficient fibroblasts 
directly impaired IRS-1 associated class la  phosphoinositide 3-kinase (PI3K) lipid 
kinase acivity. Similarly, PDGF-stimulated activation of PI3K lipid kinase activity 
was also impaired. These data suggest that loss of TSC2 impairs insulin signalling 
by affecting the turnover of the IRS-1 protein which in turn affects associated 
signalling downstream of PI3K.
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5.2 Introduction
The inherited human genetic disorder tuberous sclerosis complex (TSC) occurs via 
mutation of the TSC1 and TSC2 gene which respectively encode the proteins TSC1 
(hamartin) and TSC2 (tuberin) (Young and Povey, 1998). TSC functions as a 
complex and was identified as a negative regulator of cell size and proliferation 
(Tapon et al., 2001). Epistatic studies in Drosophila place TSC parallel to or within 
the mTOR signalling pathway (Gao et al., 2002; Potter et al., 2001) and PKB is able 
to phosphorylate TSC2 at S939 and T1462 without affecting association with TSC1 
(Dan et al., 2002; Manning et al., 2002). Loss of TSC function results in suppression 
of PKB activation and the constitutive activation of S6K1 (Kwiatkowski et al., 2002; 
Gao et al., 2002; Inoki et al., 2002; Jaeschke et al., 2002; Zhang et al., 2003a), a 
target of mTOR signalling. Over-expression of TSC specifically inhibits 
phosphorylation of S6K1 at the rapamycin sensitive T389 site (Inoki et al., 2002). 
Additionally, co-expression of TSC inhibits insulin-stimulated phosphorylation of 
4E-BP1 and represses Cap-dependent translation (Tee et al., 2002). Both S6K1 and 
4E-BP1 are specific targets of mTOR and these studies suggest TSC has a negative 
regulatory role specifically within the mTOR signalling pathway. There is no 
evidence of physical interaction between mTOR and TSC (Gao et al., 2002; Zhang et 
al., 2003a) but mTOR has been described as a mediator between TSC and S6K1 
(Inoki et al., 2002; Tee et al., 2002). However, TSC/p53-null fibroblasts (TSC2'/_ 
fibroblasts) have also been used to establish that TSC inhibits S6K1 via PI3K but 
independently of mTOR (Jaeschke et al., 2002); this suggests that TSC functions in 
both an mTOR-dependent and mTOR-independent pathway which might explain the 
constitutive activation of S6K1 with suppressed PKB activity in the absence of TSC. 
Such evidence suggests that TSC may be important in regulation of signalling 
elements upstream of mTOR and PKB.
Insulin stimulation activates the insulin receptor (IR) tyrosine kinase activity which 
initiates the recruitment and tyrosine-phosphorylation of the insulin receptor 
substrate (IRS) family of proteins, of which IRS-1 is the most well characterised 
(White, 1997). The IRS proteins have multiple tyrosine and ser/thr phosphorylation 
sites (White, 1997) and tyrosine phosphorylation of IRS-1 is the main mechanism of
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activating class la PI 3-kinases (PI3K) and the ras/MAPK pathway. Multi-site 
tyrosine phosphorylation of IRS-1 causes the recruitment and activation of PI3K 
lipid kinase activity and initiation of the insulin signalling cascade (Shepherd et al., 
1998). Insulin stimulation also mediates degradation of IRS-1 by a feedback 
mechanism involving ser/thr phosphorylation of IRS-1, a process which has been 
implicated in the development of insulin resistance (DeFea and Roth, 1997a, 1997b; 
Paz et al., 1997; Cengal et al, 1999; Li and DeFea, 1999). However, ser/thr 
phosphorylation of IRS-1 largely appears to initiate its degradation by the 
proteasome (Haruta et al., 2000). Evidence suggests that phosphorylation of serine 
residues targets IRS-1 for degradation via a wortmannin and rapamycin sensitive 
pathway (Hartley and Cooper, 2002; Hartman et al., 2001; Haruta et al., 2000; Li and 
DeFea, 1999) and it has also been reported that in response to cytokines, both mTOR 
and S6K1 are capable of phosphorylating serine residues on IRS-1 in vitro (Hartman 
et al., 2001). Taken together, the absence of TSC2 resulting in constitutively 
activated S6K1 may bring about deregulation of these feedback mechanisms 
involving IRS-1.
Since constitutively activated S6K1 is coupled to suppression of PKB activity in the 
absence of functional TSC (Kwiatkowski et al., 2002; Gao et al., 2002; Inoki et al., 
2002; Jaeschke et al., 2002; Zhang et al., 2003a), mouse embryonic fibroblasts 
(MEFs) derived from mice deficient for TSC2 and the tumour suppressor p53 (as 
described by Jaeschke et al., 2002) were used to further understand the significance 
and consequence of constitutively activated S6K1 in the absence of TSC2. The 
effects of losing TSC2 on feedback mechanisms involving IRS-1 were investigated 
by assessing IRS-1 associated class la  phosphoinositide 3-kinase (PI3K) lipid kinase 
activity.
The present findings show that the loss of TSC2 in TSC2-null/p53-null (TSC2'/_) 
mouse embryonic fibroblasts (MEFs) causes downregulation of factors in the insulin 
signalling cascade while maintaining constitutive activation of S6K1. Moreover, 
IRS-1 associated class la PI3K lipid kinase acivity was impaired due to significantly 
reduced IRS-1 levels and lipid kinase activity was not restored by activation of the 
PDGF receptor.
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5.3 Results
5.3.1 Effect of insulin stimulation on TSC2+/+ and TSC2_/~
cells
To assess the effects of the absence of TSC2 on the mTOR signalling pathway, 
MEFs derived from mice deficient for TSC2 and the tumour suppressor p53 (denoted 
throughout as TSC2'7') and control MEFs derived with TSC2 but absent of p53 
(denoted throughout as TSC2+/+) were used; these were provided by Dr R. Lamb 
(Institute for Cancer Research, London) (Jaeschke et al., 2002; Zhang et al., 2003a). 
Cells were serum starved overnight then stimulated with insulin for the times 
indicated. Whole cell lysates were blotted with various antibodies to determine the 
protein levels and phosphorylation states of certain proteins in both TSC2+/+ and 
TSC2'7* fibroblasts (Fig. 5.1). Phosphorylation of PKB at S473 indicates activation 
of PKB. This was only observed in TSC2+/+ fibroblasts as described by Jaeschke et 
al., (2002). In contrast S6K1 was constitutively phosphorylated (T389) in TSC2'/_ 
fibroblasts (Kwiatkowski et al., 2002; Gao et al., 2002; Inoki et al., 2002; Jaeschke 
et al., 2002; Zhang et al., 2003a); this was also confirmed in the total S6K1 immuno- 
blot where a slower migrating, hyper-phosphorylated form of S6K1 was observed in 
TSC2'7' fibroblasts, though total levels of protein were the same. mTOR has been 
shown to phosphorylate S6K1 at T389 and activate S6K1 activity (Burnett et al., 
1998; Isotani et al., 1999). Here, the constitutive activation of S6K1 coupled with 
downregulation of PKB activity suggests that activation of S6K1 may be 
independent of PKB in TSC2'7' fibroblasts. Western blot analysis of mTOR 
phosphorylation showed that insulin stimulated phosphorylation of mTOR at S2448 
was only observed in TSC2+/+ cells where PKB activation remained intact. mTOR- 
S2448 was not phosphorylated in the TSC2'7’ fibroblasts. Insulin stimulated 
activation of MAPK was also severely reduced in TSC2'7' fibroblasts, indicating that 
regulation of the ras/MAPK signalling pathway was impaired. Downregulation of 
MAPK, mTOR and PKB indicated that the fault in impaired insulin signalling lay 
further upstream. Indeed, western blot analysis of IRS-1 revealed that total levels of 
IRS-1 protein were almost absent in TSC2'7' fibroblasts. The general lack of IRS-1
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may be from enhanced turnover of IRS-1 which has been targeted for degradation by 
a feedback mechanism and this was likely to affect IRS-1 associated PI3K activity.
5.3.2 p85 associated lipid kinase activity in TSC2 +/+ and 
TSC2 cells when stimulated with insulin
Taking into account the lack of IRS-1 in TSC2'7' fibroblasts, we wanted to verify that 
PI3K activity itself was intact. TSC2+/+ and TSC2‘/_ whole cell lysates were probed 
for levels of p85 and pi 10 and there were equivalent levels of both PI3K sub-units 
observed (Fig. 5.2A). In accordance, the p85 associated lipid kinase activities 
assayed from both sets of fibroblasts were also comparable although p85-associated 
PI3K activity was slightly lower in TSC2_/‘ fibroblasts. This data indicated that loss 
of TSC2 did not affect p85 and pi 10 protein levels and p85-associated PI3K activity 
was intact in TSC2'/_ fibroblasts; however, the activity was independent of insulin 
stimulation.
5.3.3 IRS-1 associated lipid kinase activity in TSC2+/+ 
and TSC2-/~ cells when stimulated with insulin
Although lipid kinase activity from class la  PI3K was intact in TSC2'/_ fibroblasts, 
the total protein levels of IRS-1 in these cells suggested that there would be a 
reduction in IRS-1 associated lipid kinase activity. As expected,
immunoprecipitation of IRS-1 recovered trace amounts of tyrosine phosphorylated 
IRS-1 protein which coincided with a lack of p85 association (Fig. 5.3A). p85 
immunoprecipitates also showed lack of IRS-1 association in TSC2"7' fibroblasts 
(Fig. 5.3A). This was reflected in the lipid kinase activities associated with the IRS- 
1 immunoprecipitates in which insulin barely stimulated lipid kinase activity above 
basal from the TSC2'7' fibroblasts. This indicates that loss of TSC2 triggers lack of 
IRS-1, resulting in the reduced ability of insulin to regulate class la PI3K.
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Figure 5.1 Effect of insulin stimulation on TSC2+/+ and TSC2"7'cells
TSC2+/+ and TSC27' fibroblasts were starved overnight in serum free DMEM with 
1% antibiotic/antimycotic. Cells were stimulated with lOOnM insulin for the times 
indicated then lysed; equal amounts of protein were loaded and separated by 7.5% 
SDS/PAGE, wet transferred to PVDF then probed with the phospho-antibodies as 
indicated then stripped and reprobed for total protein. Similar results were obtained 
in three independent experiments performed in duplicate. (‘B’ denotes basal).
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Figure 5.2 p85 associated lipid kinase activity in TSC2+/+ and TSC2'7' cells when 
stimulated with insulin
TSC2+/+ and TSC2' ' fibroblasts were starved overnight in serum free DMEM with 
1% antibiotic/antimycotic. Cells were stimulated with lOOnM insulin for the times 
indicated then lysed. lOOpg of each lysate was separated by SDS/PAGE, wet 
transferred to PVDF then probed with the antibodies as shown in (A). Similar results 
were obtained in three independent experiments performed in duplicate. Equal 
amounts of the remaining lysates were immunoprecipitated with anti-p85 antibody 
and the immunoprecipitates were assayed for lipid kinase activity using 
phosphatidylinositol and [y-32P] ATP as the substrates. Reaction products were 
analysed by thin layer chromatography and autoradiography. An example o f the 
autoradiograph (autorad) obtained is shown in (A) and relative activity was 
determined in arbitrary units as shown in (B).
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Figure 5.3 IRS-1 associated lipid kinase activity in TSC2+/+ and TSC2'7' cells 
when stimulated with insulin
TSC2+/+ and TSC2'7' fibroblasts were starved overnight in serum free DMEM with 
1% antibiotic/antimycotic. Cells were stimulated with lOOnM insulin for the times 
indicated then lysed. . Equal amounts of protein were immunoprecipitated and 
probed with the indicated antibody, as shown above in (A). IRS-1 
immunoprecipitates were assayed for lipid kinase activity using phosphatidylinositol 
and [y-3 P] ATP as the substrates. Reaction products were analysed by thin layer 
chromatography and autoradiography. An example of the autoradiograph (autorad) 
obtained is shown in (A) and the lipid kinase activity is expressed as mean fold over 
basal ± SEM as shown in (B), n=2 in duplicate.
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5.3.4 Phospho-tyrosine associated lipid kinase activity in 
insulin-stimulated TSC2+/+ and TSC2"7' cells
The loss of insulin stimulated lipid kinase activity due to lower levels of IRS-1 
protein in the TSC2'7' fibroblasts may be compensated for by other IRS proteins e.g. 
IRS-2. Therefore, phospho-tyrosine (Py-99) immunoprecipitations were performed 
to assess whether lack of lipid kinase activity was due to an overall reduction in 
tyrosine phosphorylated proteins available for recruitment of p85. Consistently, no 
IRS-1 was detected in anti-Py-99 immunoprecipitates from TSC2'/_ fibroblasts 
compared to TSC2+/+ (Fig. 5.4A) indicating that any available IRS-1 is poorly 
tyrosine phosphorylated and so inadequate for p85 recruitment (Fig. 5.4A). The lipid 
kinase profile obtained from anti-Py-99 immunoprecipitations (Fig. 5.4B) was 
identical to that observed with IRS-1 immunoprecipitation (Fig. 5.3 B), indicating a 
general deficiency of tyrosine phosphorylated proteins. The lack of tyrosine 
phosphorylated proteins may be from impaired insulin-receptor tyrosine kinase 
activity.
5.3.5 Phospho-tyrosine associated lipid kinase activity in 
TSC2+/+ and TSC2 /_ cells when stimulated with PDGF
The defect in insulin mediated lipid kinase activity via IRS-1 and phospho-tyrosine 
associated proteins raises the question as to whether the PI3K pathway can be 
activated via another receptor tyrosine kinase. The PDGF receptor was considered 
since it does not phosphorylate IRS-1 (Shepherd et al., 1998) and therefore any PI3K 
lipid kinase activity would bypass the requirement of IRS-1 signalling. To test this 
hypothesis PDGF (BB) was used to stimulate TSC2+/+ and TSC2'7' fibroblasts. Anti- 
Py-99 immunoprecipitates recovered from PDGF stimulated cells did not stimulate 
PI3K lipid kinase activity; in fact the lipid kinase activity profile observed was 
identical to that observed with insulin stimulation of TSC2'/_ cells. This suggests that 
PDGF activation of class la PI3K lipid kinase activity is also impaired but the defect 
must occur independently of the lack of IRS-1 protein.
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Figure 5.4 Phospho-tyrosine associated lipid kinase activity in insulin- 
stimulated TSC2+/+ and TSC2 ' cells
TSC2+/+ and TSC2'A fibroblasts were starved overnight in serum free DMEM with 
1% antibiotic/antimycotic. Cells were stimulated with lOOnM insulin for the times 
indicated then lysed. Equal amounts of protein were immunoprecipitated and probed 
with the indicated antibody, as shown above in (A). Anti-Py-99 (phospho-tyrosine) 
immunoprecipitates were assayed for lipid kinase activity using phosphatidylinositol 
and [y-3 P] ATP as the substrates. Reaction products were analysed by thin layer 
chromatography and autoradiography. An example of the autoradiograph (autorad) 
obtained is shown in (A) and the lipid kinase activity is expressed as mean fold over 
basal ± SEM as shown in (B), n=2 in duplicate.
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Figure 5.5 Phospho-tyrosine associated lipid kinase activity in TSC2 +/+ and 
TSC2 ' '  cells when stimulated with PDGF
TSC2+/+ and TSC2'7' fibroblasts were starved overnight in serum free DMEM with 
1% antibiotic/antimycotic. Cells were stimulated with 20 ng/ml PDGF (BB) for the 
times indicated, then lysed. Equal amounts of protein were immunoprecipitated with 
anti-Py-99 antibody and the immunoprecipitates were assayed for lipid kinase 
activity using phosphatidylinositol and [y- 2P] ATP as the substrates. Reaction 
products were analysed by thin layer chromatography and autoradiography. An 
example of the autorad obtained is shown in (A) and the activity is expressed as 
mean fold over basal ± SEM as shown in (B), n=2 in duplicate.
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5.4 Discussion
Recent studies implicate TSC as a factor in the insulin signalling cascade, acting as a 
negative regulator of mTOR and its downstream targets S6K1 and 4E-BP1. 
However, suppression of PKB activity coupled with constitutive activation of S6K1 
in TSC2’7’ mouse embryonic fibroblasts (MEFs) suggested impaired insulin 
signalling upstream of mTOR itself. Evidence here suggests that the defect is due, at 
least in part, to significantly lower levels of IRS-1 which directly affects IRS-1 
associated class la  PI3K lipid kinase acivity. Activation of the PDGF receptor did 
not restore phospho-tyrosine associated PI3K lipid kinase activity, suggesting 
additional defects in signalling upstream of TSC and mTOR in TSC2'/_ fibroblasts.
As described previously, loss of TSC causes the constitutive activation of S6K1 
(shown by phosphorylation at T-389 and activity assays) despite suppression of 
insulin-stimulated PKB activation (Kwiatkowski et al., 2002; Gao et al., 2002; Inoki 
et al., 2002; Jaeschke et al., 2002; Zhang et al., 2003a). Constitutively 
phosphorylated S6K1 (T389) was detected in vivo (as described by Jaeschke et al., 
2002; Zhang et al., 2003a) in TSC2'/_ fibroblasts; however, S2448 phosphorylation 
was not stimulated by insulin in TSC2'/_ fibroblasts and this was likely due to 
suppressed PKB activation. In contrast, knocking out TSC in HEK cells by RNAi 
(where PKB activity is unperturbed) increases mTOR-S2448 phosphorylation (Inoki 
et al., 2002). Whether mTOR phospho-S2448 is significant for mTOR activity is 
unclear, as discussed in Section 4.4. Constitutively active S6K1, in the absence of 
TSC, remains rapamycin sensitive (Gao et al., 2002; Kwiatkowski et al., 2002; 
Zhang et al., 2003a), suggesting that mTOR is the cause of constitutively activated 
S6K1. If mTOR is the cause of constitutive S6K1 activation in the TSC2'7' 
fibroblasts it seems to be via a PI3K/PKB independent pathway. TSC is reported to 
inhibit mTOR in vitro kinase activity toward S6K1 (Inoki 2002). In contrast, Zhang 
et al., (2003a) reported that TSC does not influence mTOR autokinase activity, in 
vitro kinase activity towards 4E-BP1 or cellular phosphatase activity (Zhang et al., 
2003a). The in vitro kinase activity of mTOR may not reflect in vivo mTOR kinase 
activity (Hara et al., 1998; Dennis et al., 2001) and the effect of TSC on mTOR 
activity may require intermediate signalling proteins in vivo.
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What is apparent is that defects in insulin signalling in TSC2"7' fibroblasts are 
extended to the MAPK pathway which was down-regulated in the presence of 
insulin. Therefore, despite constitutive activation of S6K1, suppression of PKB 
activation and the MAPK pathway suggested a defect in upstream insulin signalling; 
this was confirmed by western blotting for the IRS-1 protein. TSC2'/’ fibroblasts had 
significantly lower levels of IRS-1 compared to TSC2+/+ fibroblasts and thus much 
lower levels of tyrosine-phosphorylated IRS-1 in response to insulin stimulation. 
Recruitment and phosphorylation of the IRS family of proteins by the insulin 
receptor is the main mechanism of activating class la PI 3-kinases (Shepherd et al., 
1998). The lack of IRS-1 caused a decrease in IRS-1 associated PI3K lipid kinase 
activity despite evidence that p85-associated PI3K activity remained intact in the 
TSC2_/' fibroblasts. Although, IRS-2 can substitute for the loss of IRS-1 in the 
activation of PI3K, IRS-1 has a more dominant role in PI3K activation in embryonic 
fibroblasts (Bruning et al., 1997). The complete lack of lipid kinase activity from 
phospho-tyrosine immunoprecipitates suggests that there was an overall lack of 
phospho-tyrosine associated PI3K activity, implying that there was no overall 
compensation by other IRS isoforms. Undoubtedly, the lack of IRS-1 and phospho- 
tyrosine associated PI3K lipid kinase activity caused suppression of PKB activation 
and the Ras/MAPK pathway. PKB activation primarily requires activation of PI3K 
lipid kinase activity via recruitment by IRS-1 to produce the lipid second messenger 
phosphatidylinositol (3,4, 5) triphosphate (Ptdlns (3,4, 5)Ps) (Shepherd et al., 1998). 
Ptdlns (3, 4, 5)P3 induces the recruitment of proteins containing the pleckstrin- 
homology (PH) domain which includes phosphoinositide-dependent kinase 1 
(PDK1) and protein kinase B (PKB); therefore the lack of IRS-1 would thereby 
inhibit activation of proteins in the insulin signalling cascade through lack of Ptdlns 
(3, 4, 5)P3 production. The low level of IRS-1 may stem from a general problem 
with the insulin receptor tyrosine kinase activity and/or from a feedback mechanism 
due to constitutively activated S6K1. Our collaborators (Harrington et al., 2004) 
have shown that constitutively active S6K1 in TSC2_/" fibroblasts modulates the 
expression of IRS-1 by directly phosphorylating serine residues at a region proximal 
to the IRS-1 phospho-tyrosine binding (PTB) domain (residues 108-516). 
Suppression of activation by insulin in TSC2'/_ fibroblasts is likely due to serine
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phosphorylation of IRS-1 by S6K1, which inhibits tyrosine phosphorylation and 
results in IRS-1 degradation (Harrington et al., 2004). The presence of TSC can 
therefore prevent IRS-1 degradation. However, it must also be considered that in 
response to cytokines, both mTOR and S6K1 are able to phosphorylate serine 
residues on IRS-1 (between residues 511-722) but only mTOR is able to 
phosphorylate IRS-1 on serine residues which block tyrosine-phosphorylation of 
IRS-1 (Hartman et al., 2001). This suggests that mTOR may also play a part in 
regulating the feedback mechanism which controls the levels of IRS-1.
Because of the lack of IRS-1 associated lipid kinase activity we considered whether 
activation of the PDGF receptor would overcome dysfunction in phospho-tyrosine 
associated class la  PI3K lipid kinase activity. The IRS proteins are not 
phosphorylated by the PDGF receptor and therefore activation of PI3K by the PDGF 
receptor would bypass the loss of IRS-1. PDGF was also unable to stimulate 
phospho-tyrosine associated lipid kinase activity in TSC2'7' fibroblasts, suggesting 
that signalling via the PDGF receptor was also deficient. Zhang et al., (2003a) 
recently reported impaired insulin, IGF-1 and PDGF signalling in the same 
TSC2/p53 null MEFs. In accordance with results presented here, there was a 
significant lack of PI3K lipid kinase activity in TSC2"7' fibroblasts when treated with 
PDGF (BB). Their extended findings show that reduced PI3K activity from PDGF 
stimulation is a result of reduced PDGF receptor expression (both a and p isoforms). 
PI3K and PKB activation was restored by the ectopic expression of the PDGF 
receptor (Zhang et al., 2003a).
Although defects in PDGF signalling are attributable to reduced expression of the 
PDGF receptor in TSC2’7' fibroblasts the defect in insulin signalling via 
downregulation of IRS-1 suggests that another signalling mechanism exists to 
maintain cell survival and proliferation in TSC2'7' fibroblasts. Additional data from 
the Shepherd lab (C. Ktori, unpublished 2003) suggests that dysfunction of the 
‘classical’ insulin signalling pathway via class la  PI3K may be overcome, in part, by 
up-regulation of the class II PI3-kinases. Class II PI3Ks are large 170kDa proteins 
predominantly associated with the membrane fraction of cells, though it is not clear 
which phospholipids they produce in vivo (Vanhaesbroeck and Waterfield, 1999).
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They are activated by insulin and function in a manner discreet from class la PI3K 
(Brown et al., 1999). Specifically, class II PI3K activity is around 2 fold higher in 
TSC2"/_ fibroblasts than in control TSC2+/+ fibroblasts with insulin or PDGF 
stimulation, suggesting that there may be some compensation of growth factor 
signalling via class IIPI3K.
The TSC2'/_ fibroblasts used here were also p53'A. This was necessary to make the 
cells proliferate in culture and as shown here, loss of both these elements has 
extensive effects on both insulin and PDGF signalling. Although the authors of 
Jaeschke et al., (2002) verified that the loss of p53 in MEFs did not disturb the S6K1 
signalling pathways; we must consider reports that p53 is negatively regulated by 
mTOR signalling particularly in malignant cell lines (Castedo et al., 2001, 2002; 
Huang et al., 2001). Therefore, the additional loss of p53 in the TSC2 null 
fibroblasts may affect mTOR activity or influence its effects on IRS-1 turnover.
In summary, evidence suggests that loss of TSC2 impairs both insulin and PDGF 
mediated class la  PI3K signalling. The loss of TSC2 induces constitutive activation 
of S6K1 which causes increased turnover of IRS-1 via a feedback mechanism. The 
mechanism seems to be independent of PKB activation and ultimately leads to down­
regulation of IRS-1 associated class la  PI3K signalling. The PDGF signalling 
pathway did not restore phospho-tyrosine associated class la  PI3K signalling 
because of additional PDGF signalling deficiencies. While reports indicate TSC2 to 
be a negative regulator of mTOR, data here suggests TSC2 may also be a positive 
regulator of insulin signalling.
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6 General Discussion
mTOR is a member of the PIK-related kinase family and has demonstrated protein 
kinase activity to both S6K1 and 4E-BP1, the phosphorylation of which promotes the 
translation of specific subsets of mRNA to allow cell growth and proliferation, a 
process dependent on an overall increase in protein synthesis. Cellular control of 
protein synthesis is closely coupled to mitogen stimulation and nutrient availability, 
factors which converge at mTOR. While the domains of mTOR are well defined, the 
precise mechanisms by which mTOR is regulated are not well understood. The 
catalytic domain of mTOR has been of regulatory interest following the 
identification of S2448 as a nutrient sensitive and mitogen stimulated 
phosphorylation site; the significance of S2448 phosphorylation remains to be 
characterised.
The objectives of the present studies were to identify possible mechanisms by which 
mTOR is regulated and to determine the functional significance of regulation on 
downstream effectors.
The C-terminal catalytic domain of mTOR is thought to have regulatory significance, 
especially in view of identification of the S2448 PKB phosphorylation site (Nave et 
al., 1999; Sekulic et al., 2000; Reynolds et al., 2002; Bolster et al., 2002). S2448 
phosphorylation is stimulated by insulin and negatively regulated by nutrient 
deprivation which led to the hypothesis that phosphorylation of an adjacent residue 
or residues may prevent S2448 phosphorylation; this was supported by Scansite 
analysis (Obenauer et al., 2003) of the region surrounding S2248 which revealed a 
number of phosphorylatable ser/thr, most notably T2446. By producing a phospho- 
specific antibody to T2446 we found it to be a novel mTOR phosphorylation site. 
Moreover, phosphorylation at T2446 was negatively regulated by insulin and 
positively regulated by nutrient deprivation, conditions converse to those which 
promote S2448 phosphorylation. The data suggested that these sites were mutually 
exclusive.
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In identifying T2446 as a novel nutrient regulated phosphorylation site we found that 
conditions supporting T2446 phosphorylation also correlated with activation of 
AMPK. Further, activation of AMPK by AICAR and DNP also increased 
phosphorylation at T2446. Though in vitro kinase assays with mTOR peptides 
suggested that AMPK could phosphorylate the region containing the T2446 
phosphorylation site, in vitro kinase assays with AMPK and full length mTOR 
proved inconclusive. Although direct phosphorylation of mTOR by AMPK could 
not be demonstrated, the existence of the mutually exclusive T2446/S2448 
phosphorylation sites suggests a level of nutrient regulated control of mTOR. 
Interestingly there are examples where integration of nutrient signals is regulated by 
mutually exclusive phosphorylation events, where sites are separated by a single 
amino acid. Two examples, which co-incidentally involve AMPK, are acetyl CoA 
carboxylase which is phosphorylated at S77 by AMPK and at S79 by Protein Kinase 
A (PKA) (Munday, 2002) and hormone sensitive lipase (HSL) which is 
phosphorylated at S563 by PKA and at S565 by AMPK (Garton et al., 1989; Garton 
and Yeaman, 1990). The kinase responsible for T2446 phosphorylation remains to 
be elucidated, though based on studies here we could exclude PKB and S6K1 
regulation of the T2446 site and it is likely that additional phosphorylation sites exist, 
though these sites remain to be identified.
mTOR activity is sensitive to cellular levels of ATP (Dennis et al., 2001) and 
evidence presented in this dissertation implicates AMPK in the regulation of mTOR 
in response to ATP levels; however, depletion of cellular ATP levels can lead to 
inhibition of protein synthesis via an mTOR-independent pathway involving AMPK. 
Activation of AMPK leads to inhibition of protein synthesis via increased 
phosphorylation of elongation factor 2 (eEF2) but not by association of eIF4E with 
4E-BP1 (Horman et al., 2002; McLeod and Proud, 2002). eEF2 regulates translation 
elongation and is inactivated by phosphorylation at T56 by eEF2 kinase (Browne and 
Proud, 2002); insulin stimulates dephosphorylation of eEF2 to allow elongation, a 
process in which mTOR is peripherally involved because S6K1 can inactivate eEF2 
kinase by phosphorylating S366 (Wang et al., 2001). Studies show that eEF2 
phosphorylation is rapidly induced and protein synthesis inhibited by AICAR
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treatment (Horman et al., 2002; McLeod and Proud, 2002), implicating AMPK in the 
negative regulation of eEF2. AMPK cannot directly phosphorylate eEF2, as it is a 
poor AMPK substrate (Horman et al., 2002), but recently AMPK was shown to 
directly phosphorylate eEF2 kinase at S398 which stimulates eEF2 kinase activity 
(Browne et al., 2004). Activation of AMPK by depletion of ATP enhanced 
phosphorylation of eEF2 kinase at S398 and increased phosphorylation of eEF2 
(Browne et al., 2004). Under the same conditions, mTOR signalling was not 
impaired. Furthermore, ATP depletion inhibits S6K1 and 4E-BP1 phosphorylation 
with slower kinetics than those of eEF2 phosphorylation, suggesting that inhibition 
of elongation is independent of the mTOR pathway (Horman et al., 2002; McLeod 
and Proud, 2002), or that the mTOR pathway is involved only after severe depletion 
of ATP (Dennis et al., 2001; Horman et al., 2002). However, in vivo studies in rats 
show that AICAR activation of AMPK does inhibit protein synthesis via an mTOR- 
dependent pathway, primarily through down-regulation of PKB, mTOR (S2448 
phosphorylation), S6K1 and 4E-BP1 (Bolster et al., 2002). AICAR treatment 
activates AMPK (Corton et al., 1995) but may have cellular effects aside from 
AMPK activation (Kemp et al., 1999). Downregulation of the mTOR pathway with 
AICAR treatment may involve factors additional to AMPK. However, studies in 
which AMPK was activated by alternative methods, such as glucose withdrawal or 2- 
deoxyglucose treatment, also demonstrate inhibition of S6K1 activity by an mTOR- 
dependent signalling pathway (Inoki et al., 2003b; Kimura et al., 2003).
The above studies do suggest a linkage between the mTOR and AMPK pathways and 
the fact that AMPK activation and T2446 phosphorylation are stimulated by similar 
conditions suggest they operate in a common and/or a parallel ATP sensitive 
pathway. Metformin is an oral anti-diabetic drug used to treat type-2 diabetes which 
can activate AMPK in skeletal muscle (Zhou et al., 2001). AMPK activation is 
dependent on the AMP: ATP ratio (Hardie et al., 1998; Carling, 2004); however, a 
distinct signalling pathway exists whereby metformin activates AMPK 
independently of the AMP: ATP ratio (Fryer et al., 2002). A preliminary immuno- 
blot (data not shown) of H2K myotubes treated with metformin showed a 
concomitant increase in T2446 and AMPK (T172) phosphorylation which suggests 
that stimulation of mTOR-T2446 phosphorylation is closely coupled to both AMPK
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regulatory pathways. These findings need further exploration and the functional 
significance of T2446 phosphorylation in relation to AMPK activation needs to be 
determined.
Currently, the involvement of AMPK and TSC in the mTOR signalling pathway is 
being delineated. Much like AMPK, TSC has been implicated in or parallel to the 
mTOR pathway; moreover, TSC2 is directly phosphorylated by PKB at S939 and 
T1462 (Dan et al., 2002; Manning et al., 2002) and more recently TSC2 was also 
shown to be directly phosphorylated by AMPK at T1227 and SI345 (Inoki et al., 
2003b). Unlike mTOR, the TSC -PKB and -AMPK phosphorylation sites are not 
separated by a single residue. 2-deoxyglucose treatment of HEK293 cells activated 
AMPK to mediate phosphorylation of TSC2 and decrease signalling through the 
mTOR pathway. Furthermore, AMPK mediated phosphorylation of TSC2 improved 
co-immunoprecipitation between TSC2 and AMPK and enhanced its ability to 
negatively regulate the mTOR pathway (Inoki et al., 2003b); this suggests an 
important regulatory role for TSC and AMPK in the regulation of the mTOR 
pathway. Future investigation into the interplay of the AMPK, TSC and mTOR 
signalling pathways should provide a novel perspective on the regulation of protein 
synthesis in response to cellular energy levels.
Following identification of the mutually exclusive nature of the phosphorylation at 
T2446 and S2448, we wanted to determine the functional significance of 
phosphorylation at each site by mutational analysis. Experiments presented here 
were pre-empted by those of Sekulic et al, (2000); however, data here concurred with 
their findings. Thus, mutation of S2442, T2446 or S2448 to alanine or glutamic acid 
does not appear to affect S6K1 activity in response to insulin or nutrient availability 
when compared to the wildtype rapamycin resistant construct (Ml). Though these 
findings were mainly negative it remains possible that both the T2446 and S2448 
phosphorylation sites have some functional effect. Firstly, the aforementioned 
rapamycin resistance mutations (Section 1.4.1.2 and 4.4), which include S2035T 
(used here) and S2035I, affect substrate selectivity (McMahon et al., 2002), so the 
specific effects of T2446 and S2448 site mutations cannot be properly assessed. 
Secondly, phosphorylation of T2446 and S2448 may not necessarily be coupled to
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S6K1 activation. Studies show that binding of mTAbl or deletion of the mTAbl 
epitope (2433-2450) in mTOR, which contains both the T2446 and S2448 
phosphorylation sites, has relatively little effect on S6K1 phosphorylation compared 
to phosphorylation of 4E-BP1 (McMahon et al., 2002). It is therefore possible that 
phosphorylation of sites in the mTAbl epitope has no specific effect on S6K1 
activity and an alternative substrate may be more suitable to assess the effect of 
T2446 and S2448 phosphorylation e.g. IRS-1 (Section 1.6.4), PKC6 and e (Section 
1.6.5). However, since these two residues reside within the activating mTAbl 
epitope, it suggests there is potential importance in their phosphorylation in the 
regulation of mTOR activity.
A recurring difficulty is the assessment of mTOR kinase activity under different 
isolation conditions, leading to inconsistencies in interpreting mTOR kinase activity 
and function. aTOR antibody was used because it was able to immunoprecipitate 
mTOR with in vitro kinase activity (Section 4.3.7). aTOR has the same epitope as 
mTAbl, the mTOR-activating antibody (Brunn et al., 1997b) which functions by 
overcoming repression induced by the region of its epitope (residues 2433-2450) 
(Sekulic et al., 2000). However, we were not able to consistently obtain mTOR 
kinase activity and the antibody may act to artificially induce mTOR activity in vitro. 
Brunn et al., (1997b) reported that mTOR phosphorylated 4E-BP1 at residues T37, 
T46, S65 and T70 (minus 1 for numbering to rat sequence). However, 
phosphorylation at S65 and T70 was not observed by other groups whether the 
mTAbl antibody was used (Gingras et al., 1999a) or not (Burnett et al., 1998). 
Therefore, mTAbl provides mTOR with the capability to phosphorylate all the 4E- 
BP1 sites in vitro but this activation may be artificial and other factors may be 
implicated in vivo, particularly mTOR interacting proteins.
mTOR is a large protein and it is not unusual that it should act as a scaffold for 
associated proteins particularly since it contains a HEAT domain towards its N- 
terminus; the hydrophobic nature of the HEAT domain makes it a likely target for 
protein: protein interaction and associated proteins have had reported effects on 
mTOR kinase activity. Specifically, an mTOR-associated kinase has been co­
purified with mTOR immunoprecipitates, though its identity and mechanism of
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interaction remain to be identified (Heesom and Denton, 1999). An identified 
interacting protein is Raptor, a 150kD regulatory protein associated with mTOR that 
can also interact with S6K1 and 4E-BP1 (Hara et al., 2002). Raptor association 
seems essential for mTOR activity towards 4E-BP1 (Hara et al., 2002) but not S6K1 
(Hara et al., 2002; Kim et al., 2002). Raptor is an external factor affecting mTOR 
kinase activity, and the Raptor-mTOR complex is highly sensitive to salt, detergent 
and rapamycin, factors which would similarly affect purification of additional mTOR 
interacting proteins. The discovery of Raptor will be important for determining other 
mTOR interacting proteins which may include TSC2 and AMPK. dTSC2 interacts 
strongly with dTOR but there is no evidence of mammalian TSC2 and mTOR 
interaction (Gao et al., 2002; Zhang et al., 2003a); similarly, the AMPKyl subunit 
was found to interact with the mTOR kinase domain but not but not with full length 
mTOR (Kimura et al., 2003). Kim et al., (2002) suggested that mitochondrial 
metabolism or oxidative stress participates in the regulation of the Raptor-mTOR 
complex, specifically via intracellular levels of ATP. Raptor may also be important 
for interaction of mTOR with energy sensing-AMPK. Careful isolation of 
complexes with Raptor will determine if it scaffolds these proteins together. Raptor 
interacts primarily with the N-terminus of mTOR via the HEAT domain (residues 
728-897) and it has fewer contacts with the C-terminus (Kim et al., 2002); so 
whether T2446 or S2448 phosphorylation is important for protein: protein interaction 
is as yet undetermined.
mTOR kinase activity is seemingly dependent on many external factors, thus 
phosphorylation at T2446 and S2448 may still prove functional under certain 
conditions. Significantly, S2448 phosphorylation has been demonstrated in vivo 
(Bolster et al., 2002) and in situ in rat skeletal muscle, where hypertrophy induced an 
increase in S2448 phosphorylation and atrophy induced a decrease in S2448 
phosphorylation (Reynolds et al., 2002). Hypertrophy induces an increase in mRNA 
translation, up-regulation of protein synthesis (via an increase in S6K1 activation) 
and an increase in muscle mass (Baar and Esser, 1999; Bodine et al., 2001; Shah et 
al., 2000); therefore, an associated increase in S2448 phosphorylation demonstrates it 
as having a physiologically relevant role in the control of protein synthesis.
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Although the mTOR phosphorylation site mutants produced had no apparent effect 
on the activation of S6K1, the mutants may still prove a useful tool in assessing 
mTOR localisation, trafficking or interactions with other proteins such as Raptor, 
PP2A/a4 or TSC.
The final part of this study related to the involvement of TSC within the insulin 
signalling pathway. Much evidence implicates TSC in the negative regulation of the 
mTOR pathway (Inoki et al., 2002; Tee et al., 2002) but equally, evidence suggests 
that TSC functions in an mTOR independent pathway (Jaeschke et al., 2002).
TSC2'7' fibroblasts were used to investigate the role of TSC in upstream insulin 
signalling. Loss of TSC2 dramatically reduced levels of IRS-1 which had a knock- 
on reduction in IRS-1-associated class la PI3K signalling, confirmed by reduced 
signalling through PKB, mTOR (S2448 phosphorylation) and MAPK. 
Downregulation of IRS-1 can be attributable to constitutively active S6K1 in TSC2"7' 
fibroblasts; S6K1 increased phosphorylation of IRS-1 on ser/thr residues in vivo and 
in vitro and thus reduced levels of IRS-1 via a feedback mechanism. Partial recovery 
of IRS-1 tyrosine phosphorylation was observed with use of rapamycin (Harrington 
et al., 2004). TSC therefore appears to have an important positive regulatory role in 
insulin signalling. The dramatic effects of constitutive S6K1 activation on IRS-1 
turnover observed here maybe cell-type specific. Over-expressing TSC2 in HEK293 
cells caused inhibition of mTOR-S2448 phosphorylation and reduced activity of 
S6K1; knocking out endogenous TSC2 by RNAi in HEK293 cells promoted mTOR- 
S2448 phosphorylation (Inoki et al., 2002). The findings of Inoki et al., (2002) were 
conducted in HEK293 cells in which components of the insulin signalling cascade 
were intact, albeit with interference in expression of TSC, and support the role of 
TSC in an mTOR-dependent pathway. The TSC2"/_ fibroblasts used here suggest an 
mTOR-independent pathway because of reduced signalling through PKB and 
mTOR-S2448 phosphorylation. However, mTOR-dependent signalling to S6K1 
could also operate if it were independent of PKB activation.
The TSC2'7' fibroblasts interfered not only with insulin signalling but also with 
reduced signalling through down-regulation of the PDGF receptor (Zhang et al.,
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2003a). Moreover, additional data from our lab (C. Ktori, unpublished 2003) suggest 
that impaired activation of class la  PI3K via IRS-1 can be compensated by class II 
PI3K. The significance of up-regulated class II PI3K activity in TSC2'7' fibroblasts 
in response to insulin and PDGF remains uncertain but it may be a cell survival 
mechanism to overcome the impairment imposed by reduced IRS-1 availability and 
lack of the PDGF receptor (Zhang et al., 2003a) in the TSC2'/_ fibroblasts.
Ultimately, the evidence suggests that TSC is involved in both mTOR-dependent and 
-independent pathways. As mentioned previously (Section 5.4) the TSC2"7" 
fibroblasts were also p53'/_ which may also affect mTOR function (Castedo et al., 
2001; Castedo et al., 2002; Horton et al., 2002; Huang et al., 2001). Though 
constitutive S6K1 was found to be the cause of IRS-1 down-regulation (Harrington 
et al., 2004) the possible participation of mTOR cannot be ignored, not only because 
S6K1 is under the regulation of mTOR but because mTOR itself is implicated in 
down-regulation of IRS-1 signalling (Hartman et al., 2001; Haruta et al., 2000) and 
in the sub-cellular redistribution of IRS-1 (Takano et al., 2001). The functional 
effects of mTOR in the TSC2_/' fibroblasts should prove interesting and the mTOR 
mutants could be utilized again for further studies. Additionally, we tested the 
phospho-T2446 mTOR antibody in western blot analysis of TSC2_/‘ lysates. 
However, blotting conditions were not optimal and the results were inconclusive so 
the impact from loss of TSC2 on T2446-mTOR phosphorylation remains to be 
determined.
Recent evidence has implicated the TSC2 GAP (GTPase-activating protein) activity 
toward Rheb in the regulation of mTOR signalling (Castro et al., 2003; Inoki et al., 
2003a; Tee et al., 2003). GAPs function by downregulating activated small GTP- 
bound proteins by accelerating GTP hydrolysis to produce the inactive GDP bound 
form. The GAP activity of TSC2, when in complex with TSC1, is directed to the 
small G-protein Rheb (Ras homolog enriched in brain) which is related to the Ras, 
Rap and Ral super family of small GTP binding proteins (Yamagata et al., 1994). 
The functions of Rheb are poorly understood though it is predominantly GTP bound. 
Rheb was identified as a direct target of TSC2 GAP activity in vivo and in vitro 
where over-expression of TSC1 and TSC2 increased levels of Rheb-GDP (Zhang et
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al.9 2003b); mutations in the GAP domain were associated with tumorigenesis and 
abolished GAP activity. Further, epistatic studies in Drosophila place Rheb in the 
insulin signalling cascade downstream of dTSC and upstream of dTOR and dS6K 
(Saucedo et al.9 2003; Stocker et al., 2003; Zhang et al., 2003b). Furthermore, 
activated Rheb has been demonstrated to be a positive regulator of the mTOR 
signalling pathway as indicated through mTOR S2448 phosphorylation (Inoki et al.9 
2003a) and the rapamycin-sensitive phosphorylation of S6K1 (Castro et al.9 2003; 
Inoki et al.9 2003a; Tee et al.9 2003) and 4E-BP1 (Inoki et al.9 2003a). Over­
expression of Rheb promoted S6K1 phosphorylation in the absence of amino acids 
(Inoki et al.9 2003a; Saucedo et al.9 2003; Tee et al.9 2003; Zhang et al.9 2003b) and 
under conditions of energy depletion (Inoki et al.9 2003a); this evidence suggests that 
Rheb can also act in a nutrient and energy sensitive manner. Positive signalling 
through Rheb and mTOR was negatively regulated by TSC1/TSC2 (Castro et al.9 
2003; Inoki et al.9 2003a; Tee et al.9 2003). The additional findings regarding Rheb 
introduce a further level of regulation to the mTOR signalling pathway via TSC. 
TSC is still a relatively new addition to the mTOR pathway and time restraints 
limited the number of studies performed with the TSC2'/_ fibroblasts. Further 
experiments with the mTOR and PI3K reagents described here should prove useful 
in dissecting further the mTOR-dependent and -independent pathways, particularly 
in resolving the roles of AMPK and Rheb in -nutrient and -energy signalling to TSC 
and mTOR. The data presented here and the future experiments suggested should 
help unravel the intricacies of mTOR signalling and the complex pathways in which 
it is involved.
In summary, T2446 was identified as a novel mTOR phosphorylation site which is 
negatively regulated by insulin and positively regulated by nutrient deprivation, 
conditions which are converse to those which promote S2448 phosphorylation. 
AMPK may be involved in regulation of T2446 phosphorylation. Phosphorylation at 
T2446 and S2448 appears to be mutually exclusive and phosphorylation at these two 
sites may integrate growth factor signalling and nutrient availability. The current 
data suggest that the individual phosphorylations at T2446 or S2448 are not enough 
to affect downstream S6K1 activity and the functional significance of 
phosphorylation at these sites remains to be determined. Additionally, loss of TSC2
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caused down-regulation of IRS-1 dependent class la PI3K activation as a result of 
deregulated S6K1 (Harrington et a l 2004).
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